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Abstract
Strengthening the public downstream SLD supply chain
for MDR-TB: Lessons learnt from a Western Cape Case
Study
E. Coetzee
Department of Industrial Engineering,
University of Stellenbosch,
Private Bag X1, Matieland 7602, South Africa.
Thesis: MEng (Industrial)
2015
Systemic problems in the supply chain of second-line anti-TB drugs (SLDs)
for multidrug-resistant tuberculosis (MDR-TB) are well documented and con-
tribute significantly to the diﬃculties preventing successful control of the dis-
ease. Though literature contains a wealth of proposed changes to global SLD
supply chain policies, there is a significant research gap related to quantitative
modelling of the SLD supply chain to accurately predict the expected impact
of these proposed changes on the availability and delivery of SLDs. The global
SLD supply chain consists of two components: (i) the “upstream” component
which includes all activities from the manufacturing of the active pharmaceu-
tical ingredient through to the warehousing of drugs prior to shipment; and
(ii) the “downstream” component which includes in-country warehousing and
delivery of drugs to various healthcare facilities. In this research study, a down-
stream SLD supply chain is modelled using real-world data. The model is built
for one SLD used in the MDR-TB treatment regimen, namely amikacin. This
research forms part of a bigger study that will eventually incorporate both the
upstream and the downstream components of the supply chain into a single
model. A model of the current downstream segment of the supply chain for
SLDs in the Western Cape was developed using a System Dynamics modelling
approach. The model has been built and validated using real-world data pro-
vided by the Western Cape Department of Health (WCDoH). This model has
been used as a platform for: (i) studying the behaviour and stability of the
downstream component of the global SLD supply chain; and (ii) testing the
ii
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impact of various supply chain policy changes that have been proposed. In
addition to the modelling results, an analysis of the WCDoH data has also
produced a number of insights into the function of the downstream supply
chain, examples of these include:
• 13% of SLDs ordered by the Cape Medical Depot (CMD) are only re-
ceived more than three months after the order date by suppliers; and
• 267% more units of amikacin than what is required on average are avail-
able at the CMD every month, leading to ineﬀective inventory manage-
ment.
The modelling results show that the factor that will most likely lead to the
biggest improvement in the performance of the SLD supply chain is reduced
lead time. Therefore, selecting suppliers that provide shorter lead times should
be a priority. Furthermore, the results show that significant opportunities
could be unleashed by adjusting the policy for determining the desired mini-
mum and maximum levels of stock at the CMD. This research makes a contri-
bution by: (i) increasing the understanding of the strengths and weaknesses
of the SLD supply chain; (ii) quantitatively evaluating the expected impact
of suggested changes to the global SLD supply chain; and (iii) proposing a
methodology that can be used to model and evaluate other downstream med-
ication supply chains.
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Uittreksel
Versterking van die openbare ‘stroomaf’ SLD
voorsieningsketting vir MDR-TB: Bevindinge van ’n
gevallestudie wat op die Wes-Kaap gefokus is
E. Coetzee
Departement Bedryfsingenieurswese,
Universiteit van Stellenbosch,
Privaatsak X1, Matieland 7602, Suid Afrika.
Tesis: MIng (Bedryfs)
2015
Sistemiese probleme in die voorsieningsketting van tweede lyn teenmiddels
(SLDs) vir multi-weerstandbiedende tuberkulose (MDR-TB) is goed gedoku-
menteer en dra aansienlik by tot die voorkoming van die probleem en om die
siekte suksesvol te beheer. Alhoewel literatuur menigte voorgestelde wysigings
vir die globale SLD ketting beleide bevat, is daar ‘n beduidende navorsings-
gaping wat verband hou met kwantitatiewe modellering van die SLD ketting.
Dit lei daartoe dat die verwagte impak van hierdie voorgestelde wysigings aan
die beskikbaarheid en die lewering van SLDs nie akkuraat kan voorspel word
nie. Die globale SLD voorsieningsketting bestaan uit twee komponente: (i)
die “stroomop” komponent wat alle aktiwiteite van die vervaardiging van die
aktiewe farmaseutiese bestanddeel insluit tot by pakhuise van die teenmid-
dels voor dit versprei word; en (ii) die “stroomaf” komponent wat binnelandse
pakhuise en aflewering van die teenmiddels na verskeie gesondheidsfasiliteite.
In hierdie navorsingstudie is ‘n stroomaf SLD voorsieningsketting gemodelleer
met behulp van werklike data. Die model is gebou vir een SLD wat gebruik
word in die MDR-TB behandelingsstelsel, naamlik amikasien. Hierdie na-
vorsing vorm deel van ‘n groter studie wat beide die stroomop en stroomaf
komponente van die voorsieningsketting in ‘n enkele model inkorporeer. ‘n
Model van die huidige stroomaf afdeling van die voorsieningsketting vir SLDs
in die Wes-Kaap is ontwikkel deur ‘n Stelsel Dinamika Modellering benade-
ring. Die model is gebou en bekragtig met behulp van werklike data wat deur
die Wes-Kaapse Departement van Gesondheid (WKDvG) voorsien is. Hierdie
iv
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model is gebruik as ‘n platform vir: (i) die bestudering van die gedrag en stabi-
liteit van die stroomaf komponent van die globale SLD voorsieningsketting; en
(ii) om te toets wat die impak van verskeie voorgestel voorsieningsketting be-
leidsveranderinge is. Bykomend tot die modellering resultate, het ‘n ontleding
van die WKDvG data ook ‘n aantal insigte van die funksie van die stroomaf
voorsieningsketting geidentifiseer. Voorbeelde van hierdie sluit in:
• 13% van SLDs wat bestel word deur die Kaapse Mediese Depot (CMD)
word slegs meer as drie maande na die beveldatum deur verskaﬀers ont-
vang; en
• 267% meer eenhede van amikasien as wat benodig word, word gemiddeld
beskikbaar gestel deur die CMD elke maand, wat lei tot oneﬀektiewe
bestuur van voorraad.
Die modellering resultate toon dat die faktor wat waarskynlik sal lei tot die
grootste verbetering in die doeltreﬀendheid van die SLD voorsieningsketting
is, om lei tyd te verminder. Daarom moet die keuse van verskaﬀers wat korter
lei tyd aanbied ‘n prioriteit wees. Verder toon die resultate dat beduidende
verbeteringe geskep kan word deur die beleid vir die bepaling van die gekose
minimum en maksimum vlakke van voorraad aan die CMD aan te pas. Hier-
die navorsing lewer ‘n bydrae tot: (i) die verhoging van die begrip van die
sterk- en swakpunte van die SLD voorsieningsketting; (ii) die kwantitatiewe
evaluering van die verwagte impak van voorgestelde wysigings aan die globale
SLD voorsieningsketting; en (iii) stel ‘n metode voor wat gebruik kan word om
ander stroomaf medikasie voorsieningskettings te evalueer.
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of MDR-TB
Runge-kutta integration A numerical method used to solve diﬀerential equa-
tions (involves successive approximations)
Z-score Statistical measurement that indicates how many standard deviations
an element is from the mean
Model Variables
¯DHF Average monthly health facility demand
↵ Exponential smoothing constant
BCMD Backlogged orders at the CMD
C¯A Average monthly drug consumption
CH Holding costs
CO Ordering costs
COb Obsolescence costs
CS Shortage costs
DCMD CMD demand
DHF Health facility demand
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Nomenclature xix
EOQ Economic order quantity
IP Inventory position
L¯T Average monthly supplier lead time
LT Supplier lead time
OAm Obsolete drugs
PC Production cycle
PP Procurement period
R Supplier reliability
ROP Reorder point
S0 Drugs to CMD
S1 Drugs to health facilities
SCMD Inventory on hand at the CMD
SDC Standard deviation of consumption
SDLT Standard deviation of lead time
SF Safety factor
SL Service level
SS Safety stock levels
CT Total costs
TE Shelf-life of amikacin
Tmax Maximum desired level of stock in months
Tmin Minimum desired level of stock in months
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Chapter 1
Introduction
This chapter introduces the global problem of multidrug-resistant tuberculosis
(MDR-TB) and therefore the rational for this study. The primary focus of
this research project is expressed in terms of the aim and objectives listed in
section 1.3. The outline of the methodology that will be followed to achieve
the aim of this research is shown in Figure 1.2, followed by a description of
the structure of this report.
1.1 Background
Starting in 2008, the Institute of Medicine’s (IOM) forum have held six work-
shops across the globe to address the global drug-resistant tuberculosis (DR-
TB) crisis. The goals of these workshops, amongst others, were to: understand
the magnitude of the drug resistance problem; identify the key barriers to ef-
fective control of the spread of the disease; and develop an execution plan
for confronting the global crisis. These workshops have highlighted the fact
that the under-performance of the supply chain that delivers second-line drugs
(SLD) for the treatment of DR-TB specifically, is hindering the eﬀorts to con-
trol DR-TB; thereby creating the need to investigate the performance of the
SLD supply chain.
1.2 Problem Definition
With 1.4 million deaths per year globally, tuberculosis (TB) is the second
largest infectious disease killer. TB is caused by the Mycobacterium tubercu-
losis bacterium that mainly aﬀects the lungs, but can also attack any other
part of the body, such as the kidney, spine, and brain. TB is contagious and
is transmitted from person to person through air; however is completely cur-
able with a standard six month treatment regime. Regrettably however new
drug-resistant strains of TB have emerged due to interrupted or incomplete
1
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TB treatment. One of the strains that have developed is MDR-TB, which
is resistant to the two most powerful first-line anti-TB drugs (FLDs) used
to treat drug susceptible TB (DS-TB): isoniazid (INH) and rifampin (RIF).
Extensively drug-resistant TB (XDR-TB) is another more serious strain that
has emerged, as this strain is resistant to INH, RIF, as well as other anti-TB
drugs. DR-TB strains therefore require new drugs for treatment, known as
SLDs. MDR-TB has become a public health emergency across the globe, with
the BRICS (Brazil, Russia, India, China and South Africa) countries carrying
the burden of almost 60% of all notified DR-TB cases (International Union
Against Tuberculosis and Lung Disease, 2012). In 2011, only one in five pa-
tients estimated to be infected with MDR-TB were diagnosed and treated,
showing the true magnitude of this health crisis (International Union Against
Tuberculosis and Lung Disease, 2012). The incidences of MDR-TB and XDR-
TB are increasing globally; cases of diagnosed MDR-TB increased from 62, 000
to 84, 000 between 2011 and 2012 (World Health Organization, 2013b). There
are many causes for the spread of the disease, however research has shown that
the under-performing supply chain for SLDs accounts for most of these causes
(Nicholson et al., 2013; Olson et al., 2014). The MDR-TB SLD supply chain is
under-performing in terms of the timely procurement and delivery of quality
SLDs to the infected patients. This results in patients missing critical doses
of medicine and further contributes to the resistance of the bacteria.
The global SLD supply chain faces many challenges and barriers, which directly
increases the TB bacteria’s resistance to drugs used to treat drug susceptible
TB. Some of these challenges include demand uncertainty, a lack of suppliers
and fragmentation in the SLD supply chain. These challenges are discussed
in Chapter 2 in more detail. Many of these issues are interrelated, making
it diﬃcult to isolate which interventions will have the greatest positive im-
pact on the supply chain. There have been many suggestions made by various
speakers at each of the IOM workshops to improve the eﬃciency of the SLD
supply chain, however few have actually been tested or put into practise. It
is therefore suggested that the SLD supply chain be modelled in order to test
the suggestions made and to assess the impact these proposed solutions will
have on the supply chain. Developing this model will be a start to finding the
key solutions to the problems faced within the SLD supply chain, in order to
improve the existing supply chain. A successful supply chain has the potential
to contribute significantly to ensuring an uninterrupted supply of SLDs to ev-
ery patient suﬀering from DR-TB, at prices that are reasonable enough for the
majority of patients, in hopes of treating DR-TB successfully on a global scale.
The global SLD supply chain is divided into an upstream segment operated
internationally and a downstream segment operated domestically. However
only the downstream segment of the supply chain will be modelled in order to
test the changes and the impacts thereof on a smaller, more accurate scale.
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Figure 1.1 shows that the highest number of MDR-TB cases estimated to
have occurred amongst notified pulmonary TB cases occurs in Russia, China,
and India; however relative to a population of 143 million, 1, 386 million and
1, 252 million respectively, the relative burden is higher in South Africa with a
population of only 53 million (World Health Organisation, 2014). Furthermore
Table 1.1 shows the actual number of notified MDR-TB cases in 2013 in each
of these countries. Both Figure 1.1 and Table 1.1 illustrate that South Africa
is a good representation of MDR-TB globally due to the high burden, and
therefore will be the focus of this study. In order to scale down an area for
investigation for this research project even further, Table 1.2 shows that the
over the years 2005-2010, KwaZulu Natal and the Western Cape have had the
highest prevalence of MDR-TB in South Africa specifically (Statistics, 2012).
Therefore for the purpose of this study, only the downstream segment of the
SLD supply chain in the Western Cape, South Africa, will be modelled, as it
provides a good representation for the global burden.
Figure 1.1: Number of MDR-TB cases estimated amongst notified pulmonary
TB cases in 2013 (Source: Global Tuberculosis Report. WHO, 2014.)
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 1. INTRODUCTION 4
Table 1.1: Number of notified cases of MDR-TB in 2013 (Source: World Health
Organisation (2014))
Country MDR-TB cases
China 4, 183
India 35, 385
Russian Federation 13, 521
South Africa 26, 023
Table 1.2: Number of diagnosed cases of MDR-TB in each province in South
Africa, 2005-2010 (Source: Alrabea (2012))
Province 2005 2006 2007 2008 2009 2010
Eastern Cape 545 836 1, 092 1, 510 1, 858 1, 782
Free State 151 198 179 381 253 267
Gauteng 676 732 986 1, 028 1, 307 934
KwaZulu-Natal 1, 024 2, 200 2, 208 1, 573 1, 773 2, 032
Limpopo 40 77 91 185 204 126
Mpumalanga 134 139 506 657 446 312
North West 203 225 397 363 520 158
Northern Cape 155 188 199 290 631 353
Western Cape 1, 192 1, 179 1, 771 2, 220 2, 078 1, 422
1.3 Aims and Objectives
1.3.1 Aim
Develop a model of a downstream MDR-TB SLD supply chain in the Western
Cape, and use this model to make recommendations on the most eﬀective
mechanisms for strengthening this supply chain.
1.3.2 Objectives
• Develop a model of the Western Cape public healthcare downstream
MDR-TB SLD supply chain;
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• Develop a thorough understanding of the strengths and weaknesses of the
downstream MDR-TB SLD supply chain by assessing and comparing to
the SCOR model;
• Test the impact of changes to the downstream supply chain as proposed
by the IOM Forum by using the model;
• Test the impact of changes to the operational parameters on the supply
chain based on the analysis of the strengths and weaknesses; and
• Make recommendations on the changes to the SLD supply chain that
will be the most eﬀective in strengthening this supply chain.
1.4 Research Design
This project will be undertaken as an empirical study into potential suggestions
for improvement of the SLD supply chain. This research relies on both primary
and secondary data, analysing quantitative and qualitative data for modelling
and simulation. The primary data collection consists of semi-structured inter-
views, telephone calls and emails to obtain both qualitative and quantitative
data. A range of secondary data is used for this study, namely: books; journals;
articles; and websites. The main source of secondary data is provided by the
Western Cape Department of Health (WCDoH), which consists of numerical
data regarding the orders and dispatches of SLDs to and from the Cape Medi-
cal Depot (CMD). The data provided by the WCDoH is necessary to evaluate
the performance of the current SLD supply chain and develop a model of the
supply chain. This data is analysed and explored in order to find meaningful
relationships and trends that will aid in evaluating the performance.
1.5 Research Methodology
Figure 1.2 illustrates the steps that will be followed to achieve the aim and
objectives set out in Section 1.3 for this research project. The model developed
will represent one SLD in the downstream segment of the SLD supply chain
in the Western Cape, and will be verified and validated using real-world data
provided by the WCDoH.
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Research literature pertaining to
MDR-TB and the SLD supply chain
Research complexities
in drug supply chains
Research complexities in the MDR-
TB SLD supply chain specifically
Investigate supply chain
modelling techniques
Investigate suggestions for improvement
based on IOM findings and SCOR model
Evaluate performance of current
SLD supply chain for specific issues
Analyse current issues and poten-
tial IOM suggestions to select the
appropriate modelling technique
Model the real-world downstream SLD
supply chain in the Western Cape
Validation and verification of the model
Perform scenario modelling based
on suggestions for improvement
Provide recommendations based on
the findings of the scenario modelling
Figure 1.2: Research methodology
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1.6 Structure of the Report
Chapter 2 describes, in detail, the global problem of MDR-TB and more specif-
ically the barriers faced in confronting the crisis. This chapter also includes
background on the MDR-TB SLD supply chain and the challenges currently
being faced with regard to eﬀectively procuring and delivering quality assured
SLDs to patients. Chapter 2 also briefly describes the treatment of MDR-TB
and more specifically paediatric MDR-TB.
Chapter 3 classifies a supply chain as a complex adaptive system (CAS), based
on the defining criteria of a complex adaptive system. Chapter 3 then proceeds
to describe the process of building a model and provides information on the
modelling techniques that are currently used to model supply chains specifi-
cally. These techniques include: analytical modelling; process modelling; and
simulation modelling. The paradigms within these modelling techniques are
then discussed in detail, with the focus on simulation modelling specifically.
Chapter 4 lists the suggestions and solutions proposed by the participants in
the IOM Forums on how to confront the global MDR-TB crisis. Furthermore,
the performance attributes highlighted in the Supply Chain Operations Ref-
erence (SCOR) model that will be tested to evaluate the current downstream
SLD supply chain is also listed. The best practises that are used to improve
these performance attributes are added to the IOM suggestions made to im-
prove the supply chain. Based on these suggestions that will be tested with
the model, systems dynamics is chosen as the simulation paradigm that will
be used to model the downtream SLD supply chain.
Chapter 5 describes the process of how the supply chain model is developed
and validated using three of the five phases of systems dynamics: problem
structuring; causal loop modelling; and dynamic modelling. The performance
of the current supply chain is also evaluated in this chapter by testing the
attributes: reliability; responsiveness; and robustness.
Chapter 6 describes the final two phases of the five phases of systems dynamics:
scenario planning and modelling; and implementation. The various policies,
variables and strategies that will be simulated to test the suggestions proposed
at the IOM workshops, and the suggestions made based on the performance of
the supply chain are listed and discussed. The variables and policies that will
be tested include: supplier lead time; supplier reliability; desired stock levels;
safety stock levels; and reorder policies. The results obtained after running
these scenarios are recorded and discussed.
Chapter 7 analyses the results obtained from the simulations using a pareto
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set. Recommendations are then provided on how to decide on the optimal
pareto solution. These recommendations include using: gross domestic prod-
uct (GDP); quality-adjusted life-year (QALY) calculations; and population
simulations. Moreover, recommendations on the methodology used to com-
plete this study will be presented, based on the limitations of systems dynam-
ics as a simulation paradigm. Finally, recommendations for future research in
this field will be provided and discussed.
1.7 Conclusion: Introduction
This chapter gives a concise description of the global MDR-TB crisis, the
challenges that are currently being faced with confronting this problem and
therefore the need for this research. The over-arching aims and objectives for
this research project, as well as the methodology that will be followed in order
to achieve these objectives are also discussed. Chapter 2 will discuss, in detail,
the challenges that are being faced globally in addressing the the MDR-TB
crisis, with focus on the under-performing MDR-TB SLD supply chain.
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Chapter 2
Real-World Problem
This chapter provides background on both DS-TB and DR-TB, focusing on
MDR-TB and how this specific strain developed. The IOM Forum held various
workshops across the globe with the aim of understanding the magnitude of
the drug-resistance problem and determining the key issues to eﬀective treat-
ment. These specific barriers and key issues that are hindering the control of
eﬃcient distribution of quality assured anti-TB drugs and the prevention of
the transmission of MDR-TB are discussed in detail in this chapter. The IOM
workshops recognised that one of the biggest issues is the under-performing
MDR-TB SLD supply chain. Therefore each of the bottlenecks throughout the
SLD supply chain that are preventing the eﬃcient procurement and delivery
of quality drugs to patients are highlighted and discussed; with the aim of
finding solutions to strengthen this supply chain.
2.1 Management of Tuberculosis
(TB) is a contagious and airborne disease that mainly aﬀects the lungs. TB
has been around for millennia and is also known as the disease of poverty (The
Global Fund to Fight AIDS, Tuberculosis and Malaria, 2014). It is caused by
the bacterial micro-organism, tubercle bacillus or Mycobacterium tuberculosis,
and is potentially fatal (National Institute of Allergy and Infectious Diseases,
2009). Globally, TB is one of the leading causes of deaths by infectious dis-
eases, second only to AIDS (Giﬃn and Robinson, 2009). It is estimated that
one-third of the global population carry the bacillus Mycobacterium tuberculo-
sis ; and although many will never become active, the bacillus is responsible for
approximately 4, 700 deaths daily (Keshavjee and Seung, 2008; Olson et al.,
2011).
DS-TB can however be treated by a regimen of FLDs over a certain time
period, depending on the infection. FLDs are the standard and preferred choice
for treating TB and consist of: INH; RIF; ethambutol; pyrazinamide; and
9
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streptomycin (World Health Organization, 2010). However new, potent strains
of TB have emerged that are resistant to some of the available FLDs. DR-TB
is becoming a major global health risk that is accelerating. The drug-resistant
strains can be grouped into either MDR-TB or XDR-TB. MDR-TB is defined
as the strain of TB bacteria that has become resistant to at least two of the
best antibiotics in the first line drug regimen, namely INH and RIF. Globally it
is estimated that 450, 000 people developed MDR-TB and 170, 000 people died
from MDR-TB in 2012 (World Health Organization, 2013a). The worst case of
DR-TB is XDR-TB, as it is resistant to at least: INH; RIF; any fluoroquinolone
(an antibiotic); and at least one of the second-line injectable drugs: kanamycin;
capreomycin; streptomycin; or amikacin (World Health Organization, 2013d).
In general SLDs are necessary when certain FLDs fail to treat the disease, or
when the disease becomes resistant to the FLDs. Therefore SLDs have become
necessary to eﬀectively treat patients with DR-TB. SLDs used to treat DR-TB
are grouped as follows (World Health Organization, 2010):
• First Line Oral Agents (FLDs);
• Injectable Agents;
• Fluoroquinolones; and
• Oral Bacteriostatic Second Line Agents.
Although FLDs are used to treat drug susceptible TB, ‘First Line Oral Agents,’
namely: ethambutol and pyrazinamide can also be used in combination with
the SLDs used to treat MDR-TB if the microorganism is not yet resistant to
those drugs. The SLDs used to treat DR-TB are not only very expensive, less
potent and more toxic in comparison to the FLDs used to treat susceptible
TB, but they also require a drug regimen that can last up to two years or more
(Nicholson et al., 2013).
To control TB, the World Health Organisation (WHO) launched a global pro-
gramme called ‘directly observed treatment, short-course’ (DOTS) in the early
1990s, where an appointed agent directly monitors patients swallowing their
anti-TB drugs (Volmink and Garner, 2007). The Global Drug Facility (GDF)
was established in 2001 to increase access to high quality TB drugs in order
to expand the DOTS program. DOTS is based on a six month treatment
regimen with FLDs: isoniazid, rifampin, pyrazinamide, and ethambutol for
new patients and an eight month regimen with streptomycin added to the
original regimen for re-treatment patients (Pooran et al., 2013). The World
Health Organization (2014) emphasises that the DOTS strategy combines five
components, namely:
• Political commitment with increased and sustained financing;
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• Case detection through quality-assured bacteriology;
• Standardised treatment regimen with supervision and patient support;
• An eﬀective drug supply and management system (uninterrupted supply
of anti-TB drugs); and
• Monitoring and evaluation system and impact measurement.
2.2 Management of MDR-TB
MDR-TB developed due to: (i) a lack of stringent quality control on the drugs
used to treat TB, allowing substandard and counterfeit drugs to enter the mar-
ket; and (ii) patients not taking their medicine on a daily basis in the correct
doses. This resulted in a resistance to the TB drug regimen (Nicholson et al.,
2013).
DOTS was however designed for drug susceptible TB and therefore did not
address MDR-TB; leading to the introduction of DOTS-Plus. DOTS-Plus
is built upon the five DOTS components to include treatment of MDR-TB
with SLDs. The goal of DOTS-Plus is to prevent the further spread of MDR-
TB; however the barrier to implementation of the strategy was the limited
access to, and the high costs of SLDs (World Health Organization, 2000). The
Green Light Committee (GLC) initiative was therefore established between
1998 and 2000 by the WHO and the Stop TB Partnership in response to the
high demand for low cost SLDs. The GLC serves as a technical advisory
body to the WHO and the Stop TB Partnership, and performs tasks such as:
reviewing applications from countries that request quality assured (QA) SLDs
at reduced prices and promoting technical assistance. This initiatives aim is
to control the emergence of resistance to SLDs by ensuring the use of only QA
SLDs at aﬀordable prices. Quality assurance programs help guarantee that
patients receive drugs that are safe, eﬀective and are of an acceptable quality
thereby contributing to controlling the further spread of DR-TB.
2.3 Key Issues around MDR-TB
There have been six workshops across the globe, organised by the IOM: two
in Washington DC; China; India; Russia; and South Africa. These workshops
addressed DR-TB and the problems associated with controlling the disease.
The names of these IOM workshops, where each particular one took place, and
in which year are listed in Table 2.1.
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Table 2.1: Institute of Medicine Forum workshops
Code Workshop Country Year
W1 Addressing the threat of drug-resistant
tuberculosis: A realistic assessment of the
challenge
Washington
DC
2008
W2 The emerging threat of drug-resistant
tuberculosis in Southern Africa. Global and
local challenges and solutions
South Africa 2010
W3 The new profile of drug-resistant
tuberculosis in Russia. A global and local
perspective
Russia 2010
W4 Facing the reality of drug- resistant
tuberculosis in India. Challenges and
potential solutions
India 2011
W5 Developing and strengthening the global
supply chain for second-line drugs for
multidrug-resistant tuberculosis
Washington
DC
2012
W6 The global crisis of drug-resistant
tuberculosis and leadership of China and
the BRICS: Challenges and opportunities
China 2013
All of the six workshops have reached the same conclusion: DR-TB has become
a major global issue and there are many aspects that need to be addressed be-
fore the disease can be: (i) treated at lower costs for the patients; and (ii)
prevented on a global level. The reports written on each of the workshops
summarised the key themes discussed at the respective workshops. The key
topics of conversation at each IOM workshop are summarised in Table 2.2.
The issues listed in Table 2.2 are either: (i) due to an under-performing SLD
supply chain; or (ii) negatively aﬀect the SLD supply chain to some extent.
To eﬀectively treat patients with MDR-TB, an uninterrupted supply of QA
SLDs is necessary. Therefore a well-performing global SLD supply chain is
critical to ensure the timely procurement of high-quality SLDs in order to con-
trol the spread of the disease and treat the patients that are currently infected.
This study will focus on identifying the key factors that negatively aﬀect the
performance of this supply chain. The supply chain for QA SLDs has many
barriers and inadequacies that make the supply chain as a whole ineﬀective in
delivering an uninterrupted supply of SLDs. Addressing these weaknesses in
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the supply chain is critical to preventing TB strains with more drug-resistance
and to controlling the strains that already occur.
Table 2.2: Key issues discussed at each IOM workshop
Key Issues W1 W2 W3 W4 W5 W6
Regulatory challenges x x x x
Information management x x x x x x
Drug shortages x x x
Financing of MDR-TB SLDs x
Limited and erratic demand x
Limitations of global TB
estimates
x x
The role of HIV in the spread
of MDR-TB
x x x
The importance of
infection/transmission control
x x x x x
Limited diagnostic capacity x x x x x
Low rates of treatment x x x
The need for new TB drugs x x
DR-TB in children x x x x
Surveillance and tracking of
DR-TB
x
2.4 The MDR-TB Supply Chain
There is general agreement around research pertaining to this field of study
that the spread of DR-TB is mainly due to the under-performing SLD supply
chain (Yadav, 2011; Mostaghim, 2012; Nicholson et al., 2013). “The SLD
supply chain remains in a state of disarray” (Yadav, 2012). One of the key
messages identified by individual speakers at the IOM workshop in Washington
DC, 2012 was that the failure to target and amend the SLD supply chain
issues will lead to drug resistance, morbidity and ultimately increased mortality
(Nicholson et al., 2013). Furthermore Mostaghim (2012) states that addressing
two crucial barriers in the SLD supply chain: (i) the high prices; and (ii) the
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limited availability of QA drugs could potentially: reduce the incidence of
infection; and increase the number of patients on treatment.
2.4.1 Complexities in Drug Supply Chains
A potential result of ineﬃcient supply chains, that do not succeed in the timely
procurement and delivery of the right drugs to the right patients, is the in-
creased spread of disease and sickness. Shah (2004) is of the opinion that most
drug supply chains, including the MDR-TB SLD supply chain, face the same
diﬃculties and complexities:
• Uncertainty in demand.
This uncertainty arises due to: competition; discontinuation of drugs due
to new formulations; and price.
• Uncertainty in the approval of new drugs.
There is uncertainty about which drugs will be successful in trials, aswel
as which treatment regimen will be optimal and with what dosage.
• Production development.
This complexity arises during the development of the actual process by
which the drugs should be manufactured. Chemistry and yield optimi-
sation will drive the development of this process.
• Capacity planning.
The problem of allocating manufacturing capacity to sites during clinical
trials. This complexity arises specifically in the design phase, where
capacity needs to be balanced with future demand.
• Production planning and scheduling.
Section 2.4.2. gives a detailed overview of the complexities encountered in the
SLD supply chain, specifically for MDR-TB.
2.4.2 Unique Characteristics of the MDR-TB SLD
Supply Chain
The presentations given by Keshavjee and Seung (2008); Yadav (2012); Mostaghim
(2012) and Atun (2012) at the IOM workshop that took place in Washington
DC, 2012 give an overview of the barriers, challenges and needs that prevent
the SLD supply chain from delivering an uninterrupted supply of SLDs to
MDR-TB patients. The report written on the workshop summarises these
presentations, revealing that although thoughts on the specific weaknesses in
the SLD supply chain might diﬀer in severity, fundamentally there is an agree-
ment on the majority of the challenges that are being faced (Nicholson et al.,
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 2. REAL-WORLD PROBLEM 15
2013). Figure 2.1 illustrates the basic MDR-TB SLD supply chain.
Figure 2.1 shows that the SLD supply chain is divided into upstream and
downstream segments. The upstream supply chain is global, while the down-
stream is domestic. Due to the fact that the supply chain for MDR-TB SLD is
predominantly donor funded, the upstream and downstream segments of the
supply chain are decoupled from one another (Yadav, 2012). This has unique
implications with regard to price, demand, scale-up and financing. Yadav
(2012) stressed the fact that the relationship between price and volume is not
the same as the relationship between cost and volume. The extent to which
the change in producer cost is reflected in the buyer price is dependent on the
market structure that is itself dependent on the competition in the market
and the eﬀectiveness of the procurement institutions (Nicholson et al., 2013).
Yadav (2012) performed a modelling exercise where he doubled the demand
for one SLD treatment; however the cost of the drugs for the suppliers only
decreased by a maximum of approximately 17% and the price for consumers
by 8%.
Furthermore the two segments are financed diﬀerently: the upstream segment
is financed by the GDF and the downstream is financed domestically by each
respective country. Yadav (2012) states that a unique situation therefore exists
with regards to demand elasticity due to this financial structure. He explains
that demand is relatively inelastic to changes in the internationally financed
segment, meaning that a small change in cost will barely aﬀect the demand. On
the other hand, the domestically financed segment is demand elastic, where a
small change in price will have a large impact on the demand from consumers.
The demand curve will therefore be uniquely shaped with the beginning of
the curve being relatively flat with a change in cost, followed by a jump at a
certain point, where the domestic segment is predominant. More research is
however required to identify the point at which the demand will trigger a price
decrease for consumers (Nicholson et al., 2013).
2.4.3 General MDR-TB SLD Supply Chain Challenges
The remaining part of this chapter discusses in more detail the unique chal-
lenges faced by the SLD supply chain, as listed in Table 2.2. This section
discusses the challenges faced throughout both the upstream and the down-
stream segments of the supply chain. Subsections 2.4.4 and 2.4.5 will discuss
the specific challenges faced within each segment.
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Manufacture starting material
‘Active pharmaceutical in-
gredient’ manufacturing
‘Finished pharmaceutical
product’ manufacturing
Procurement,financing
and forecasting
Warehousing (prior to shipment)
In-house
warehousing
Clinics/
Hospitals
Patients
China and India
GDF and GLC
Figure 2.1: The basic MDR-TB SLD supply chain (adapted from Yadav
(2012))
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2.4.3.1 Regulatory Challenges
MDR-TB patients’ access to SLDs is restricted due to the regulatory pathway
shown in Figure 2.2. Figure 2.2 also shows that low-income countries have to
wait much longer for QA SLDs than high-income countries, as they are highly
dependent on donor procurement.
Product research and
development (R&D)
Approval by Food and Drug
Administration (FDA) and Euro-
pean Medicines Agency (EMA)
Prequalification by
WHO (if donor funded)
National registration in recipient
country (approval by NRA)
Patients in high-
income countries
receive drugs
Patients in high-
income countries
receive drugs
Patients in low-
income countries
receive drugs
Figure 2.2: Drug regulatory pathway (adapted from Ahonkhai (2012))
In high-income countries the Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) can approve products in one-step, creating
a direct pathway to patients. These countries also procure the drugs themselves
creating an eﬃcient pathway. However the low-income countries are faced with
a slow, three-step process for donor procurement, either from the Global Fund
or from UNITAID. UNITAID is a global health organisation hosted by the
WHO to increase funding for greater access to treatments for HIV, Malaria
and TB in low-income countries (UNITAID, 2014). The three-step process
faced by low-income countries includes:
• Approval by regulatory authorities (FDA and EMA) in the manufactur-
ing country;
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• WHO prequalification; and
• Approval from the National Regulatory Authority (NRA) in the country
of delivery.
In order for low-income countries to be eligible for SLD procurement with
donor funding, the desired SLDs must pass through the WHO pre-qualification
(PQ) process to aﬃrm its quality and safety. This PQ process is especially
a problem as there are extra delays in registering new suppliers, as both the
response and uptake to invitations for PQ is low (Hedman, 2012). The drug
must then be registered by the NRA in the beneficiary country, otherwise it
cannot be procured by the donor agency. This regulatory pathway is not only
fragmented between low- and high-income countries; further fragmentation
occurs in the low-income countries as the NRA approval time varies for each
country of delivery (Ahonkhai, 2012).
Regulatory harmonization was found to improve this fragmented system. The
African Medicines Regulatory Harmonization (AMRH) was therefore formalised
and launched in 2012 in East Africa to streamline approval for regulators and
manufacturers and to increase access to safe, eﬀective products. This collabo-
ration moved from a system with many countries in Africa, to six regions each
with a group of countries in Africa. The countries are grouped into the six
regions that are illustrated in Figure 2.3. In other words, the AMRH aims to
improve the fragmented system of product registration in Africa, by focusing
on regions within the African continent (Ahonkhai, 2012).
Figure 2.3: Regulatory harmonisation for the six regions in Africa (adapted
from Ahonkhai (2012))
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2.4.3.2 Information System Challenges
Table 2.2 illustrates that information management was one of the issues dis-
cussed at each of the six workshops, showing the importance of this factor.
Information systems are critical to the success of the SLD supply chain, as
information management can be applied in multiple ways to address issues
associated with the SLD supply chain (Nicholson et al., 2013; Olson et al.,
2014). Nordenberg (2013) states that the data and information that is used
to support a global supply chain is a supply chain on its own. Public health
programs require the following three supply chains to be successful: human re-
sources, products, and information supply chains. However Nordenberg (2013)
states that many challenges still exist with information distribution in the rural
healthcare system, as there is poor integration with hospitals at national and
regional levels. The WHO Global Laboratory Initiative (GLI) stated that “the
critical lack of TB laboratory capacity constitutes a global crisis, requiring a
paradigm shift in providing laboratory policy guidance, quality assurance and
knowledge creation within a global and integrated laboratory network”. Not
only is laboratory capacity insuﬃcient, but laboratories have programs that
are focused on specimens, therefore their information system requirements are
not aligned with clinics or public health programs. Nordenberg (2013) states
that “Information is a public health intervention,” and a proper TB/DR-TB
information supply chain will be able to:
• Prevent emergence of drug resistant strains;
• Treat patients more eﬀectively;
• Track infection control risks; and
• Improve contact tracing and follow up.
If MDR-TB cases are identified earlier, less resistance will develop and fewer
people will spread the disease; therefore diagnosis should be used to drive
treatment. However the data produced by diagnostics need to be collected,
managed and shared properly for the disease to be controlled (Olson et al.,
2012).
Information systems have many advantages, and can strengthen the SLD sup-
ply chain in many ways. Improving the eﬃciency of information management
systems could make demand forecasting more accurate and prevent stock-outs,
thereby strengthening the supply chain (Olson et al., 2014). An information
system with the correct type and amount of data can aid in evaluating the
impacts of treatment regimen time-lines and appropriateness of the treatment
regimen for each patient. Electronic medical records (EMR) systems is an
example of this type of information system. EMR’s can be used to store in-
formation about patients, which will provide more accurate and reliable data
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for forecasting. Although collecting the information for EMR is relatively
straightforward, the challenge lies in finding the appropriate resources (tools
and training) for the information to be accurate. EMR’s integrate information
management into the broader health system. Some of the core variables that
should be collected and stored in an EMR are (Fraser, 2012):
• Demographics;
• Program enrolment date;
• Start date for drugs;
• Drug regimen (drugs and doses);
• Smear and culture results;
• Previous medications;
• Adverse events;
• Treatment status;
• Treatment outcome; and
• Outcome date.
Evidence of reduced medication errors and better follow-up of diseases has
driven the implementation of EMR in hospitals; however developing countries
still oﬀer challenges such as lack of infrastructure and lack of local technical
support and knowledge.
2.4.3.3 Second-line Drug Shortages
The risk of stock-outs occurring is high due to the high price and the short
shelf-life of SLDs, therefore DOTS programs have been specifically focused on
reducing stock-outs (Yadav, 2011). These stock-outs result in delayed treat-
ment initiation and treatment interruptions, triggering a temporary subopti-
mal treatment regimen until the appropriate drugs are available again. This
increases the challenge of eﬃciently procuring and delivering the SLDs. Drug
shortages can occur at both global and national levels:
• Global-Level SLD Shortages.
Pre-made SLDs are often stored in warehouses for several months before
the required paperwork and procurement processes are completed for
shipment, after which the drugs are then kept in additional warehouses
(Nicholson et al., 2013). Thereby the shelf-life is already low before it
is received by the patient. SLDs are too expensive to manufacture if
the completed drug is kept in storage for the majority of its shelf-life,
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which is only 24 months, thereby creating hesitancy to produce SLDs
without proper forecasts. Global shortages are also a result of reliance
on a single source for QA active pharmaceutical ingredients (API) and a
limited supplier pool. Furthermore many SLDs have only one producer,
therefore a shortage is likely to occur if a problem occurs with even one
batch of drugs.
• National-Level SLD Shortages.
The leading cause of stock-outs at a national-level is the uncertainty in
the timing of the availability of funds. The funds for the purchase of
the drugs have to be available before the procurement process can begin
(Olson et al., 2012). Due to the fact that strict regulations must be
followed before the GDF can distribute funds, delays occur frequently
and it becomes diﬃcult to predict when funds will become available
(Yadav, 2011).
2.4.3.4 Financing Challenges
Every process in the supply chain requires financial support from multiple or-
ganisations in both the private and public sector. Since the SLD supply chain
is predominantly donor funded, the dynamics and financial drivers diﬀer sig-
nificantly from a commercial supply chain. This is due to the fact that the
donors are non-profit organisations. The GDF collaborates with the Green
Light Committee (GLC) and is predominantly funded by the Global Fund,
UNITAID, and USAID.
One of the organisations that fund the SLD supply chain is the United States
Agency for International Development (USAID). Cheri Vincent, TB team
leader of USAID described the following SLD supply chain challenges from
the USAID’s perspective.
• Funding mismatch and inflexibility.
An analysis of 21 countries that compared the number of MDR-TB pa-
tients enrolled in a treatment regime to the number of available treat-
ment regimes revealed that only 39% of the funds available were used for
MDR-TB treatment (Vincent, 2012). Moreover, the countries that don’t
meet their MDR-TB treatment objectives lose these unused funds and
SLDs. However, countries that are scaling up MDR-TB treatment faster
than SLDs are available to them cannot benefit from these SLDs that
aren’t being used in other countries. It is therefore suggested that more
flexibility in funding would allow resources to be matched to countries
more appropriately (Nicholson et al., 2013).
• Ineﬃcient country supply chain system.
Vincent (2012) lists the following as causes for the ineﬃciencies:
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– Slow government procurement and financial processes;
– Limited capacity to forecast due to unpredictable MDR-TB pro-
gram scale-up rates;
– Complicated Global Fund procedural and grant requirements; and
– Decentralised and parallel supply chain systems.
• Limited number of suppliers and high prices for SLDs.
These two issues are interrelated, as an increase in suppliers will promote
competition and therefore reduce prices. Vincent (2012), states that
having two suppliers for each SLD is an important milestone; however few
suppliers are willing to produce QA SLDs due to the limited incentives
(Vincent, 2012).
UNITAID is essentially a central pharmaceutical drugs purchasing facility,
that negotiates reductions in prices from pharmaceutical firms. UNITAID is
unique in the fact that a large amount of the funding they receive come from
the air ticket levy mechanism (UNITAID, 2015). The organisation (UNITAID)
explains that this mechanism includes charging passengers an air ticket levy
above the cost of the ticket. This levy is simply added to an existing airport
tax and can range from $1 for economy-class tickets to $40 for first class pas-
sengers. Thus far nine countries have implemented this mechanism. UNITAID
funding not only allowed the GeneXpert to be rolled out in 21 recipient low-
and middle-income countries, but also achieved a 40% price reduction for this
rapid TB test. Furthermore, UNITAID’s response to the frequent stock-outs
was the strategic rotating stockpile (SRS). The SRS includes enough medicine
for 5,800 MDR-TB treatments which can be accessed at short notice for emer-
gency situations (UNITAID). The lead times for urgent orders decreased from
101 days in 2007 to 30 days in 2011. In order to ensure that the medicines
are kept within their shelf-life limits, the medicines are routinely checked and
rotated by the CDC.
Although there are many initiatives and funding options available from these
organisations, the SLD supply chain still faces many problems. Atun (2012)
highlights the major funding shortfall, which has a direct impact on MDR-TB
diagnosis and treatment. It was estimated that funding requirements for MDR-
TB would be $7.1 billion, of which only $ 3.6 billion was approved by the GDF
in 116 countries between 2002 and 2010. However as specified by Atun (2012),
domestic funding needs to be mobilised to address the emerging MDR-TB, as
the GDF target is to fund 50 % of the MDR-TB treatment needs. He also states
that the funding shortfall is preventing the implementation of push and pull
mechanisms. Push mechanisms are required to create incentives for suppliers
and manufacturers to enter the market, while pull mechanisms are required for
demand creation. This is as a result of supplier and manufacturer hesitancy
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to enter this kind of market. Without these mechanisms, the supply chain will
continue to under-perform without the opportunity to scale-up (Atun, 2012).
2.4.4 Upstream Supply Chain Challenges
These issues are specific to the upstream segment of the supply chain. Mostaghim
(2012) explained that the two biggest challenges in the upstream segment are
the high prices and the limited availability of QA SLDs. These challenges are
as a result of: limited and unpredictable demand; restricted market structure;
and low volumes of API and finished pharmaceutical products (FPP) produc-
tion.
Mostaghim (2012) lists the four elements that factor into pricing of SLDs by
manufacturers as:
• True cost of manufacturing;
• Monopoly premium;
• Risk premium; and
• Economies of scale.
The ‘true cost of manufacturing’ relates to the actual costs of raw materials
and labour for all the manufacturing processes that are involved in producing
SLDs. The ‘monopoly premium’ refers to the fact that there is a lack of com-
petition amongst manufacturers in the SLD market. The ‘risk premium’ refers
to the premium that manufacturers charge due to the risk they feel they are
taking when investing in the SLD market, as there is poor visibility into the
market (Mostaghim, 2012). Lastly the ‘economies of scale’ or the ‘cost of sub-
scale manufacturing’ refers to the high costs that are associated with sub-scale
batch size manufacturing. The batch sizes are driven by demand, emphasising
the need for volume of demand to be high and consistent (Mostaghim, 2012).
The combination of these four elements factor into why SLDs are so expensive
to manufacture. The three elements: ‘monopoly premium’; ‘risk premium;
and ‘cost of sub-scale manufacturing’ are eﬀectively non-essential elements of
price and can be eliminated by increasing volumes and creating competition
between manufacturers (Kimerling, 2012).
Olson et al. (2012) highlight that these high prices not only strain national TB
programs but also exacerbate drug shortages.
2.4.4.1 Limited and Erratic Demand
The most prominent problem with the upstream supply chain is the limited
and unpredictable demand. This is as a result of:
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• Limitations of global TB estimates.
Globally approximately 94, 000 patients with MDR-TB were notified to
the World Health Organisation (WHO) in 2012, however the WHO esti-
mates this to be number to 450, 000 (World Health Organization, 2013a).
Of the 94, 000 people eligible for MDR-TB treatment, 77, 000 started on
treatment in 2012. The most recent available treatment success rate is
from the statistics available from patients that started MDR-TB treat-
ment in 2011, which was 48% globally. Giﬃn and Robinson (2009) is of
the opinion that the incidences of DR-TB are underestimated due to the
fact that: drug resistant surveys have not been conducted in many of
the countries in Africa; the current diagnostic methods are inadequate
for HIV infected people; and the availability of diagnostic laboratories
are limited in many countries. However, the World Health Organization
(2013a) highlights that one of the main reasons for the low detection
rates in many parts of the world is the existence of the private sector, in
which national authorities are not notified of TB cases.
• Lack of pooled procurement.
The WHO have restrictions about conducting pooled procurement and
the ability to negotiate prices with suppliers, which according to Keshav-
jee and Seung (2008), are the key barriers to improving SLD prices. All
procurement using Global Fund dollars are required to go through the
GLC which is an agency of the WHO, restricting pooled procurement.
Keshavjee and Seung (2008) is of the opinion that manufacturers have
no real forecast of the potential demand to work with due to the lack
of pooled procurement. According to Comstock (2012), there are many
benefits of enforcing pooled procurement:
– The promotion of a fair strengthened market;
– The management of gaps and duplication in supply;
– The increased product availability (avoid stock-outs);
– The compliance with national and donor rules;
– The enhancement of purchasing power;
– The ability to focus on product harmonisation;
– The implementation of stringent quality requirements; and
– The access to broad expertise and best practices.
However the challenges with implementing pooled procurement include:
customer specific product requirements, country registration demands,
constraints of donor or national procurement regulations and weak col-
laboration between donors and national authorities (Comstock, 2012).
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• Poor demand forecasting.
Demand forecast models play very significant roles in the supply chain of
SLDs. Amongst other roles, the models: match the supply with the de-
mand in order to eliminate the lag time; allow funders to plan purchases
and allocate resources eﬃciently; and encourages the development of new
drugs as manufacturers have a realistic picture of the future market po-
tential (Giﬃn and Robinson, 2009). Insuﬃcient forecasting contributes
to opaque markets for drug manufacturing and therefore results in a lim-
ited number of manufacturers and the lack of new drug developments.
An 80% accurate forecasting model, two months into the future and
projecting at least 24 months is necessary to improve the drug supply
(Bloom, 2013). After all six IOM workshops were completed, it was
suggested that aggregated requests from various countries for SLD pro-
curement would provide better demand forecasts and therefore a more
stable total demand. Reliable forecasting requires information such as
(Bloom, 2013):
– Number of patients enrolled for each TB program;
– Number of patients taking drugs;
– Types of drugs being used by each patient;
– Lead times for shipping each drug; and
– Lead times for manufacturing each drug.
• Fragmentation.
Fragmentation occurs at each point in the supply chain in a number of
diﬀerent ways. Fragmentation results in too many alternatives and there-
fore prevents the formation of an eﬃcient and streamlined supply chain.
Firstly, there is no standard regimen for the treatment of MDR-TB with
SLDs, which results in fragmentation in the demand for specific SLDs.
It is proposed that the introduction of new drugs and regimens into the
market will only fragment the market more by giving clinics more op-
tions for drug administration to their patients (Nicholson et al., 2013).
However, new drugs are vital to treat new strains of DR-TB, therefore
the supply chain needs to be eﬃcient, stable and robust enough to handle
the changes without failing (Giﬃn and Robinson, 2009). The definition
of the quality of these SLDs also varies between countries resulting in
fragmentation in the market amongst the drug manufacturers. The next
stage of fragmentation occurs at the packaging level. The same drugs are
packaged diﬀerently and therefore require diﬀerent procurement agents.
Therefore, although diﬀerent manufacturers are available for a single
drug, diﬀerent specifications for inner and outer packaging result in only
one eligible manufacturer for each specific mode of packaging and ten-
dering. In eﬀect this results in a monopoly of each manufacturer and
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procurement agent, thereby increasing the prices of the drugs (Nichol-
son et al., 2013). The time taken for approval of the drugs also varies
between countries and therefore further increases fragmentation in the
TB drug market. Finally, the manner in which patients are managed
and the methods used for record-keeping vary amongst locations and pa-
tients, further fragmenting the supply chain (Giﬃn and Robinson, 2009).
The GLC procurement process, and any other approved programs should
therefore be aligned, clear and consistent to reduce the fragmentation.
2.4.4.2 Restricted Market Structure
According to Olson et al. (2012), the markets for SLDs are small and uncer-
tain. This is due to the fact that the suppliers and manufacturers are at risk
of producing and supplying drugs that will not be purchased, and the health
facilities are at risk of purchasing drugs that will not be used. SLD manufac-
turing is often order-driven, rather than forecast-driven due to the limited and
erratic demand. Due to the high costs of suboptimal batch manufacturing,
many manufacturers have minimum volume thresholds for production; how-
ever waiting for the volume of orders to reach this minimum threshold results
in longer lead times (Yadav, 2011). Furthermore, some manufacturers only
procure the API’s after receiving the purchase order even though very few
sources of API’s are available, lengthening the time taken to receive orders.
This erratic demand prevents manufacturers and suppliers from having stock
of SLDs on hand and makes new suppliers and manufacturers hesitant to enter
the SLD market. The lack of suppliers is not only increasing the price, but
is hindering the drug procurement process (Olson et al., 2012). In 2012 there
were 12 formulations on the WHO list for pre-qualified SLDs, produced by
only three manufactures. This small group of suppliers also exposes the global
supply chain to the risk of stock-outs if the demand outweighs the supply ca-
pacity (Nicholson et al., 2013).
Moving toward a functional SLD market requires three principles (Olson et al.,
2012):
• Quantifying the risk;
• Aggregating the risk on a global level; and
• Sharing the risk amongst the individuals involved in the supply processes.
Risk can be quantified by having accurate demand forecasting, as this would
aid in allowing manufacturers and suppliers to plan ahead based on future
demand. This would result in less hesitancy from suppliers and manufacturers
to enter the SLD market. Risk can be aggregated by global, rather than
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country-by-country ordering for the purpose of smoothing the erratic demand.
One way of sharing the risk between countries would be to implement a rotating
stockpile where countries can shift supplies to one another if drug consumption
projections are not met (Olson et al., 2012). This virtual stockpile could also
prevent stock-outs on a national-level.
2.4.4.3 Low Volumes of API and FPP
The batches of APIs that are currently manufactured are relatively small due
to the limited demand. Suboptimal batch manufacturing is more expensive
and results in inflated prices for the FPP. Eighty five percent of the world’s
TB APIs, which includes the API’s used for SLDs, are supplied by China as
they are the world leaders in fermentation chemistry (which the production
of API relies on). This causes a problem because the availability of these
API’s have been limited due to the fact that the producers in China have
not been pre-qualified by WHO to sell the drugs internationally (Nicholson
et al., 2013; Olson et al., 2014). The API’s are the most important component
in the production of SLDs, therefore this has a major impact on the overall
availability of SLDs.
2.4.5 Downstream Supply Chain Issues
The downstream segment of the SLD supply chain includes: the in-house
warehousing storage; the delivery of drugs to the clinics and hospitals; and
the treatment of patients. The challenges faced by the downstream segment
include;
• Public tendering;
• Ineﬀective inventory management;
• Limited diagnostic capacity;
• Suboptimal adherence to treatment regimens;
• Lack of transmission control;
• Low rates of treatment; and
• Need for new drugs and regimens.
2.4.5.1 Public Tendering
South Africa is one of the countries with the highest prevalence of TB, however
most TB drugs in South Africa are procured on a competitive basis through
the public sector.
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Public tendering can be a problem when the submitted tender is too small for
the demand. If this is the case, the National Department of Health (NDoH)
would have to do a buy-out to replace stock-outs, which is significantly more
expensive than a tender. Countries that procure SLDs through donor-funding
(predominantly high MDR-TB burden countries) are financially constrained
and are therefore highly dependent on these public tenders to ensure stock-outs
don’t occur.
2.4.5.2 Ineﬀective Inventory Management
As discussed in Subsection 2.4.3.3, one of the biggest issues within the sup-
ply chain is the occurrence of stock-outs. Ineﬀective inventory management
increases the risk of experiencing shortages. Running a well-functioning inven-
tory system is one of the biggest challenges within the downstream segment
of the SLD supply chain. This is due to the fluctuating demand. Schaaf
(2014) highlights the fact that, with the exception of the Cape Medical Depot
(CMD), the medical depots in South Africa frequently experience shortages.
In addition to the restrictions experienced due to the regulatory pathway,
Schaaf (2014) lists the following factors that contribute to shortages occurring
at health facilities:
• Health facilities forget to order on time;
• Health facilities forget to order; and/or
• Health facilities don’t order enough.
Yadav (2012) emphasises the need for determining the optimal stocking pat-
tern in order to reduce the occurrence of shortages and keep the holding costs
to a minimum. However, determining the optimal stocking pattern requires ac-
curate demand forecasts and well-functioning reorder policies. Reorder policies
within medical depots are often unable to accurately ensure the right amount
of stock, due to poor forecasting. Furthermore, shortages occur because of
delays in procurement due to an inadequate number of suppliers.
2.4.5.3 Limited Diagnostic Capacity
The WHO set the targets of having at least one culture laboratory per five
million people and at least one laboratory that has the capability for drug
susceptibility testing (DST) per five million people. South Africa has reached
both of these targets; however 14 of the 27 high MDR-TB burden countries
had not reached the targets by 2012 (World Health Organization, 2013a).
The 27 ‘high burden’ countries are: Armenia; Azerbaijan; Bangladesh; Be-
larus; Bulgaria; China; Democratic Republic of the Congo; Estonia; Ethiopia;
Georgia; India; Indonesia; Kazakhstan; Kyrgyzstan; Latvia; Lithuania; Myan-
mar; Nigeria; Pakistan; Philippines; Republic of Moldova; Russian Federation;
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South Africa; Tajikistan; Ukraine; Uzbekistan; and Viet Nam.
In order to have accurate global MDR-TB estimates, eﬀective methods of
diagnosis along with diagnostic capacity need to be used. Sputum smear mi-
croscopy was developed over 125 years ago, and is usually the first TB diag-
nostic test done, especially in countries with a high rate of TB infection (Lawn
and Nicol, 2012). Sputum is a fluid produced in the lungs and is tested for
the presence of TB bacteria. If TB bacteria are present in the sputum then
the results are recorded as smear positive (World Health Organization, 2010).
However, the results of patients co-infected with HIV will be recorded as smear
negative. The problem lies in the fact that patients are only diagnosed with
TB if the results are smear positive, therefore the data on the incidence of
TB is highly underestimated. In order to properly control TB, more accu-
rate data on the incidence of TB is of paramount importance. Unfortunately
90% of people infected with TB come from low- and middle-income countries,
where sputum smear microscopy and chest radiology are still heavily relied
upon for diagnosis, due to the fact that it is inexpensive (Lawn and Nicol,
2012). However, although this method is inexpensive and easy to perform it
cannot diﬀerentiate between drug-resistant and drug susceptible TB (Van Rie
et al., 2010). Only after the patient has been diagnosed with TB are additional
culturing tests done to diagnose MDR-TB.
Culture tests are highly sensitive and can therefore: diﬀerentiate between drug
susceptible and drug-resistant TB; and diagnose TB in HIV-infected individu-
als (Van Rie et al., 2010). However the drawbacks of this method, as stated by
Van Rie et al. (2010), include: a turnaround time between two and six weeks
due to the slow growth of TB bacilli; the need for biosafety infrastructure;
the high costs associated with these tests; and the complexity when com-
pared to sputum microscopy. Therefore this method cannot be implemented
in resource-limited settings.
Sputum smear microscopy and culturing tests require that the samples taken
from the patients be transported to a laboratory for testing. The laboratories
then need to test the samples for TB, after which the results then need to
be transported or transmitted (i.e. electronically) back to the health facility
from where it came. Although the procedure for smear examination is quite
fast (1 day), culturing takes considerable longer, delaying treatment initiation
(CDC, 2011). Due to the drawbacks experienced with both of these methods,
cost-eﬀective and accurate point-of-care (POC) TB testing is critical to ensure
treatment can begin immediately after diagnosis. POC implies that a diagnosis
can be made at the point where consultation occurs and provides a result
that allows treatment to start on the same day as the consultation. Due
to increased investments in TB research in the past decade, there have been
many breakthroughs with regard to POC testing (World Health Organization,
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2013a). In 2008, line probe assay tests (LPA) were recommended by WHO to
detect MDR-TB. These rapid molecular tests use positive sputum specimens or
cultures to detect resistance to RIF. In 2010, a new device called the GeneXpert
MTB/RIF had been created to simultaneously detect TB and the resistance of
the bacteria to RIF. This device detects MDR-TB in only two hours as opposed
to the four weeks taken for culturing. The GeneXpert cartridge system has
the following features:
• Macro- and microfluidics can be processed;
• Large volumes can be concentrated and purified;
• Contamination is unlikely as it is a closed system; and
• Analysis can be performed immediately.
This has increased the number of patients diagnosed with MDR-TB and the
time in which they have been diagnosed. By the end of June 2013, 3.2 million
test cartridges had been procured globally, with South Africa procuring 60%
of the total. South Africa is aiming to position the GeneXpert MTB/RIF as
a replacement for microscopy in detecting TB (World Health Organization,
2013a).
2.4.5.4 Suboptimal Adherence to Treatment Regimens
The critical advantage of this rapid diagnosis with POC is the reduction of
patient dropout.
Throughout the process of diagnosis to initiation onto the appropriate treat-
ment, many patients are ‘lost’ in the system. These patients dropout due
to:
• The diagnosis process taking too long, i.e. laboratory testing;
• The patient not being able to return to the clinic to receive his/her
results; and
• Not obtaining the results from the laboratory or the clinic.
It is therefore assumed that POC will help with initiation of treatment, as the
result is available while the patient is still in the health-care facility - whether
it be a house, clinic or a hospital (Olson et al., 2011a). The challenge however
still lies in the fact that treatment regimens cannot be adhered to and com-
pleted unless there is a constant supply of QA SLDs.
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2.4.5.5 Lack of Transmission Control
Infection with drug-resistant TB is not only due to inadequate TB treatment,
but also due to transmittance. MDR-TB can be transmitted directly from
one person to another further spreading the drug-resistant strains. Therefore
the importance of undiagnosed cases in the spread of the disease is under-
appreciated (Giﬃn and Robinson, 2009). Furthermore, eﬀective global trans-
mission control is critical in order to prevent the proliferation of the disease.
However implementing eﬀective transmission control in resource-limited set-
tings involve a number of challenges including (Nardell, 2008):
• Ventilation systems that are too expensive to install and maintain;
• Lack of technical expertise to implement building design for triage and
separation;
• Health workers and patients not wearing respirators as they feel stigma-
tised;
• Infected health workers in high burden settings (therefore they don’t
practice transmission control);
• Lack of technical expertise for the use of germicidal UV lamps;
• The belief that DOTS will solve the MDR-TB problem; and
• The mistaken belief that drug-resistant strains are less virulent than drug
susceptible strains.
A lack of transmission control exacerbates the spread of the MDR-TB, putting
more pressure on the SLD supply chain, further accelerating the need for a
scale-up of the supply chain.
2.4.5.6 Low Rates of Treatment
Currently treatment levels for MDR-TB cases are low, as MDR-TB treatment
projects have only two options for procurement of SLDs (Keshavjee and Seung,
2008):
• Procuring QA SLDs from the GDF, through the GLC; and
• Procuring drugs of unknown quality through state procurement mecha-
nisms or the open market.
Only 0.2-0.5 % of the estimated five million cases of MDR-TB were treated
with QA SLDs through GLC-approved programmes between the years 2000
and 2009, while approximately 70% received either drugs of unknown qual-
ity or no treatment at all. Keshavjee and Seung (2008) estimate that less
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than 10% of the 70% will receive drugs of unknown quality and under vary-
ing programmatic conditions. The rest of the patients aﬀected with MDR-TB
(approximately 29.5 %) passed away (Nicholson et al., 2013). Therefore the
majority of MDR-TB cases are left untreated. The World Health Organization
(2013c) emphasised that the majority of new MDR-TB cases occurred in the
‘BRICS’ countries (60%). The ‘BRICS’ countries being: Brazil; the Russian
Federation; India; China; and South Africa.
2.4.5.7 Need for New Drugs and Regimens
The lack of new drugs to fight both drug susceptible and drug-resistant TB
is a gap in the global fight against TB. Chou et al. (2008) observed that the
last major breakthrough in TB treatment was the discovery of rifampin in
the 1970s. He also noted that TB drug development experienced its ‘golden
age’ between the 1940s and the 1960s when all the most common FLDs were
discovered and developed. TB drug research has since then been stagnant,
which threatens the gains made by antiretrovirals (ARV), as people infected
with HIV risk dying from the curable disease, TB. According to Chou et al.
(2008), there are seven new drug candidates in the TB pipeline, however this
number is not suﬃcient to address the millions that are infected. As not all
of these drugs will be approved, the pool of novel drug candidates needs to be
kept full. It is also not suﬃcient that candidate drugs are merely entering the
TB pipeline; these drugs need to be better than the existing ones by ensuring
(Chou et al., 2008):
• Decreased duration of treatment;
• Decreased pill burden;
• Trouble-free dosing with ARVs;
• Increased eﬃcacy against drug-resistant TB; and
• The ability to treat paediatric TB.
Not only are the current candidate drugs in the TB pipeline associated with
side eﬀects, but some have not been tested in people taking ARVs, even though
TB is the leading killer of people infected with AIDS. Children are also typ-
ically excluded from TB drug research and none of the candidate drugs have
been tested in children (Chou et al., 2008).
2.5 MDR-TB Treatment
MDR-TB is not only diﬃcult to treat, as the bacteria is resistant to the two
most powerful anti-TB drugs, but it is also very costly. The cost of just the
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drugs for MDR-TB patients can be 50 to 200 times higher than the drugs for
TB patients (Falzon et al., 2010). This is due to the fact that SLDs cost more
than FLDs and the treatment regime for MDR-TB lasts longer.
2.5.1 Adult MDR-TB Treatment
Table 2.3 shows the grouping of the SLDs used to treat MDR-TB. The SLDs
are grouped according to eﬃcacy and drug class, with Group One containing
the most potent drugs. The FLDs used to treat TB (except INH and RIF)
are in Group 1 of MDR-TB treatment, as they are the most potent and the
best tolerated if the bacillus is not yet resistant to these drugs (World Health
Organization, 2010).
The guidelines for the treatment of TB (2010) states that the MDR-TB treat-
ment regimen should consist of at least four drugs with almost certain eﬀec-
tiveness against the infecting organism; one from each Group in hierarchical
order. If there is resistance to all drugs in a one Group, the number of remain-
ing drugs needed to complete a regimen of at least four drugs should come
from Group Four. Only if a regimen has fewer than four eﬀective drugs should
drugs from Group Five be added to the regimen.
The intensive phase is the duration of treatment that includes an injectable
agent from Group Two, which should continue for six to eight months. The
continuation phase starts right after culture conversion and should continue
for a minimum of 18 months (this includes the intensive phase) using the same
drugs as in the intensive phase, without the injectable agent. According to
the ‘Standard Treatment Guidelines and Essential Medicines List for South
Africa’, 18 months of treatment is usually required for a person suﬀering from
MDR-TB. The patient should be hospitalised for the initial four months of the
intensive treatment, after which a clinic will do the follow-ups until the end
of treatment. The dosages of drugs are administered depending on the mass
of the patient according to the ‘Standard Treatment Guidelines and Essential
Medicines List for South Africa’. Table 2.4 shows which drugs are used from
each Group, along with the doses for MDR-TB treatment in South Africa
specifically. If a patient is specifically following the regimen shown in Table 2.4,
that patient will use: kanamycin; moxifloxacin; ethionamide; terizidone; and
pyrazinamide during the intensive phase, followed by using all drugs except
kanamycin for the duration of the treatment (continuation phase).
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Table 2.3: Groups of drugs to treat MDR-TB (Source: World Health Organi-
zation (2010))
Group Name Drugs
1 First-line oral agents
Pyrazinamide (Z)
Rifabutin (Rfb)
Ethambutol (E)
2 Injectable agents
Kanamycin (Km)
Amikacin (Am)
Capreomycin (Cm)
Streptomycin (S)
3 Fluoroquinolones
Ofloxacin (Ofx)
Levofloxacin (Lfx)
Moxifloxacin (Mfx)
4 Oral bacteriostaticsecond-line agents
Ethionamide (Eto)
Protionamide (Pto)
Cycloserine (Cs)
Terizidone (Trd)
Para-aminosalicylic acid (PAS)
5 Agents with uncleareﬃcacy
Clofazimine (Cfz)
Linezolid (Lzd)
Amoxicillin/Clavulanate (Amx/Clv)
Imipenem (Ipm)
Thiacetazone (Thz)
High-dose Isoniazid (High-dose H)
Clarithromycin (Clr)
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Table 2.4: Standardised regimen for MDR-TB treatment in South Africa
(Source: National Department of Health (2012))
Drug <50 kg 50-65 kg >65 kg
Kanamycin 500  700 mg 1000 mg 1000 mg
Moxifloxacin 400 mg 400 mg 400 mg
Ethionamide 500 mg 750 mg 750  1, 000 mg
Terizidone 750 mg 750 mg 750  1, 000 mg
Pyrazinamide 1, 000  1, 750 mg 1, 750  2, 000 mg 2, 000  2, 500 mg
2.5.2 Paediatric MDR-TB Treatment
The eﬀorts to control MDR-TB in children face additional challenges, as TB
drug research does not typically include children. DR-TB in children is under-
diagnosed and under-reported, therefore eﬀorts are underfunded (Perez-velez
et al., 2010). It is estimated that globally, one million cases of paediatric TB
occur annually (Olson et al., 2011). According to an epidemiological surveil-
lance undertaken at the Tygerberg Children’s Hospital in the Western Cape
between 1994 and 2009, there is a high prevalence of drug-resistant TB specif-
ically in the Western Cape, with an increasing number of children contracting
DR-TB (Olson et al., 2011a).
It has been found that MDR-TB in children results mainly from transmit-
ted drug-resistance (90%) (Olson et al., 2011a). Schaaf (2014), Department
of Paediatrics and Child Health, University of Stellenbosch strongly suggests
that once adults in a household present with TB, the entire household should
be screened. Schaaf (2014) states that the biggest problem with treating chil-
dren that have DR-TB is that the drugs are not designed for children. SLDs
are rarely produced in paediatric formulations or appropriate tablet sizes. The
dosages in each pill are too high for children and the pills either need to be cut,
crushed or diluted to get the right dosage. The basic principles of the MDR-
TB treatment regimen are the same as for children as for adults, however the
dosages are subject to age-related change and mass. The pharmacokinetics,
which include: absorption; distribution; metabolism; and excretion as well as
the toxicity of drugs in children diﬀer from those in adults (Poorana Ganga
Devi and Swaminathan, 2013). The current dosing recommendations for chil-
dren are based on adult mg/kg doses that are scaled down. Therefore dosing
is likely to be inaccurate, leading to blood concentrations that are either toxic
or sub-therapeutic which results in vomiting after children have ingested the
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drugs. (Poorana Ganga Devi and Swaminathan, 2013; Lessem et al., 2013).
In South Africa it is expensive to register a new drug with the Medicines
Control Council (MCC), therefore even if companies do have the right drugs
for children, they are reluctant to register these drugs. Schaaf (2014), stated
that the FDA and EMA need to create rules to ensure that new drugs are
child friendly. Extensive research must still be done on child-friendly formula-
tions and paediatric pharmacokinetics to make the treatment of MDR-TB in
children eﬀective.
2.6 Conclusion: Real-World Problem
This chapter discussed the global epidemic of MDR-TB, highlighting the under-
performing SLD supply chain as one of the main causes for the spread. Six
IOM workshops have been held around the world to discuss the growing prob-
lem of DR-TB. This chapter highlights the main themes and findings presented
at these workshops. The specific issues in both the upstream and downstream
segments of the supply chain that are acting as barriers to the success of the
supply chain are also summarised in detail.
Chapter 3 will discuss the techniques available for modelling supply chains, in
order to model the real-world downstream supply chain.
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3
Modelling Supply Chains
This chapter describes the concept of modelling supply chains and why models
are so useful for decision-making. Furthermore a supply chain is characterised
as a complex adaptive system (CAS) to be modelled appropriately for decision-
making. Finally, the paradigms of modelling techniques available for modelling
supply chains are described; along with their suitability to specific problems.
In an attempt to increase supply chain performance and achieve the supply
chain management objective of meeting customer demand with minimal lead-
times for high quality products at low costs; companies need to have a bet-
ter understanding and better visibility of the entire supply chain (Keramati,
2011). Supply chains are integrated systems involving upstream and down-
stream flows that are rarely ever linked in a linear way, therefore supply chain
decision-making is a complex process. Modelling and analysis is therefore crit-
ical in the decision stage to gain a better understanding and to predict system
performance (Biswas and Narahari, 2003). Appropriate models and studies are
needed to aid in making decisions in such complex networks (Behdani, 2012).
3.1 Modelling
Very simply, a model can be described as a miniature representation of some-
thing and more specifically a graphical, mathematical or physical representa-
tion of a concept, system or an aspect of the real-world. Models are developed
because they are on a smaller scale and thus easier to work with than the
real system. Models use equations to represent the interconnectedness of a
real-world system and only contain the relevant features to achieve a specific
objective (Ford, 2009).
Modelling can therefore be described as the action of building a simplified rep-
resentation of a system, with the goals of: facilitating understanding; provid-
ing predictions of the system’s performance measures; and/or solving problems
37
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 3. MODELLING SUPPLY CHAINS 38
(Altiok and Melamed, 2010).
3.2 Complex Adaptive Systems
3.2.1 Overview of Complex Adaptive Systems
Organisations that exhibit adaptivity and exist in complex environments with
numerous interactions should be identified as a complex adaptive system (CAS)
(Pathak et al., 2007). Throughout literature there is general agreement with
regard to the specific characteristics that define a CAS. The definitions and
properties of a CAS as described by Choi et al. (2001); Surana et al. (2005)
and Behdani (2012) are summarised below.
Choi et al. (2001) list the principles of a CAS, stating that the underlying
dynamics of CASs fall under three main sections: internal mechanisms, envi-
ronment and the co-evolution of both the internal mechanisms and the envi-
ronment. These principles are listed in Table 3.1.
Table 3.1: Underlying dynamics of a CAS
Internal Mechanisms Co-evolution Environment
Self-organisation & Emergence Quasi-equlibrium Dynamism
Connectivity Non-linear Rugged landscape
Dimensionality Non-random future
Surana et al. (2005) have a very similar viewpoint and list the typical charac-
teristics of a CAS as:
• Non-linear dynamics involving spatial and temporal eﬀects;
• Coexistence of competition and cooperation;
• Strongly coupled degrees of freedom;
• Quasi-equilibrium state;
• Adaption and evolution;
• Structures spanning several scales; and
• Emergent behaviour and self-organisation.
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Finally, Behdani (2012) classifies the properties that characterise a CAS into
micro- and macro-level properties. The micro-level properties refer to the
building blocks of the system and the macro-level properties describe the outer
structure of the system. Table 3.2 divides the list of characteristics used to
describe a CAS under either micro- and macro-level properties.
Table 3.2: Micro- and macro-level properties of a CAS
Micro-Level Properties Macro-Level Properties
Numerousness & Heterogeneity Emergence
Local interactions Self-organisation
Nestedness Co-evolution
Adaptiveness Path dependency
The characteristics that define a CAS, as described by Choi et al. (2001);
Surana et al. (2005) and Behdani (2012) are all very similar and can be
summarised under the main headings: emergence and self-organisation, co-
evolution and adaption, coexistence of competition and cooperation, non-linear
dynamics, quasi-equilibrium, nestedness and path dependency.
3.2.1.1 Emergence and Self-organisation
Surana et al. (2005) state that emergent systems emerge through a natural
process of order and spontaneity. Furthermore, as emphasised by Choi et al.
(2001) and Behdani (2012), the behaviour of the CAS as a whole also emerges
from the interactions between the individual sub-systems, thereby making it
self-organising. Therefore emergent behaviour is the process whereby new
properties and patterns arise without external influence on the system (self-
organisation) (Choi et al., 2001; Behdani, 2012).
3.2.1.2 Co-evolution and Adaption
The components in a CAS changes over time (Behdani, 2012). According to
Choi et al. (2001), this constant evolution creates a dynamic system. Kaisler
and Madey (2009) reiterate that a CAS has the ability to change its behaviour
in response to changes in the environment to maintain some invariant state.
3.2.1.3 Coexistence of Competition and Cooperation
A CAS consists of an aggregate of agents and connections between these agents
(Choi et al., 2001). These numerous elements interact with each other at both
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social and physical levels. As stated by Surana et al. (2005), the diﬀerent
individuals in a complex system regularly have conflicting objectives, therefore
competition results in the sharing of resources or the contention of them.
3.2.1.4 Non-linear Dynamics
Complex systems behave in a non-linear manner, in other words the magni-
tude of an input is not necessarily matched to the output (Choi et al., 2001).
Therefore there is usually no direct correlation when events take place within
the system. Surana et al. (2005) specifies that the characteristics of a CAS
change as the workload and configurations change, thereby creating non-linear
behaviour.
3.2.1.5 Quasi-equilibrium
A complex system tends to maintain a quasi-equilibrium state even in response
to disturbances; however when the equilibrium state is disrupted, a structural
change results (Choi et al., 2001; Surana et al., 2005). This structural change
results in small events causing a cascade of changes which lead to a system
reconfiguration. Therefore control and stabilisation become very challenging
in such a system (Choi et al., 2001).
3.2.1.6 Nestedness/Dynamism
The environment of a CAS is made up of many smaller CASs, therefore changes
to one system cause changes to others, triggering collective environmental
changes (Choi et al., 2001; Behdani, 2012). CASs can be changed through
altering the boundaries of the system with connections amongst agents. More-
over these environment changes can impose new rules and norms within the
system (Choi et al., 2001).
3.2.1.7 Path Dependency/Non-random future
Current, and future states and decisions in a CAS depend on past states and
decisions (Choi et al., 2001). Therefore past decisions made by an individual
entity will constrain the current and future options for the entire system. Choi
et al. (2001) emphasise the fact that although determining the exact behaviour
of a system in the future is impossible, there are patterns of behaviour that
can be used for an approximate prediction due to the path dependency factor.
3.2.2 Supply Chains as Complex Adaptive Systems
CASs consists of many mutually interacting subsystems that adapt over time
without any centralised control over the system (Surana et al., 2005). Accord-
ing to Surana et al. (2005), recognising that a supply chain is a CAS can lead to
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eﬀective ways of understanding and modelling their dynamics. Supply chains
can therefore be solved and optimised by making use of approaches that are
similar to those used for CASs. A number of literature sources are available
framing supply chains as CASs. Table 3.3 summarises the properties supply
chains possess that frame them as CASs.
Table 3.3: Framing a supply chain as a CAS
CAS property Supply chain property
Emergence and
Self-organisation
A supply chain emerges with no one external factor delib-
erately controlling it (Choi et al., 2001). Decisions made
downstream lead to amplifying eﬀects upstream eg. bull-
whip eﬀect and robustness (Surana et al., 2005).
Co-evolution and
Adaption
The supply chain is constantly evolving to: keep up with
competition; and satisfy customers. A supply chain reacts
to the environment and actions of other actors in the supply
chain, thereby making changes to both organisational goals
and supporting infrastructure (Surana et al., 2005). The ac-
tors in the supply chain change their perceptions and policies
based on previous interactions and the changing economy.
Coexistence of
Competition and
Cooperation
In a supply chain, the various entities either have conflicting
or mutual objectives and therefore either share resources or
don’t (Surana et al., 2005).
Non-linear Dynamics Customers can make transactions at any time with no regard
for the existing workload at any point in the supply chain.
The characteristics of the network change as the workload
diﬀers, resulting in non-linear dynamic behaviour (Surana
et al., 2005). Furthermore, supply chains have a wide geo-
graphical span, contributing to the non-linear character of
the network.
Quasi-equilibrium The supply chain tends to remain stable in response to ex-
ternal factors.
Nested-
ness/Dynamism
Each entity in the supply chain has a plant and each of these
plants too have internal departments (Behdani, 2012). The
membership of a supplier base is constantly reshuﬄed (Choi
et al., 2001).
Path
Dependency/Non-
random
future
Each decision downstream in the supply chain influences
future states and causes oscillating changes upstream (Choi
et al., 2001). Past decisions made by an individual entity in
the supply chain will constrain the current options for the
entire system.
3.3 Supply Chain Modelling Techniques
A supply chain performs the following functions: procurement of materials;
transformation of these materials into finished products; and the distribution
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of these finished products (Ivancevich and Duening, 2005). Supply chains
have been shown to be complex and therefore require appropriate models and
simulation studies to manage this complexity and broadness. Although vast
amounts of literature are available on supply chain modelling techniques; very
few agree on the taxonomy. Furthermore there is limited literature available
regarding modelling methodologies that would aid in evaluating which tech-
niques are appropriate for specific supply chains.
Starting in 1998, supply chain modelling techniques have been grouped in
diﬀerent ways, creating various taxonomies. Beamon (1998) classified sup-
ply chain modelling into four groups namely: deterministic analytical models;
stochastic analytical models; economic models; and simulation models. Four
years later, Min and Zhou (2002) classified supply chain modelling into: de-
terministic models; stochastic models; hybrid models; and IT-driven models.
Hung et al. (2006) classified supply chain models into only two groups: an-
alytical models; and simulation models. Penlope (2007) then classified the
models into the groups: process models; statistical models; neural networks;
discrete-event models; mathematical models; and systems dynamics models.
Cope (2008) subdivided analytical models into: mathematical models; simu-
lation models; spreadsheet process maps; and hybrid models, whereas Acar
et al. (2010) subdivided analytical models into: deterministic models; stochas-
tic models; and hybrid models. Keramati (2011) divided the models into: pro-
cess models; statistical models; and mathematical models, where mathematical
models were further subdivided into hybrid models, optimisation models, IT-
driven models, analytical models and simulation models. Finally, Mohammadi
and Mukhtar (2013) classified modelling into: analytical models; process mod-
els; and simulation models, where analytical models were further subdivided
into mathematical models, statistical models and economic models.
Making use of all the diﬀerent taxonomies provided in literature, many re-
searchers support the idea that supply chain models should be classified as
deterministic, stochastic and hybrid at the broadest level (Beamon, 1998; Min
and Zhou, 2002; Keramati, 2011). Deterministic models contain only model
parameters that are fixed and certain, whereas stochastic models take random
parameters into accounts (Keramati, 2011). Hybrid models are a combination
between deterministic and stochastic models. The taxonomy for supply chain
modelling techniques that will be used for this research project is shown in
Figure 3.1, and is adapted from Mohammadi and Mukhtar (2013):
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Figure 3.1: Classification of supply chain modelling techniques (adapted from
Mohammadi and Mukhtar (2013))
The three most prominent modelling techniques for supply chains, as classi-
fied by Mohammadi and Mukhtar (2013) and shown in Figure 3.1; namely
analytical, process and simulation models will be discussed in more detail.
3.3.1 Analytical Modelling
An analytical model is created by a set of equations or algorithmic procedures,
which are then solved. The solutions to the equations are used to obtain
performance measures (Altiok and Melamed, 2010). In other words it is a set of
equations describing performance (Caliri, 2010). An analytical model describes
the collection of measured and calculated behaviours over a finite period of
time. Analytical models concisely describe a problem, provide a closed series
of solutions, allow the easy assessment of impacts caused by changes in inputs
and outputs and has the ability to reach an optimal solution (Campuzano and
Mula, 2011). However the limitations of analytical modelling may include: the
mathematics behind the problem being too complicated; or that the required
assumptions may not be realistic enough.
3.3.2 Process Models
According to Cope (2008), process models are static, deterministic tools that
do not take changes or variability in the system into consideration. These
models logically capture the systems components and behaviours with respect
to the modelling objectives. According to Keramati (2011), process models
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can be descriptive, prescriptive, iconic or symbolic. The following types of
process models are used to model supply chains:
3.3.2.1 Supply Chain Operations Reference Model
The Supply Chain Operations Reference (SCOR) model is an example of a pro-
cess model as it provides a framework for metrics, best practises and processes.
SCOR is based on six distinct management processes (Supply Chain Council,
2012): plan; source; make; deliver; return; and enable. These key manage-
ment processes focus on the eﬃciency of internal processes, which therefore
makes it more suitable for internally focused environments and not for organ-
isations looking for extended supply chain eﬃciency. SCOR also identifies five
core supply chain performance attributes: reliability; responsiveness; agility;
costs; and asset management (Supply Chain Council, 2012). This model is
therefore ideal for defining supply chains and for providing a basis for supply
chain improvements (Keramati, 2011). Moberg and Vitasek (2008) state that
the SCOR model was developed to provide a standard for measuring supply
chain performance and allowing users to address, improve and communicate
supply chain practices. This model is therefore focused on processes that use
the concept of continuous improvement in the organisation. The SCOR model
is therefore most appropriate for decision making and resource allocation.
3.3.2.2 Global Supply Chain Forum Model
According to Moberg and Vitasek (2008), the Global Supply Chain Forum
(GSCF) model focuses on the integration of services. The GSCF model shows
that supply chain management (SCM) represents a single company’s orien-
tation for total eﬀectiveness and eﬃciency by integrating eight key processes
throughout the supply chain (Campuzano and Mula, 2011):
• Customer relationship management;
• Customer service management;
• Demand management;
• Order fulfillment;
• Manufacturing flow management;
• Supplier relationship management;
• Product development and commercialisation; and
• Returns management.
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This model however does not provide benchmarking information like the SCOR
model. Therefore this model is most appropriate as an enhancement for ad-
vanced supply chains with established measurements and frameworks. The
model also works better for supply chains that have a more constant demand
(Moberg and Vitasek, 2008).
3.3.2.3 Business Process Model
A business process is the combination of activities in an organisation being
structured in logical order. A business process model provides an understand-
ing of the business process itself. The process is defined as a specific ordering
and steps of work activities with clearly defined inputs and outputs. The model
therefore illustrates the steps and activities involved in a specific process in a
business (Sparx Systems, 2004).
3.3.3 Simulation Modelling
Altiok and Melamed (2010) define simulation modelling as the process of creat-
ing a computer representation that is executed to produce a number of sample
histories. Campuzano and Mula (2011) characterise a simulation model as
being quantitative, mathematical, computer-based and dynamic. According
to Campuzano and Mula (2011), simulation models can describe highly com-
plex systems and can either be used to experiment with non-existing systems or
with existing systems. Furthermore simulation modelling is not solved through
mathematical analysis and therefore does not require advanced mathematics.
Simulation can also be an important tool in uncovering the causes and eﬀects of
supply chain performance. However the drawback with simulation modelling
is that the models cannot generate a closed set of solutions i.e. each change
in an input variable requires a separate solution, however it allows the obser-
vation of output in terms of input values. Another drawback mentioned by
Campuzano and Mula (2011), is the challenge of validating a simulated model.
The objectives of supply chain simulation are as follows (Campuzano and Mula,
2011):
• Understanding all parts of the supply chain and its processes to generate
knowledge;
• Proposing diﬀerent scenarios and performing what-if analyses to improve
the supply chain;
• Determining the robustness of a strategy without disturbing the real
supply chain; and
• Quantifying the benefits resulting from the decision making.
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According to Borshchev and Filippov (2004); Owen et al. (2010); Heath et al.
(2011) and Behdani (2012), three main paradigms have been researched for
the simulation of specifically complex systems. These paradigms are: system
dynamics; discrete-event simulation; and agent-based simulation.
3.3.3.1 System Dynamics
System dynamics (SD) can be described as a computer-aided approach for
solving complex problems in terms of policy design (Angerhofer and Angelides,
2000). SD is a deterministic modelling methodology that was created in the
1950s by Jay Forrester (Lane and Sterman, 2011). Forrester defined SD as “the
study of information feedback characteristics of industrial activity to show how
organisational structure, amplification (in policies), and time delays (in deci-
sions and actions) interact to influence the success of the enterprise” (Anger-
hofer and Angelides, 2000). To capture the complexity of the system, the
‘feedback loop’ concept was suggested by Forrester in 1969. Therefore the
feedback loop is the basic building block of a complex system and SD is a
feedback-based simulation paradigm (Behdani, 2012). Control is exercised
in SD by varying the ratio of input variables, in order to change flows and
therefore levels (outputs). Sterman (2000) states that the main objective of
modelling with SD is to understand the structural causes that result in specific
behaviour of a system.
According to Angerhofer and Angelides (2000), SD has been used in various
domains:
• Corporate planning and policy design;
• Energy and the environment;
• Economic behaviour;
• Software engineering;
• Biological and medical modelling;
• Dynamic decision making;
• Complex non-linear dynamics;
• Theory development in natural and social sciences; and
• Supply chain management.
The reason SD is applied to so many domains is because it can combine both
qualitative and quantitative information (Brailsford and Hilton, 2001; Heath
et al., 2011). The qualitative model identifies elements that are crucial to the
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system and then presents them in influence diagrams or causal loop diagrams
where they are connected by arrows and ‘S’ and ‘O’ signs to show the direction
of influence. The ‘S’ stands for same i.e. the variables move in the same direc-
tion, and the ‘O’ shows that they move in opposite directions. Feedback loops
can either be classified as ‘balancing loops’ (negative) or ‘reinforcing loops’
(positive). Balanced loops retain a steady state, whereas reinforcing loops re-
sult in uncontrolled growth (Brailsford and Hilton, 2001; Heath et al., 2011).
However the overall eﬀect of all the feedback loops in a complex system, such
as a supply chain, cannot be determined with only the causal loop diagram
as it may not be obvious which feedback loop dominates the system. This is
where it becomes necessary to quantify the system (Heath et al., 2011; Be-
hdani, 2012). In a quantitative model, the causal loop diagram gets replaced
by a flow diagram, called a ‘stock-flow model’. A series of stocks (levels) and
flows (rates) are used to model the system. Stocks are accumulations of rates
of flow and flows are outputs of decision rules (Behdani, 2012). The state
changes are continuous and the model is solved with diﬀerential equations
(mostly numerical integration) (Brailsford and Hilton, 2001; Behdani, 2012).
Making use of SD modelling for supply chain management specifically, dates
back to 1958. Forrester (1958) simulated a basic supply chain consisting of:
a factory; a factory warehouse; distributors; and retailers with information
flows throughout the supply chain. The feedback principle of SD facilitates
modelling and qualitative simulation analysis to design and control the sup-
ply chain structure (Campuzano and Mula, 2011). Furthermore Campuzano
and Mula (2011) state that SD facilitates experiments with supply chains.
SD modelling can therefore promote high-level understanding of large systems
and capture aspects of supply chain behaviour; specifically the ‘bullwhip eﬀect’
(Dale Compton et al., 2005).
System dynamics is usually used at higher, strategic levels to gain insight into
the interactions between parts in a complex system and how they influence an
overall system (Brailsford and Hilton, 2001). The aim of SD modelling is to
gain an understanding of the feedback dynamics and system behaviour. The
main strength of SD lies in modelling the adaptiveness in a complex system,
as feedback loops are the key drivers of dynamic behaviour in a SD model
(Sterman, 2000). The use of feedback loops and delays makes it possible
to model a highly complex and dynamic system at a high level over time.
However the drawback of high level modelling of complex systems is that it is
done with uncertainty, and therefore parameters must be estimated carefully
(Dale Compton et al., 2005). This uncertainty can be found in the data used
in the model, the assumptions made during modelling and the diﬃculty in
modelling human behaviour.
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3.3.3.2 Discrete Event Simulation
Discrete-event simulation (DES) models systems as networks of queues and
activities (Brailsford and Hilton, 2001). The conceptual model in DES is an
activity diagram (analogous to a causal loop diagram in SD), which shows the
logic of the flow of entities through queues and activities. According to Altiok
and Melamed (2010), in this paradigm of simulation, the model possesses a
state at a point in time. This state is a set of data that captures the vari-
ables of the system and can thus be defined in many ways. The state’s path
over time is a step function whose jumps are triggered by discrete events (Al-
tiok and Melamed, 2010). Kleijnen (2004) and Campuzano and Mula (2011)
describe the two main characteristics of DES as: (i) representing individual
events; and (ii) incorporating uncertainty. The evolution of the model is run
by a chronologically ordered event list over time. In other words, the events
are listed in their scheduled order of occurrence with the event at the top of
the list being the most impending event. The occurrence of an event results
in taking an event oﬀ the list and executing it.
The general algorithm for the DES simulator is an infinite loop of the following
steps (Altiok and Melamed, 2010):
• Step one:
Set the simulation clock to an initial time and generate and schedule
events;
• Step two:
If the event list is empty, terminate the simulation. If the list is not
empty unlink the imminent event from the event list;
• Step three:
Advance the clock to the time of the imminent event and execute it; and
• Step four:
Loop back to step two.
Altiok and Melamed (2010) state that the DES paradigm has a distinct feature
wherein nothing changes the state except the occurrence of an event. In other
words the state stays constant in-between events. Large and complex systems
can be represented by DES, as the processing of events can be as detailed
as desired, and increasingly complex systems can be built from subsystem
components (Altiok and Melamed, 2010). However the drawback is that DES
models often require large amounts of data (Brailsford and Hilton, 2001).
3.3.3.3 Agent-Based Simulation
Agent-based simulation (ABS) is based on local interaction between agents
(Macal and North, 2006). Therefore no central authority exists controlling
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the operation of the system or the movement between states. Macal and
North (2006) describe agents as discrete entities with unique characteristics
and behaviours. The essential characteristics of an agent are (Macal and North,
2010):
• An agent is uniquely identifiable;
• An agent has behaviours;
• An agent has a state that changes with time;
• An agent is social as it has dynamic interactions with other agents; and
• An agent is autonomous and self-directed.
An agent’s capability to act autonomously is the most important characteristic
of an agent. Agents can therefore act on their own and make independent
decisions without external control (Macal and North, 2010). In addition to
their essential characteristics, agents may also be: adaptive; goal-directed;
and heterogeneous (in terms of their resources, memory and sophistication)
Examples of agents range from robots to people to organisations (Macal and
North, 2006). According to Macal and North (2010), an ABS model has three
elements:
• A set of agents and their behaviours;
• A set of agent relationships and methods of interaction (a topology of
connectedness defines how and with whom they interact); and
• The agent’s environment (agents interact with both other agents and the
environment).
Agents are required to repeatedly execute their interactions for the model to
run. Agent-based modelling is unique in the fact that the modelling begins
and ends with the agent’s perspective (Macal and North, 2006). ABS models
have been applied to supply chains due to the fact that the models have proven
to be appropriate for studying complex systems. ABS models are specifically
used in the context of supply chains in two ways: (i) calibration of the agent
parameters with real-world data; and (ii) exploration of operating policies and
modes of operations (Zhang and Bhattacharyya, 2004). More specifically Owen
et al. (2010) state that ABS is most appropriate for the following supply chain
themes: information sharing; human behaviour; supply chain optimisation;
distributed supply chain; collective customer collaboration; market dynamics;
e-manufacturing optimisation; supply chain dynamics; and modelling control
elements.
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Summary of Paradigms:
The main properties of the three simulation paradigms are summarised in Ta-
ble 3.4. Furthermore, the three paradigms can also be classified according
to their approach. The ABS modelling approach models a system by mod-
elling the individual entities and interactions that make up a system; which
is described as the ‘bottom-up approach.’ Whereas SD modelling is done by
breaking a system into its main parts and modelling the component interac-
tions; known as the ‘top-down approach’ (Heath et al., 2011). According to
Behdani (2012), DES also has a ‘bottom-up approach’ in terms of modelling.
Table 3.4: Main characteristics of SD, DES and ABS (adapted from Behdani
(2012))
Property System
Dynamics
Discrete-
Event
Simulation
Agent-Based
Simulation
Oriented
toward
System Process Individual
Entities Homogeneous Heterogeneous Heterogeneous
Dynamic
behaviour
driver
Feedback loops Event
occurrence
Agents,
decisions,
interactions
Mathematical
formulation
Stock and flow Event, activity,
process
Agent,
environment
Time Continuous,
discrete
Discrete Discrete
Experiment
method
Changing
system structure
Changing
process
structure
Changing agent
rules
(interaction
rules) & system
structure
Structure Fixed system Fixed process Not fixed
system
3.4 Data Availability
The data available for the process of modelling will also be a factor when
deciding which modelling technique to make use of. Because this is a public
healthcare study, there are limitations in collecting data due to confidentiality
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and ownership of data (Nicholson et al., 2013). According to Wallengren et al.
(2011), more recent data has shown that the burden of DR-TB has been under-
estimated. Data about product-use, patient enrolment rates and plans from
in-country DR-TB programs is also lacking (Nicholson et al., 2013). As for
data transparency, there is some disagreement about whether the data should
be fully disclosed due to security concerns.
Throughout the whole MRD-TB SLD supply chain there is inadequate data
collection, which will limit the data collection process for this study. Limited
data availability will aﬀect the detail to which the model can be created, and
therefore some processes may need to be lumped together which will lead
to model simplification. The danger of model simplification is the fact that
critical system components may be missed, which may cause diﬃculties with
model validation (Chung, 2004). According to Heath et al. (2011), the data
requirements for a SD model is generally less than that for a DES model.
3.5 Conclusion: Modelling Supply Chains
This chapter introduced the concept of modelling supply chains and discussed
the modelling techniques that are available to model supply chains, namely:
analytical models; process models; and simulation models. Furthermore, the
supply chain is classified as a CAS in order to select the most appropriate mod-
elling technique. However as specified by Surana et al. (2005) and Behdani
(2012) simulation has been the primary tool for modelling CASs. This is due
to the fact that it is a challenge to determine which individual strategies leads
to the collective behaviour of such a complex system i.e. reverse engineering.
Simulation however makes these investigations possible (Surana et al., 2005).
There are also various other reviews which have investigated simulation mod-
elling in supply chains: Beamon (1998); Angerhofer and Angelides (2000); Min
and Zhou (2002); Terzi and Cavalieri (2004); Akkermans and Dellaert (2005);
Campuzano and Mula (2011). Therefore the primary focus of this chapter
is on simulation modelling, as it will be the method used to model the SLD
supply chain, discussing in detail the three main paradigms thereof: SD; DES;
and ABS.
Chapter 4 will discuss the selection methodology used to identify the paradigm
chosen to model the downstream MDR-TB SLD supply chain. Furthermore,
the suggestions made at the IOM Forum workshops for strengthening the
global MDR-TB SLD supply chain, and the best practises for supply chain
performance improvement as highlighted in the SCOR model will also be dis-
cussed. The type of issues that are tested using a model is one of the most
prominent factors when deciding which modelling technique to use. These
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 3. MODELLING SUPPLY CHAINS 52
suggestions and best practises will therefore also be evaluated to aid in the
process of selecting the appropriate modelling technique.
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Chapter 4
Confronting the Real-World
Problem
This chapter highlights the suggestions that have been proposed at the six
IOM Forum workshops to control the global spread of MDR-TB. The sugges-
tions that are both relevant to strengthening the supply chain specifically and
within the scope of this study will be analysed and then tested using a model,
to investigate their impact on the overall supply chain. Additionally this chap-
ter highlights the specific performance attributes that are used to evaluate a
supply chain, as well as the best practises that should be used to improve upon
the performance of the supply chain. The performance attributes that will be
tested include: reliability; responsiveness; and agility, as listed in the SCOR
model. Finally, based on these suggestions and best practises, the process by
which the appropriate simulation paradigm was chosen to model the down-
stream SLD supply chain is described.
4.1 IOM Suggestions for Confronting the
Global MDR TB Crisis
This section lists and describes the IOM’s potential strategies for combating
the various problems with MDR-TB, as discussed in Chapter 2. The sugges-
tions will be divided into two main categories: (i) ‘general strategies’; and (ii)
‘supply chain strategies,’ as only the proposed solutions regarding the physical
supply chain will be investigated in this study. These strategies have however
not yet been tested or implemented, thereby requiring a model to simulate the
eﬀects and impacts that these suggestions will have on the supply chain.
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4.1.1 General Suggestions
These suggestions combat the general MDR-TB crisis; and although they aﬀect
the supply chain they are not directly related to the physical supply chain.
Therefore these proposed solutions will not be able to be tested in the SLD
supply chain model.
4.1.1.1 Diagnostics and Laboratory Capacity
Due to the limitations of smear microscopy (the most common TB detection
test), there is an urgent need for point-of-care (POC) testing and an increase
in in-country laboratory capacity. Specific suggestions to address the diagnosis
problems, listed from Keshavjee and Seung (2008) in the white paper for the
Institute of Medicine of the National Acadamies include:
• Giving priority to research and funding for immediate development and
deployment of POC testing for both TB and MDR-TB, globally;
• Utilising excess laboratory capacity in wealthy regions for the TB culture
testing of low income countries;
• Improving in-country laboratory networks and coordination of private
laboratories, i.e. a central body should be in charge of the entire labo-
ratory network (Olson et al., 2014);
• Giving priority to paediatric treatment (diagnostic techniques cannot
identify many cases of paediatric TB);
• Creating long-term on-site technical assistance for TB culturing and test-
ing; and
• Increasing sustainable funding from donors for the construction of labo-
ratories.
Olson et al. (2011) state that although candidates for POC testing exist (as
discussed in Chapter 2), strategies need to be put in place to make them
mainstream. However, Olson et al. (2011a) note that developing POC testing
for the mainstream will require safe laboratory and health care infrastructure
to protect against drug-resistant TB. There is also an urgent need to develop
more laboratory tests that are capable of not only detecting drug-resistant
strains of TB but also drug susceptibility to new anti-TB drugs. According
to Hoﬀner (2013), more resources should be made available for implementing
more rapid tests, as wide as possible.
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4.1.1.2 Quality Drug Supply
One of the major causes of the rapid spread of MDR-TB is the manufacture of
counterfeit SLDs. There are a number of approaches that have been suggested
by the various participants in the workshops to address this problem; which
include:
• Increasing the number of manufacturers of QA SLDs, to both lower prices
and ensure availability (Keshavjee and Seung, 2008);
• Developing a mechanism to make these QA drugs available at pre-negotiated
prices to programs purchasing via the GDF (Keshavjee and Seung, 2008);
• Developing an operational strategy to improve demand forecasting (Nichol-
son et al., 2013; Olson et al., 2014);
• Developing a mechanism for pooled procurement to increase the pre-
dictability of the demand (Nicholson et al., 2013);
• Reducing the GDF procurement barriers to allow countries to directly
purchase drugs from their own quality assured suppliers (single suppliers
and manufacturers are not enough)(Giﬃn and Robinson, 2009; Olson
et al., 2011);
• Increasing the buﬀer stock of SLDs with optimal size, scope and design to
facilitate rapid delivery of drugs (Keshavjee and Seung, 2008; Nicholson
et al., 2013);
• Increasing options available for treating MDR-TB, by optimising current
treatment regimens (Keshavjee and Seung, 2008);
• Developing new anti-TB drugs by increasing TB clinical trial capacity
(Keshavjee and Seung, 2008);
• Providing incentives to countries to procure QA drugs (Bloom, 2013);
• Creating public-private partnerships to do what neither can do alone
(Bloom, 2013); and
• Strengthening the regulatory authorities in high burden MDR-TB coun-
tries, and in countries that export the drugs (Olson et al., 2011).
4.1.1.3 Infection Control and Treatment Delivery
The global crisis of MDR-TB can only be controlled if the further spread of the
disease can be prevented. Due to the fact that drug-resistant TB can be trans-
mitted from person to person and that it can be transmitted so easily through
the air, transmission control is critical. Suggestions pertaining to preventing
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specifically transmission of MDR-TB include: patient management; starting
treatment as early as possible to reduce transmission; and exploring whether
making use of surgery to reduce transmission is possible (Olson et al., 2012).
Nardell (2013), advocates a paradigm with the acronym FAST to refocus TB
transmission control, as it should be as important a focus of attention as new
methods for diagnosis:
• Find TB cases.
The focus should be on rapid molecular diagnosis in order to start treat-
ment as soon as possible to slow the rate of transmission.
• Active case finding.
The focus here is on cough surveillance at all entrance points of hospitals.
The cough detection should lead to diagnosis and ultimately eﬀective
therapy within a matter of days. The incidence of TB amongst the
health care workers should also be monitored.
• Separate safely and reduce exposure.
Environmental control, and respiratory protection are critical until the
eﬀective treatment is carried out. The building design and engineering
capacity need to support and implement these controls. Health care
workers should be given comprehensive preventative therapy for TB.
• Treat eﬀectively based on drug susceptibility testing (DST).
Rapid molecular DST should be done with technologies such as the Gen-
eXpert MTB/RIF in order to treat for the correct strain of TB.
Treatment delivery is just as critical as transmission control, as successful
treatment will not only prevent further transmission, but also save lives. Sug-
gestions made by Keshavjee and Seung (2008) in the white paper for the Insti-
tute of Medicine of the National Acadamies for improving treatment delivery
include:
• Promoting universal treatment for both drug susceptible and drug-resistant
TB with national TB control strategies in order to build capacity for
MDR-TB treatment;
• Integrating universal treatment for TB into HIV treatment initiatives;
• Improving the international technical assistance provision system for suc-
cessful regional MDR-TB treatment programs;
• Implementing ambulatory-based treatment, as it has the potential to be
a safe means of treating the largest amount of patients in the shortest
amount of time;
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• Training villagers to become community health workers in resource-poor
environments to establish community-based care (partnerships between
the health care system and communities);
• Scale-up of successful treatment programs;
• Collaborating with private-sector laboratories and treatment providers;
and
• Integrating infection control into national TB control strategies.
4.1.1.4 Financing
The procurement of SLDs is an expensive task, therefore the issue of how to
best finance this procurement resonated through the report written on the fifth
IOM workshop held in Washington DC in 2012. There have been many sug-
gestions with regard to innovative financing strategies. Nicholson et al. (2013)
states that participants discussed two important factors to consider with re-
gards to financing: (i) the expansion; and (ii) the increased predictability and
flexibility of the funding pool. It is suggested that the improved predictability
could potentially improve the market health and facilitate program implemen-
tation. On the other hand, the improved flexibility could possibly reduce the
finances lost to ‘use’ and match resources more appropriately with number of
patients (Nicholson et al., 2013).
Pooled financing is one of the flexible financing strategies suggested by the
participants in the workshops. This mechanism would allow the withdrawal
of funds from a larger pool, sidestepping the process of having to access funds
in advance when the requirements are uncertain, due to inaccurate demand
forecasting (Nicholson et al., 2013). Bloom (2013) suggests increased funding
from the Global Fund and an up-front pooled capital fund to reduce the need
for separate negotiations with producers. Additional financing strategies that
were proposed include ‘push’ and ‘pull’ mechanisms. ‘Pull’ mechanisms create
demand, while ‘push’ mechanisms create incentives to enter the market. Ta-
ble 4.1 lists the push and pull strategies suggested by Atun (2012), to address
the funding shortfalls and unpredictable financing.
Vincent (2012), suggests four opportunities that the Global Fund and other
donors should support through the GDF, that she assumes will half current
procurement time delays:
• Promotion of flexible and pooled funding;
• Expansion of the strategic rotating stockpile (SRS) to expedite delivery
to countries and provide flexibility to match supply with demand;
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• Supporting local production of QA SLDs in BRICS countries (high MDR-
TB burden countries) to provide incentives for them to use QA SLDs and
QA API/FPP; and
• Shifting the focus of donors from FLDs to SLDs by freeing up more funds
for SLDs.
Table 4.1: Innovative push and pull mechanisms
Push Strategies Pull Strategies
Public private partnerships Long term instruments (TB bond)
R&D credits Expanded health insurance (domestic level)
Accelerated approval Catastrophic risk insurance to cover MDR-
TB (domestic level)
Venture capital - impact funds
Outcome-based financing (reward successful
approaches)
Furthermore USAID have a three-pronged approach for making aﬀordable,
quality SLDs available around the world:
• Improve and expand global SLD supply chain.
To achieve this USAID suggest: coordinating with and providing global
support for the GDF; harmonising treatment regimes; and shifting sup-
port and data from FLDs to SLDs.
• Engage manufacturers in production of QA SLDs.
Promoting QA SLDs involves: assisting API and FPP manufacturers to
become prequalified; increasing the number of API sources; supporting
development of guidelines to expedite registration of prequalified SLDs;
supporting the development of public pharmacopeial standards; and im-
proving diagnostic tests.
• Assist countries in securing QA SLDs.
In order to do this USAID will need to provide technical assistance at
a country level. This technical assistance involves: early warning sys-
tems for stockouts; in-country and regional assistance in pharmaceutical
management; developing new training platforms; improving information
management systems; and promoting surveillance of SLD utilisation and
TB/HIV co-medication safety.
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 4. CONFRONTING THE REAL-WORLD PROBLEM 59
4.1.2 Supply Chain Strategies
These proposed suggestions directly aﬀect the physical supply chain and are
assumed to strengthen the MDR-TB SLD supply chain if they are put into
practise. Many of these suggestions have already been discussed along with
the general suggestions, however are emphasised here as solutions that relate
to the physical supply chain operations. These suggestions are only mentioned
briefly here, with all the necessary detail set out in Chapter 6, where the
diﬀerent suggestions are analysed.
4.1.2.1 Providing Incentives to Suppliers and Manufacturers
As previously mentioned, one of the biggest challenges in the SLD supply
chain is the lack of suppliers and manufacturers of QA drugs. An increase in
quality assured manufacturers will not only decrease the prices of SLDs but
also increase their availability (Keshavjee and Seung, 2008). The high risks
facing suppliers along with the low incentives are direct causes of suppliers
being hesitant to enter the SLD market. Many participants in the workshops
discussed implementing incentives to get more manufacturers and suppliers to
enter the SLD market and to get manufacturers to produce QA drugs (Nichol-
son et al., 2013). One of the ways to create incentive includes aggregating and
sharing risk between all the players throughout the drug supply chain (Giﬃn
and Robinson, 2009; Olson et al., 2012).
4.1.2.2 Operational Strategy for Improved Forecasting
The suggestion provided by Bloom (2013) to improve demand forecasting in-
cludes linking TB forecasting with the forecasting of other diseases and drugs
- such as HIV and malaria - whilst also having input from experts from both
the public and private sector. It has also been suggested that the develop-
ment of an operational strategy to improve demand forecasting be prioritised
(Nicholson et al., 2013). Furthermore regular interaction should be facilitated
with manufacturers around demand forecasting. Developing a mechanism for
pooled procurement, as well as bundling SLDs with other well-established drug
supply chains, could possibly increase the predictability and volume of demand
thereby improving demand forecasting (Nicholson et al., 2013).
4.1.2.3 Inventory Management
Nicholson et al. (2013) suggest maintaining a buﬀer inventory of SLDs with
optimal size and scope to ensure a constant supply of SLDs. This should
not only reduce lead times, but also prevent stock-outs when forecasting is
incorrect and demand surpasses the forecast. This buﬀer inventory could be
translated into either safety stock or desired drug inventory in a warehouse or
health facility. Proper inventory control policies and procedures should be put
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into practise to: (i) avoid stock-outs; and (ii) provide reliable data for esti-
mating order quantities (Phanouvong et al., 2011). Good stock management
procedures, as suggested by Phanouvong et al. (2011) include:
• Record receipt and distribution of all drugs to TB depots and health
facilities;
• Record receipt and dispensing of all drugs in inpatients and outpatients
on a regular basis;
• Store drugs appropriately i.e. no direct sunlight, access security;
• Rotate stocks to ensure shortest expiry date is in the front and most
easy to access-FEFO (first-expired first-out) and FIFO (first-in first-out)
principles should be applied;
• Review stock levels everytime an issue is made to ensure the stock is
above the set minimum level; and
• Maintain buﬀer stocks at all levels of TB care facilities.
4.1.2.4 Harmonisation and Standardisation
Fragmentation is another bottleneck in the SLD supply chain. Increased har-
monisation and standardisation in the supply chain is necessary to reduce the
barriers to entry of SLDs into the market (Olson et al., 2012). The processes
that should be standardised include:
• The WHO pre-qualification procedures;
• The quality-assured qualification process; and
• The product registration system.
The facilitation of regulatory harmonisation will reduce the delays experienced
with drug approval and distribution. Furthermore, drugs that are pre-qualified
by the WHO or stringent regional regulatory authorities should not have to
go through additional regulatory reviews within individual countries, therefore
Bloom (2013) suggests that regional regulatory agreements should be imple-
mented to avoid repeated validations by agencies in each country.
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4.1.2.5 Information Systems
Bloom (2013) is of the opinion that the most limiting factor in the supply of
drugs is a lack of information. Therefore the information systems throughout
the supply chain need to be improved upon. Nicholson et al. (2013) suggests
the development of universal, standardised bar coding for products, coupled
with mobile information technology to track drug supply and stock-outs. The
implementation of EMR systems for MDR-TB programs is also crucial for
data collection. Fraser (2012) makes the following information technology
suggestions to improve the MDR-TB SLD supply chain specifically:
• Standardised national and international coding of medical products to
track shipments;
• Standardised bar coding of medications and products containing: name,
batch number, expiry date and authentication ID; and
• Standardised reporting formats for medication stocks and status.
Giﬃn and Robinson (2009) emphasise that the most vital role that information
technology will play in the TB crisis is the sharing of diagnostic data between
countries and projects.
4.2 SCOR Best Practices
In addition to investigating the suggestions made at the IOM workshops, this
section will discuss the best practices that have been chosen by SCOR prac-
titioners due to the positive impacts these practices have on the performance
of a supply chain. SCOR defines best practices as practices that are current,
structured and repeatable (Supply Chain Council, 2012). The SCOR process
reference model was established for the evaluation and comparison of all supply
chain activities, therefore the SCOR model is used to evaluate the performance
of the current SLD supply chain and eventually provide recommendations for
improvement where necessary, based on the best practices.
4.2.1 Performance Attributes
These best practices refer to improving the following performance attributes
highlighted in the SCOR model: reliability; responsiveness; agility; cost; and
asset management eﬃciency. Due to the lack of data and the fact that it is
out of the scope of this study (based on the aim and objectives), this study
will not investigate cost and asset management. These attributes refer to how
eﬃciently finances and assets, respectively, are currently being used within the
supply chain, on which data is not available for this study. Therefore only the
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best practices applicable to reliability, responsiveness and agility will be con-
sidered and further investigated in this study. However, the additional costs
that are incurred for each scenario tested using the model will be investigated
later in the evaluation phase.
The Supply Chain Council (2012) describes a performance attribute as: “a
grouping of metrics used to describe a strategy.” As discussed in section 3.3.2.1;
the attributes used to measure a supply chain’s performance, along with their
definitions as defined by the Supply Chain Council (SCC) are discussed in
Table 4.2.
Table 4.2: SCOR performance attributes
Performance Attribute Definition
Reliability Reliability refers to the supply chain’s
ability to perform tasks: on-time, with the
right quantity, and with the right quality.
Responsiveness Responsiveness refers to the speed at which
these tasks are performed.
Agility Agility refers to the ability for the supply
chain to respond to external factors that
cannot be controlled, such as demand.
Supply chains should be robust enough to
not only adapt to these changes, but to
adapt fast.
Cost The costs referred to here are the operating
costs, such as labour, material and
transportation costs.
Asset Management
Eﬃciency
As the name implies, this attribute refers to
eﬃciently and eﬀectively utilising assets
within the supply chain, namely cash.
The SCOR model highlights the best management practices that produce bet-
ter process performance in terms of reliability, responsiveness and agility in a
supply chain. Table 4.3 lists the best practises that have been identified by
SCOR to improve the overall performance of the supply chain.
Only the best practices available for improvement on the weakest performance
points that are also in the scope of this research project will be further in-
vestigated using the model. The evaluation of the performance of the current
SLD supply chain will be completed in Section 5.4, after which the weakest
performance attributes will be identified.
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Table 4.3: SCOR best practices
Reliability Responsiveness Agility
Demand Management Transportation
Optimisation
Long Term Supplier
Agreement/
Partnership
Demand Planning Sales and Operations
Planning
Optimised Supplier
Count
Inventory
Optimisation
Inventory Management
using Supply Chain
Network Optimisation
Vendor Collaboration
Vendor Collaboration Purchase Order
Management
Business Rule Review
Sales and Operations
Planning
Long Term Supplier
Agreement
Strategic Sourcing
Convergence of SCOR
with Lean and Six
Sigma
Convergence of SCOR
with Lean and Six
Sigma
Convergence of SCOR
with Lean and Six
Sigma
4.3 Selection of Modelling Methodology
The diﬀerent modelling techniques available for supply chains have been dis-
cussed in Chapter 3, along with the suitability of each for diﬀerent situations.
As the aim of this research is to test improvements for strengthening the down-
stream MDR-TB SLD supply chain, and simulation modelling has the ability
to propose diﬀerent scenarios and perform ‘what-if’ analyses; it is the most
appropriate modelling technique for this study.
Of the three most prominent paradigms of simulation modelling (DES, SD
and ABS) that have been discussed in Chapter 3; DES and SD are the two
that are the most widely used tools for: (i) decision support systems in supply
chain management (Tako and Robinson, 2012); and (ii) problem-solving in the
healthcare domain (Brailsford and Hilton, 2001). Tako and Robinson (2012)
have explored the application of both DES and SD in the context of supply
chain management. Furthermore, the characteristics of ABS (shown in Table
3.4) are: oriented towards the individual; based on discrete time events; and
not a fixed structure with individual decisions driving the dynamic behaviour.
These are not the characteristics of a supply chain, therefore this paradigm is
not considered for this specific study.
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4.3.1 Comparison of Simulation Paradigms
In order to decide which simulation paradigm is most appropriate - assuming
the choice is between DES and SD - Lane (2000) and Brailsford and Hilton
(2001) list criteria on which the selection should be based. This list is shown
in Table 4.4. However these rules are not fixed and still require the judgement
of the modeller. Furthermore Brailsford and Hilton (2001) believe that the
decision may depend more on the purpose of the model than the actual system
being modelled.
Table 4.4: Criteria used to choose between SD and DES (adapted from Brails-
ford and Hilton (2001))
Criteria System Dynamics Discrete-Event
Simulation
Scope Strategic Operational
Variability Low priority High priority
Tracking
individuals
Low priority High priority
Number of entities Large Small
Timescale Long Short
Perspective Holistic (dynamic
complexity)
Analytic (detail
complexity)
Resolution Homogenised entities
(continuous)
Individual entities,
decisions and events
Data Sources Broadly drawn Numerical
Outputs Understanding of
structural sources of
behaviour modes
Point predictions and
performance measures
Purpose Policy making Decisions
(optimisation,
prediction)
4.3.1.1 Supply Chain Management Issues
As mentioned before, Brailsford and Hilton (2001) believe that the purpose of
the model is one of the most important criteria to evaluate when selecting a
simulation paradigm. Table 4.4 shows that the purpose of a simulation model
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is either strategic (policy making) or operational (decision making). Decisions
made within supply chain management are either: strategic; tactical; or op-
erational, therefore Tako and Robinson (2012) have identified, and grouped
into either strategic or operational categories, the most common logistics and
supply chain management issues. The list is ordered from the most strategic
issues down to the most operational issues in Figure 4.1.
The suggestions provided by the IOM workshops that will be tested in the
model fall under the following supply chain management issues: supply chain
optimisation; inventory planning/management; and planning and forecasting
demand. Figure 4.1 shows that these issues fall under operational issues. Lit-
erature available on matching the simulation paradigm to the type of issue
shows that SD and DES have both been used for strategic and operational
issues. There have been many claims that SD is more suitable for strategic
and policy level issues rather than operational issues (Borshchev and Filippov,
2004; Tako and Robinson, 2012). However, there are other views that have
expressed the suitability of using SD to model issues at operational levels.
Owen et al. (2010) has contradicted the general belief that SD modelling is
more suitable for strategic level modelling and has shown that SD can be used
eﬀectively for any issue, ranging from strategic to operational. Owen et al.
(2010) has proven this by tabulating the type of simulation paradigm that has
been used for various types of issues in many diﬀerent research areas. These
tabulated results show that although SD has been used more frequently for
strategic problems, there are many instances where SD is used to model at
an operational level. Moreover, Morecroft and Robinson (2005) states that no
straightforward distinction exists when comparing the two approaches for suit-
ability. As this research project will be developed further relating to more up-
stream supply chain strategic issues, where SD has been used more frequently,
and the research done by Owen et al. (2010) shows that SD is eﬀective for
both operational and strategic issues, SD is chosen to be the most appropriate
paradigm for this study.
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Strategic Decisions
Operational Decisions
• Supply chain structure;
• Process redesign;
• Supplier selection;
• Facilities/Capacity planning;
• Supply chain integration;
• Information sharing;
• Bullwhip eﬀect;
• Reverse logistics;
• Replenishment control policies;
• Supply chain optimization;
• Cost reduction;
• System performance;
• Inventory planning/management;
• Planning and forecasting demand;
• Production planning and scheduling;
• Distribution and transport planning; and
• Dispatching rules.
Figure 4.1: Supply chain management issues listed in order from the most
strategic to the most operational (adapted from Tako and Robinson (2012))
4.3.2 Selecting Simulation Software
There are various system dynamics simulation software packages available for
modelling supply chains. These models are built using the elements: stocks;
flows; and converters, with focus on the feedback structure of the model. Sys-
tem dynamics software is designed for simulating business systems, organi-
sational systems, simple engineering systems and scientific systems (GoldSim
Technology Group, 2007). Cavana and Maani (2000) list the general purpose
system dynamics software: Stella; Vensim; Powersim; iThink ; DYNAMO;
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 4. CONFRONTING THE REAL-WORLD PROBLEM 67
DYSMAP; and COSMIC. Furthermore, in order to address the real-world
problems in supply chains, simulation software should have the following ca-
pabilities (GoldSim Technology Group, 2007):
• Integrate uncertainty and variability.
The software must represent uncertainty regarding the input data and
the system dynamics and reveal the results in terms of the range of
possible outputs.
• Explicitly represent discrete events.
The dynamics of a supply chain are aﬀected by random discrete events.
These events will influence the overall performance and agility of the
supply chain and therefore need to be represented along with the full
range of consequences.
• Promote a top-down hierarchical structure.
The software should allow for multi-layer models to allow greater detail
at each level, as supply chains are very complex.
It would also be beneficial if the simulation software has the capability to link
with external data repositories, in order to receive the most recent information
when updating the model.
Vensim is the software chosen to model the MDR-TB SLD supply chain due to
the fact that it is used: (i) to improve the performance of real systems (Ventana
systems Inc); and (ii) is being used by other masters students at the Industrial
Engineering Department, therefore support and expertise is readily available.
According to Ventana systems Inc, Vensim emphasises: high quality; reality
checks; connections to data and sophisticated calibration methods; instant
output; and model analysis and optimisation.
4.4 Conclusion: Confronting the Real-World
Problem
This chapter summarises the suggestions for combating the MDR-TB crisis
that have been proposed by various individuals at the six IOM workshops.
The suggestions have been categorised into two main groups: (i) general sug-
gestions; and (ii) supply chain suggestions. Furthermore, the best practices
identified by SCOR for improving the performance of a supply chain are also
identified. The proposed suggestions and best practices that are in the scope
of this research study will be tested using the supply chain model, therefore
the most popular simulation paradigms are evaluated and compared in order
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to select an appropriate method for building this model. Two of the most im-
portant criteria used to compare the paradigms are the ‘scope’ and ‘purpose’
of the model. The purpose of a model is to aid in making decisions, in this
case supply chain management decisions. The proposed supply chain sugges-
tions are grouped into supply chain management themes in order to determine
what kind of decisions need to be modelled (strategic or operational). These
themes include: supply chain optimisation; inventory planning/management;
and planning and forecasting demand, which are categorised under operational
decisions. Both SD and DES modelling have been shown to be suitable for
modelling operational level decisions, however SD is selected to model the
downstream SLD supply chain as this model will be developed further for fu-
ture research encompassing strategic decisions, which SD is shown to be most
commonly suited for.
Chapter 5 will discuss the process that will be followed to develop and build
the systems dynamics supply chain model.
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Chapter 5
Modelling the Real-World
Problem with System Dynamics
The downstream MDR-TB SLD supply chain is modelled using the systems
dynamics software Vensim. This chapter outlines the five phase model-building
process, proposed by Cavana and Maani (2000), that is followed in this study
to develop and build the simulation model of the supply chain. Only the
first three phases, namely: problem structuring; causal loop modelling; and
dynamic modelling will be discussed in detail in this chapter. The final two
phases will be discussed in Chapter 6. The first three phases include the fol-
lowing steps: defining the problem; collecting the necessary data; building the
stock and flow model; performing validation on this model; and analysing the
performance of the current supply chain.
According to Altiok and Melamed (2010), building a model contains the fol-
lowing major steps:
• Problem analysis and information collection;
• Data collection;
• Model construction;
• Model verification;
• Model validation;
• Designing and conducting experiments;
• Output analysis; and
• Final recommendations.
More related to systems dynamics, the ‘original’ phases in system dynamics
model development, as proposed by Randers (1980) included: conceptualisa-
tion; model formulation; model testing; and implementation. According to
69
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Keating (1999), more recent system dynamics practices fall into five general
phases, namely: model analysis; model design; model formulation; model test-
ing; and model intervention and implementation.
Cavana and Maani (2000) have recently proposed a more refined five phase
process of systems thinking and modelling:
• Phase one:
Problem structuring;
• Phase two:
Causal loop modelling;
• Phase three:
Dynamic modelling;
• Phase four:
Scenario planning and modelling; and
• Phase five:
Implementation and organisational learning.
This five phase process of systems thinking and modelling will be applied to
the real-world problem in order to develop the simulated model of the SLD
supply chain. The activities involved in each of the first three phases, will be
described in the following subsections.
5.1 Problem Structuring
Cavana and Maani (2000) specify that this phase involves identifying the issues
to model, along with defining the scope and boundaries of the study. The
scope of this study is only focused on the downstream segment of the supply
chain, which is limited to the in-house warehousing (Cape Medical Depot)
and the health facilities. All drugs received from suppliers for the Western
Cape are stored at the CMD, from where they are dispatched to the various
health facilities, therefore the CMD and the health facilities will be the focus
of this study. The gathering of all the preliminary information and data is also
completed in this phase. The data for this study was received directly from
the CMD.
5.1.1 Themes to Model
Many suggestions have been made on how to confront the global MDR-TB
crisis at the various IOM workshops; however only the suggestions that re-
fer specifically to the strengthening of the downstream MDR-TB SLD supply
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chain and that can be tested using the model will be evaluated. Furthermore,
the performance of the current downstream SLD supply chain in the Western
Cape will be evaluated based on the attributes as highlighted in the SCOR
model: reliability; responsiveness; and agility. The best practices that are
available for improving upon the weakest attributes in the supply chain, based
on the performance analysis and that can also be tested with the model will
be evaluated along with the relevant IOM suggestions.
The performance of the current supply chain is evaluated and analysed in
Section 5.4. The final themes that will be tested using the supply chain model
are based on: (i) the IOM suggestions; and (ii) the results of the performance
analysis. These themes are listed and discussed in Section 6.1.
5.1.2 Input Data Collection
The following list of data required to build the supply chain model was re-
quested from the WCDoH, dating back to 2004:
• A list of all of the CMD’s suppliers of second-line anti-TB drugs and the
list of medication supplied by each of them to the CMD.
• A list of all of the facilities that are supplied by the CMD.
• The complete list of orders for second-line TB drugs received by the
CMD, containing the following data fields:
– From which facility;
– For what quantity of each drug ordered;
– On which dates; and
– An order identifier ID (if available).
• The complete list of second-line TB drugs orders dispatched by the CMD,
containing the following data fields:
– From which facility;
– For what quantity of each drug ordered;
– On which dates; and
– An order identifier ID (if available).
• The complete list of second-line TB drugs orders placed by the CMD,
containing the following data fields:
– From which facility;
– For what quantity of each drug ordered;
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– On which dates; and
– An order identifier ID (if available).
• The complete list of second-line TB drugs received by the CMD, con-
taining the following data fields:
– From which facility;
– For what quantity of each drug ordered;
– On which dates; and
– An order identifier ID (if available).
• A complete list of stock-outs and obsolete stock;
• A complete list of the running balances for each drug in inventory; and
• The reorder quantity calculation method.
5.2 Causal Loop Modelling
This phase involves identifying the main variables in the supply chain, as well
as their relationships to each to other in order to develop a causal loop diagram
(CLD).
CLDs depict the causal relationships between various variables in a system.
Variables and arrows are the basic elements in a CLD. Cavana and Maani
(2000) define a variable as a condition, action or decision that can be influenced
by other variables, while arrows indicate association between two variables.
The relationships between variables can either move in the same (S) direction
if they are directly correlated, or in opposite (O) directions if they are inversely
correlated. Once variables are linked together in a connected path, a causal
loop is formed (Cavana and Maani, 2000). This path need not be circular,
but it needs to be closed, starting and ending on the same variable. The
two general types of causal loops - balancing and reinforcing loops - represent
feedback processes for all causal loops:
• Balancing Loops:
Cavana and Maani (2000) define balancing loops as self-regulating loops
that seek stability and return to control i.e. negative feedback loops. A
balancing loop could also aim for a specific goal, which would result in
the cycle repeating itself until the target is reached.
• Reinforcing Loops:
Cavana and Maani (2000) define reinforcing loops as positive feedback
loops that can represent either ‘growing’ or ‘declining’ systems. In a
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growing system the variables continue to increase for each cycle in the
loop, whereas in a declining system the opposite takes place. Any action
in a reinforcing loop influences more of the same action in the loop.
Figure 5.1 illustrates the relationships between each variable in the down-
stream MDR-TB SLD supply chain, with ‘S’ depicting the same behaviour
and ‘O’ depicting opposite behaviour. This CLD is inclusive of variables that
influence or aﬀect the downstream SLD supply chain and variables that are
influenced and aﬀected by the supply chain, however not all of these variables
are tested and will therefore not be integrated into the dynamic model. The
core loops in the CLD are named with either ‘Bs’ or ‘Rs’ to indicate balancing
or reinforcing processes. Furthermore, the CLD illustrates that the total cost
of the supply chain within the scope of the study includes: cost of backlogs
(shortage costs); obsolescence costs; and inventory holding costs.
Model: C:\Users\16195051\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.Outlook\AB62NQ0G\CMD Causal loop_Examiners.mdl View:  View 1
CMD demand
CMD orders
CMD inventory
on hand
Drugs to health facility
S
S
S
Health facility demand
CMD order backlog
S
S
S
O
O
Obsolete stock
S
Desired level of stock
S
S
Safety stock
S
Cost of backlogs
Cost of obsolete
stock S
S
Total cost
S S
Holding costs
S
S
B1
B2
R1
S
Infectiousness
Customer demand
S
S
S
Drugs to patients
S
O
Patient drop-out
S
O
Drug resistance
S
S
Number of suppliers
and manufacturers
O
Supplier lead timeS
S
S
Diagnosis
S
Number of
awareness campaigns
S
Number of
POC rollouts
S
Cost of SLDs
O
O
Supplier reliability
S
Laboratory capacity
S
Figure 5.1: Causal loop diagram for the MDR-TB SLD supply chain
Figure 5.1 will be broken up into the core balancing and reinforcing loops that
are present in the CLD in order to describe the relationships between the most
important variables. The balancing loops (B1 and B2) are illustrated in Fig-
ure 5.2 and the reinforcing loop (R1) in Figure 5.3.
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Balancing loop ‘B1’ includes the CMD demand, CMD orders and CMD inven-
tory on hand. An increase in the demand placed by the CMD, increases the
number of orders placed, which in turn increases the CMD inventory on hand.
However an increase in the CMD inventory on hand will decrease the CMD
demand. Balancing loop ‘B2’ consists of the same variables as in ‘B1’, but also
includes the CMD order backlog. An increase in CMD inventory on hand will
decrease the CMD order backlog and therefore also decrease the CMD demand.
CMD demand
CMD orders
CMD inventory
on hand
S
S
O
B1
(a) B1
CMD demand
CMD orders
CMD inventory
on hand
S
S
CMD order backlog
S
O
B2
(b) B2
Figure 5.2: Balancing loops in the CLD
CMD demand CMD orders
CMD inventory
on hand
Drugs to health facility
S
S
S
R1
S
Figure 5.3: Reinforcing loop in the CLD
Finally each variable in the reinforcing loop ‘R1’ which includes: CMD de-
mand; CMD orders; CMD inventory on hand; and drugs dispatched to health
facilities will influence more of the same action for each cycle in the loop i.e. an
increase in the CMD demand increases the CMD orders sent which increases
the CMD inventory on hand, thereby enabling the CMD to dispatch more
drugs to the health facilities.
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5.3 Dynamic Modelling
Causal loop modelling is a powerful tool for qualitative data, however CLDs
are no longer eﬀective when quantitative data need to be analysed. Deeper
dynamic issues can be investigated in a computer simulation model. The
advantages of a computer simulation model include (Cavana and Maani, 2000):
• Storing vast amounts of information;
• Clearly formulating assumptions and causal relationships;
• Modifying assumptions for other experiments with ease;
• Multiple use for alternative model experiments;
• Performing experiments with diﬀerent policies and structures with the
same model;
• Explicitly integrating uncertainties into the model;
• Identifying sensitive parameters easily by repeating simulations;
• Graphically representing results; and
• Understanding the behaviour of the real-world system.
Cavana and Maani (2000) also lists the advantages of using the systems dy-
namics approach specifically to model real-world systems. These advantages
include:
• Clear understanding of nature and direction of relationships in the sys-
tem being modelled;
• Altering policies throughout the simulation as they are dependent on the
state of the system at a point in time (the state is changed by feedback
eﬀects of past actions);
• Including both linear and non-linear relationships in the model;
• Integrating delays (physical and information) into the model; and
• Modelling information lacking statistical data, such as ‘soft’ behavioural
relationships.
The first steps of the dynamic modelling phase, as described by Cavana and
Maani (2000) involve developing a conceptual model, followed by defining all
the relevant variables to develop a stock-flow diagram of the system. In this
study the stock-flow diagram will be developed in Vensim. Detailed data
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and information is then collected and integrated into the stock-flow diagram
in order to develop a simulation model. Once the simulation model is ready,
steady state i.e. business as usual conditions are simulated in order to carry out
validation of the model. The final step in this phase requires that a sensitivity
analysis be performed; which includes varying all of the model parameters by
approximately 10%, as suggested by Cavana and Maani (2000), to test whether
the overall eﬀect on the system is what one would reasonably expect with such
a small change.
5.3.1 Conceptual Model
This conceptual model is merely developed to give an overall map of the sys-
tem. In this case, the conceptual model only illustrates the downstream seg-
ment of the supply chain in the Western Cape. Therefore this model will
centre around the warehouse (specifically the CMD), showing the supply of
the drugs from the suppliers to the CMD and the dispatch of these drugs to
the relevant health facilities. The conceptual model for this supply chain is
shown in Figure 5.4.
CMD
inventory
Available
supplier
capacity
Health
facility
demand
Drugs in
transit
Drugs in
transit
Order
for drugs
Order
for drugs
Figure 5.4: Conceptual model for the downstream MDR-TB SLD supply chain
5.3.2 Stock-Flow Diagram of MDR-TB SLD Supply
Chain
A system that is modelled with system dynamics is described in terms of stocks
(levels), flows (rates), converters and feedback loops. The stocks are depicted
as blocks and represent accumulated quantities, while flows are depicted as
double lined arrows that represent the changes to the stock over time (‘physi-
cal’ flows). Converters are merely variables that represent intermediates, such
as constants and behavioural relationships in the system. Converters make
the model easier to understand by splitting complicated equations into sim-
pler components (Cavana and Maani, 2000). The stock-flow diagram of the
SLD supply chain, built in Vensim is illustrated in Figure 5.5. As described in
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Subsection 3.3.3.1 the arrows in the stock-flow diagram illustrate the relation-
ship between variables and the letter ‘S’ describes the same direction of flow
while ‘O’ communicates the opposite direction of flow.
The following subsection describes the process followed to develop the stock-
flow diagram, as shown in Figure 5.5.
5.3.2.1 Model Boundaries
The time boundary for this model is between 0 and 120 months representing all
the months between December 2004 and December 2010. The results are calcu-
lated in time steps of 0.03125 months, but saved every month in the simulation.
Euler and Runge-Kutta (up to fourth-order) are the techniques available for
numerical integration of the diﬀerential equations in Vensim. Euler integra-
tion is the default in Vensim as it is the most basic integration technique,
however it is not always appropriate. Euler is appropriate for higher levels of
uncertainty in the model, higher speed requirements and a lack of specificity
requirements (Musango et al., 2015). Higher-order Runge-Kutta methods are
more accurate than Euler methods and therefore require more computation
time, however these methods cannot be used when large uncertainties are
present (Simonović, 2009). This supply chain model is small enough so that
execution speed is not a factor, the majority of the parameters are certain,
and accuracy is required for the purpose of this model; therefore fourth-order
Runge-Kutta integration is used in this model.
Referring to the CLD in Figure 5.1 and the stock and flow diagram in Figure
5.5, the exogenous, endogenous and excluded variables are listed to commu-
nicate the model boundaries. An exogenous variable refers to a factor whose
values is independent of the other variables in the system, whereas an endoge-
nous variable’s value is determined by other variables in the system.
• Endogenous variables:
– Safety stock;
– Reorder point;
– CMD demand;
– CMD orders;
– CMD order backlog;
– Drugs to CMD inventory;
– CMD inventory on hand;
– Inventory position;
– Obsolete stock;
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– Drugs to health facilities;
– Drug resistance.
• Exogenous variables:
– Health facility demand;
– Supplier lead time;
– Supplier reliability;
– Desired levels of stock (min and max);
– Service level (Z-score);
– Cost of SLDs;
– Production cycle; and
– Amikacin expiration time.
• Excluded variables:
– Number of POC rollouts;
– Number of awareness campaigns;
– Laboratory capacity;
– Diagnosis;
– Customer demand;
– Number of manufacturers and suppliers;
– Patient drop-out;
– Infectiousness; and
– Drugs to patients.
5.3.2.2 Modelling Methodology
The treatment regimen for MDR-TB includes at least four drugs that should be
taken for the duration of treatment (18 to 24 months), however the injectable
agent should only be taken for the first six to eight months of treatment. As
discussed previously in Section 2.5, the injectable agents include: amikacin;
kanamycin; capreomycin; and streptomycin. Crofton et al. (1997) state that
amikacin and kanamycin should be considered as the same drug as resistance
to any one of them induces complete cross-resistance. Cross-resistance in this
case is defined as the resistance to a drug due to exposure from a similar acting
drug. Crofton et al. (1997) further state that resistance to amikacin-kanamycin
also induces resistance to streptomycin, however retains susceptibility to capre-
omycin. Therefore resistance to amikacin will most likely lead to resistance
of kanamycin and streptomycin, leaving capreomycin as the only susceptible
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drug to MDR-TB in Group 2. Therefore only amikacin (Am) will be modelled
in the supply chain as it also represents both kanamycin and streptomycin.
In order for the model to represent the real-world supply chain, the real total
demand for only amikacin from each health facility to the CMD for the past
10 years was integrated into the model as a lookup function, called health fa-
cility demand (DHF ). The lookup function returns the value of the real total
demand for amikacin from each of the health facilities that the CMD supplies
to for each month starting in December 2004 and ending in December 2014.
The health facility demand is then used to calculate the reorder point (ROP )
for the CMD, shown in (5.3.1). Currently, as defined by the CMD, the reorder
point is a function of the average health facility demand per month ( ¯DHF )
over the previous 12 weeks (three months) and the minimum desired level of
inventory on hand, expressed in months (Tmin).
ROP = ¯DHF ⇥ Tmin. (5.3.1)
The minimum and maximum desired level of inventory on hand can be changed
as often as desired by the pharmacist responsible for that section of the ware-
house, based on demand, and therefore cannot be modelled accurately. How-
ever based on historical data, the minimum level is set at three levels: lower;
intermediate; and upper. These values were determined based on data and
trends over the past 10 years. At times when the average demand over the
previous three months ( ¯DHF ) exceeds the overall average demand over the 10
years, the intermediate variable is used, when ¯DHF is double the overall av-
erage demand the maximum variable is used and finally when ¯DHF is lower,
Tmin is replaced by the lower variable.
If the inventory on hand at the CMD (SCMD) reaches this reorder point and if
the level of inventory at this reorder point is greater than the inventory position
(IP ), then an order should be placed by the CMD. The CMD inventory on
hand is increased by the drugs that are in transit to the CMD from the suppliers
(S0), shown in (5.3.6) and decreased by: (i) the drugs that are dispatched
to the health facilities (S1); and (ii) the drugs that have become obsolete
(OAm). The obsolete stock is calculated as any inventory that stays in the CMD
for longer than 30 months (shelf-life). The inventory position is dependent
on: the inventory on hand at the CMD; the stock that has been ordered by
the CMD but not received yet i.e. drugs in transit to the CMD (S0); the
backlogged orders at the CMD (BCMD) i.e. shortages; and the drugs that
are dispatched to the health facilities (S1). The drugs that are dispatched
to the health facilities is equal to the health facility demand (DHF ), unless
there is insuﬃcient inventory on hand (SCMD), in which case the inventory
on hand is dispatched and the outstanding quantity is backlogged. The CMD
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order backlog (BCMD) is defined as the health facility demand that cannot be
filled due to shortages in stock at the CMD. These variables are calculated as
follows:
SCMD(t) = SCMD(0) +
Z
[S0   S1  OAm]dt, (5.3.2)
IP = SCMD + S0   BCMD   S1, (5.3.3)
BCMD = DHF   S1. (5.3.4)
The quantity of the order that needs to be placed by the CMD (reorder quan-
tity) is represented by the variable CMD demand (DCMD) and is a function
of: the average consumption of drugs per month (C¯A) over the previous three
months; the maximum desired level of inventory on hand, expressed in months
(Tmax); the level of safety stock (SS); and the inventory position (IP ). Tmax is
calculated in the same way as Tmin discussed earlier, with lower, intermediate
and upper values. The level of safety stock (SS) for the base case model is
zero as the CMD does not have safety stock policies, however this variable will
be altered during scenario planning. The formula for reorder quantity is as
follows:
DCMD = Tmax ⇥ C¯A + SS   IP. (5.3.5)
The CMD demand can only be fulfilled by suppliers if the suppliers have
the capacity. Therefore the number of drugs in transit to the CMD (S0) is
dependent on: the reliability (R) of the suppliers for each type of drug; the
supplier lead time for each drug (LT ); and the CMD demand (DCMD), as
shown in (5.3.6). The reliability of the suppliers and their lead times are
calculated from real data. The supplier reliability value used in the model
is the calculated average over the 10 year period, whereas the lead time is
integrated into the model as a normal distribution random function with the
lead times varying between the minimum and maximum based on the average
and standard deviation of the data.
S0 =
DCMD ⇥R
LT
. (5.3.6)
5.3.2.3 Initial Stock Values
The stocks in the model require initial values before the simulation can be
executed. An initial value of zero is assumed for all the stocks in the model,
except for CMD inventory on hand and the CMD orders. The initial value for
these variables were taken from real data as the at the end of December 2004.
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5.3.3 Validation and Verification
Sargent (1998) emphasises that model verification and validation are critical
when developing a simulation model. The verification process refers to ensuring
that the computer program and implementation are correct, whereas validation
refers to the process of substantiating that a model possesses a satisfactory
range of accuracy consistent with the purpose of the model (Sargent, 1998).
Both Sargent (1998) and Cavana and Maani (2000) stress that there is no set
of specific tests that can be applied to validate a dynamic model. Coyle (1983)
highlights the main tests that a system dynamics model should be subjected
to: validation tests for the overall behaviour of the model; verification tests to
confirm that the operating mechanisms in the real system have been correctly
recorded in the model; and legitimisation tests to ensure the model obeys
the ‘laws’ of system structure. Furthermore, Coyle (1983) lists the following
criteria to carry out the validation, verification and legitimisation tests:
• The causal loop diagram should correspond to the statement of the prob-
lem and the ‘laws’ of system structure;
• The equations should correspond to the causal loop diagram i.e. the
individual ‘relationships’ in the model should be defendable in their own
right;
• The model’s equations should be dimensionally valid;
• The model should not produce any unrealistic outputs;
• The model should behave ‘like’ the real system;
• The behaviour of the model should be plausible;
• The model should maintain ‘conservation of flow’ (i.e. the total quantity
entering the system should be accounted for with the quantities within,
and leaving the system); and
• The equations should make sense when inputs take on extreme values
(i.e. test the model when it is shocked).
Additionally, a System Dynamics Model Documentation Tool (SDM-Doc) is
used to create a HTML - based document of the supply chain model built
in Vensim. This SDM-Doc lists and describes all of the equations and vari-
ables that are used to develop the model. This document helps with model
assessment and development, highlighting structural issues, and is therefore
a further validation of the physical structure of the model. Moreover, this
document can be referred to in order to understand the model and to expand
upon for further research. This SDM-Doc is included in Appendix C.
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5.3.3.1 Validation and Verification Results
The tests listed above were carried out with the simulated base case model of
the supply chain that is illustrated in Figure 5.5. The processes followed to
perform these tests, and the results thereof are discussed below:
• CLD validity:
The problem statement of the study is: to evaluate the performance
of the downstream SLD supply chain; to test proposed suggestions for
improvement to the supply chain; and to provide further suggestions for
improvement. The causal loop diagram includes all the relevant variables
in the supply chain, and the relationships between them in order to carry
out the aim of the study.
• Equation validity:
An inspection of the model equations showed that the directions of the
relationships in the CLD match the direction of the equations in the
simulated model. In other words the equations result in the correct
action of each variable based on their relationships with other variables.
• Dimensional consistency of equations:
All equations are dimensionally valid as all the units on the right-hand
side of each equation match the units on the left-hand side. In Vensim
every equation in the simulated model is subjected to dimensional anal-
ysis in order to ensure dimensional consistency. Vensim showed no unit
errors on the completed model.
• Unrealistic results:
Analysing the outputs of each variable that cannot show negative results
showed that no unrealistic outcomes are present in the results i.e. neg-
ative inventory or negative demand. The analysis of the results of the
base case model also show that no variable produces runaway results.
• Similarity to real system:
In order to determine whether the model behaves like the real system, a
statistical analysis was done on the two sets of data (modelled and real)
for the following variables:
– CMD demand;
– CMD inventory on hand; and
– Drugs to health facility.
However, due to the fact that the data is a time series, the data has to
be classified as ‘stationary’ before any correlation analysis can be done.
A stationary time series is defined as a dataset with constant statistical
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properties over time (Nason, 2006). If non-stationary time series data is
used in a regression model, there is a possibility that the results could
show significant relationships even if the variables are unrelated. This is
known as spurious regression. A qualified statistician confirmed that the
data is indeed stationary data. Once the data is classified as stationary,
the data can be seen as independent points and therefore correlation
analysis can be done to test the similarity of the data. The similarity of
the data was evaluated by calculating the intraclass correlation coeﬃcient
(ICC). The appropriateness of using this coeﬃcient was confirmed at
the Centre for Statistical Consultation (CSC) at Stellenbosch University.
The ICC is a measure of the reliability of measurements, in this case the
reliability of the model data compared to the real data. These data sets
represent a two-way model as the data is measured at the same points for
both datasets, and the diﬀerences at these points are relevant, therefore
the ICC of absolute agreement will be tested. The results of the ICC of
agreement for the amikacin model is shown in Table 5.1. The closer the
ICC is to one, the greater the similarity.
Table 5.1: Intraclass correlation coeﬃcients
Variable ICC
Drugs to health facility 0.85
CMD inventory 0.69
CMD demand 0.60
Due to the dynamism of the SLD supply chain, and the fact that reorder
policies can be overridden in times of crisis, the model will not be able to
represent the real-world with 100% accuracy. For example in 2008 there
was a significant spike in the demand for amikacin, which the current
reorder policies would not have been able to cover, therefore the CMD
ordered a larger quantity of amikacin than what the reorder equation
recommended. This reorder policy flexibility has a direct eﬀect on the
CMD demand, which is the variable with the lowest ICC value, and
an indirect eﬀect on the CMD inventory, which explains why the model
does not accurately represent the real data in these emergency instances.
This is shown in Figures 5.6 and 5.7. However the model follows the
overall trend of the real data and shows ICC values above 0.5, therefore
representing the real supply chain adequately enough to perform scenario
analyses.
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Figure 5.6: Similarity of CMD demand real-world and modelled data
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Figure 5.7: Similarity of CMD inventory real-world and modelled data
• Plausibility:
The model behaves in the way that it is expected to behave. The aim
of the model is for the CMD to deliver the drugs to the health facilities
based on the demand received from the health facilities, whilst minimis-
ing shortages as far as possible. The results of the base case model show
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that the drugs that are dispatched to the health facilities are always
following the same pattern as the health facility demand.
• Conservation of flow:
This involved a thorough check of all stocks and flows. All inputs into the
model are balanced with the outputs i.e. all the health facility demand
integrated into the model is accounted for by either being fulfilled by the
CMD or backlogged.
• Extreme conditions:
The model was subjected to a pulse train function in the health facility
demand to shock the system. This involved a 150% increase at months
30, 60, 90 and 120. The behaviour of this pulse function is illustrated
in Figure 5.8. This situation could occur if more people are diagnosed
with MDR-TB due to either awareness and diagnosis campaigns or the
rollout of POC testing in certain areas. Although the demand increases
by 150% in a month, this is moderated by the fact that the reorder
point is based on the average demand from the previous 3 months and
the fact that the minimum levels of stock are also increased when de-
mand increases, thereby increasing the CMD demand. Since the extra
demand puts pressure on both the CMD and the suppliers there are ex-
tra backlogged orders i.e. shortages, however the results of the extreme
test shows that this model is robust enough to be able to satisfy the
spikes in demand. This is due to the fact that the demand is dynamic
and unstable under normal circumstances.
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Figure 5.8: Pulse increase in demand to test model behaviour
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 5. MODELLING THE REAL-WORLD PROBLEM WITH SYSTEM
DYNAMICS 87
This test demonstrates the ability of the model to return to base case
conditions after the shock, which demonstrates that the balancing and
reinforcing loops are working well.
5.3.4 Sensitivity Analysis
During the development of a model, initial parameters are often estimated or
unknown. Therefore in order to use a model with confidence, the behaviour
of the model when these uncertain parameter values are varied considerably
must be studied (Cavana and Maani, 2000). Pruyt (2007) states that sensi-
tivity analysis is a common way to reduce uncertainties in the field of systems
dynamics. Furthermore, Cavana and Maani (2000) state that the purpose of
a sensitivity analysis is to identify the most sensitive parameters in order to
put more eﬀort into improving the estimates of these parameters. The magni-
tude of the change in the model behaviour with the model parameter changes
will determine the degree of sensitivity of each model parameter. The most
important variables (key variables) in the model and therefore the ones that
will be monitored for the purpose of the sensitivity analysis include:
• Cumulative drugs to health facility;
• Cumulative order backlog; and
• Cumulative CMD inventory on hand.
The exogenous variables that are altered in the base case model to perform
the sensitivity analysis are summarised in Table 5.2. Each variable will be
increased and decreased by 10% to test the sensitivity of the model. The
health facility demand is not a constant variable, as it varies every month and
therefore increases and decreases by 10% every month with a step function in
Vensim.
The results of the sensitivity analysis are depicted in Table 5.3. The base
case values for each key variable are shown in the top row of Table 5.3. The
values shown in columns to the left are the new cumulative values for each
key variable with either a 10% increase or decrease in the exogenous variables.
The key variables are tested at the end of the 10 year period and are therefore
cumulative values over the 10 year period. The values in the columns to
the right show the percentage change in the key variables after altering the
exogenous variables. These values show that the cumulative changes observed
aren’t significant, as a small change in the exogenous variables only produces
small, realistic changes in the key variables.
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Table 5.2: Sensitivity experiments
Variables Base Case 10% decrease 10% increase
CMD min level
(months)
2 1.8 2.2
CMD max level
(months)
4 3.6 4.4
Supplier lead time
(months)
1.2 1.08 1.32
Supplier reliability
(%)
0.98 0.88 1.08
Health facility demand
(drugs/month)
STEP(-10%) STEP(+10%)
Table 5.3 shows that the most sensitive exogenous variable, which results in
the biggest eﬀect on the key variables, is the health facility demand. Therefore
the health facility demand will aﬀect the model the most and should be the
most accurate. The health facility demand is based on real data and is built
into the model as a lookup function, ensuring its accuracy. The second most
sensitive exogenous variable is the supplier lead time, which varies from 0.25
months to 5.6 months, however the lead time that is used in the model varies
around the mean value using a random normal function.
Furthermore, Table 5.3 indicates that the key variable that is most aﬀected
by altering the exogenous variables is the cumulative order backlog. To test
how sensitive this variable is, a Monte Carlo simulation is done. Monte Carlo
simulation explores the sensitivity of a complex system by varying certain
parameters within constraints. To test the sensitivity of cumulative order
backlogs, a Monte Carlo simulation is done in Vensim with the supplier lead
time changing between the minimum and maximum, as it is the most sensitive
exogenous variable that is not 100% accurate. The results of the Monte Carlo
simulation, with a minimum and maximum lead time of 0.25 and 5.6 respec-
tively, are shown in Figure 5.9. The model is shown to be well reasoned in
Figure 5.9 as the variability of shortages increases significantly with a change
in supplier lead time. A 100% confidence interval shows that the shortages
can range from anywhere between 35, 000 and 200, 000 units of amikacin as
the lead time changes, which is exactly what is expected of the model.
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Figure 5.9: Sensitivity of supplier lead time on cumulative CMD order backlog
5.4 Performance Analysis of the Current SLD
Supply Chain
The completion of the dynamic modelling phase is followed by the scenario
modelling and planning phase. However prior to any scenario modelling, the
current performance of the supply chain will be evaluated. The performance
will be tested by evaluating the performance attributes set out in the SCOR
model, as discussed in Subsection 4.2.1. The performance of the current SLD
supply chain is analysed with the data provided for all of the drugs listed in
Table A.1. The equations used to evaluate each performance attribute (re-
liability, responsiveness and agility), and the subsequent results thereof are
discussed in the following subsections. SCOR metrics will be used as a stan-
dard for measurement of the performance of the supply chain. There are three
levels of metrics used to evaluate the performance attributes. SCOR defines
level one metrics as the diagnostics for the overall health of the supply chain.
Level two metrics in turn help to identify the root causes of performance gaps
for a level one metric, while level three metrics serve as diagnostics for level
two metrics. The three performance attributes will be tested as follows:
5.4.1 Reliability
‘Perfect order fulfilment’ is the level one metric used to measure supply chain
reliability. Perfect order fulfilment is based on four level two components,
namely: quantity delivered; delivery time compared to customer commit date;
documentation accuracy; and product condition upon delivery. However the
data provided by the CMD allows only the evaluation of the quantity deliv-
ered. The quantity delivered is calculated with the level two metric ‘% of
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orders delivered in full’ defined in (5.4.1). As defined in SCOR, an order is
only delivered in full if the quantities received match the ordered quantities i.e.
are not less or more than the quantities ordered by the customer. Therefore
perfect order fulfilment will be based on only the ‘% of orders delivered in full’
component. Perfect order fulfilment will be evaluated for both the suppliers
that supply to the CMD and the CMD that supplies to the health facilities
in the Western Cape. In terms of this model the variables ‘Health facility
demand,’ will be compared to ‘Drugs to health facility’ and ‘CMD orders,’ will
be compared to ‘Drugs to CMD inventory’. It is important to note that this
attribute is evaluated independently of the time taken to fulfil the orders.
The SCOR model calculates the ‘% of orders delivered in full’ as follows:
(Total number of orders delivered in full)
(Total number of orders delivered)
⇥ 100%. (5.4.1)
5.4.1.1 Supplier: ‘% of orders delivered in full’
Each MDR-TB SLD is supplied to the CMD by a supplier that has been
contracted for up to two years. On average the suppliers have delivered 95%
of the orders they have received in full over the past 10 years. The reliability
for each year is illustrated in Figure 5.10.
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Figure 5.10: Supplier reliability between the years 2005 and 2014
The trendline in Figure 5.10 shows a steady increase in the reliability of the
supply of amikacin over the past 10 years. The decrease in reliability in the
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years 2008 and 2009 can be attributed to the sudden increase in demand for
amikacin during those years. Figure 5.10 illustrates that the reliability of the
current suppliers is acceptable. However is should be noted that this perfor-
mance attribute was calculated with a disregard to time and partial deliveries
of drugs i.e. only the final quantity delivered was evaluated. There were many
instances where the delivery was only partially delivered at first with the re-
maining drugs being delivered at a later stage.
The time taken to deliver the drugs to the CMD will be evaluated in the
following subsection, when the responsiveness of the supply chain is evaluated.
5.4.1.2 CMD: ‘% of orders delivered in full’
The CMD distributes second line anti-TB drugs to 345 health facilities across
the Western Cape. The results show that, on average, approximately 91.5% of
the orders have been filled perfectly over the past 10 years, regardless of the
lead time. The reliability for each year is illustrated in Figure 5.11.
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Figure 5.11: CMD reliability between the years 2005 and 2014
Figure 5.11 shows a decreasing trend for the reliability of the CMD, despite the
increase in the supplier reliability. Again the significant decrease from almost
100% to 82% in 2008 can be attributed to the significant spike in demand in
2008. However, despite the decreasing trend, the past three years have shown
a steady increase with 2014 showing 96% reliability.
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5.4.2 Responsiveness
‘Order fulfilment cycle time’ is the level one metric used to evaluate respon-
siveness in a supply chain. This cycle time starts from the time an order is
received and ends with the customer acceptance of each individual order. The
level two metrics that contribute to the total cycle time are: source cycle time;
make cycle time; deliver cycle time; and delivery retail cycle time. However the
data available does not show the time taken to perform each of these activities,
but rather the total time taken between the day an order is placed and the
day the order is either delivered to the CMD or dispatched by the CMD. The
order fulfilment cycle time is calculated using (5.4.2). Therefore this fulfilment
cycle time is the cumulative cycle time for all the activities that are required
to fill and deliver an order (Supply Chain Council, 2012).
Sum cycle times for all orders delivered
Total number of orders delivered
. (5.4.2)
5.4.2.1 Supplier responsiveness
The order fulfilment cycle times for the suppliers for each year are illustrated in
Figure 5.12. The majority of the orders take longer than 40 days to be delivered
to the CMD, with the average cycle time in 2008 being approximately 70 days.
The figure does however show a decreasing trend, illustrating that the suppliers
are improving on their responsiveness with an order taking an average of only
30 days to be delivered in 2014.
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Figure 5.12: Supplier responsiveness between the years 2005 and 2014
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Additional calculations were done to determine the responsiveness of the sup-
pliers if the orders are required to be filled within two weeks, and then one
month, which is necessary for perpetual purchasing. Finally the supplier re-
sponsiveness is evaluated by determining the percentage of orders that take
longer than 3 months to be filled. These results are illustrated in Figure 5.13.
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Figure 5.13: Supplier responsiveness for specific time intervals
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Figure 5.14: Supplier responsiveness by percentage
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The pie chart in Figure 5.14 shows that only 57% of all orders are filled within
one month from the time an order is placed. Furthermore, 13% of the orders
are only fulfilled after 3 months. Supplier responsiveness is therefore one of
the most prominent problems within the SLD supply chain.
5.4.2.2 Cape Medical Depot Responsiveness.
The Annual Report, written by the Western Cape Department of Health (WC-
DoH (2011) evaluates the service level of the CMD for orders that are dis-
patched within 48 hours of receipt. Figure 5.15 illustrates the percentage of
all orders placed by health facilities that were dispatched within two days from
the CMD. These results show an average responsiveness of 76% over the 10
year period. The CMD could increase this value with sales and operations
planning, which will be discussed in more detail in Section 6.1.
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Figure 5.15: CMD responsiveness between the years 2005 and 2014
5.4.3 Agility
Agility refers to the ability of supply chain management policies to withstand
unplanned changes in external variables. Supply chain flexibility is the level
one metric used to test this attribute. The Supply Chain Council (2012) cal-
culates this flexibility by calculating the number of days required to achieve
an unplanned sustainable 20% increase in quantities delivered. This includes
the time required to achieve a 20% increase in: raw materials; production;
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and quantity delivered. To test the number of days required to achieve a sus-
tainable 20% increase in quantities delivered, a step function is incorporated
into the health facility demand to evaluate how long it will take to achieve a
sustainable 20% increase in drugs delivered to the health facilities. The results
show that the 20% increase in demand is satisfied immediately, owing to the
fact that the CMD’s order quantities are based on having stock for a maxi-
mum time of either 4, 5 or 6 months, depending on the previous 3 months’
consumption and the purchasing is based on perpetual purchasing.
A series of spikes in demand of 20% were also included in the model to test for
agility against a more aggressive change. These results also show that the sup-
ply chain is very robust and can handle relatively small increases in demand
(such as 20%).
Evaluation of the current supply chain has shown that a combination of long
lead times and unpredictable demand exists. Rushton (2010) explains that
this combination tends to lead to high levels of safety stock to ensure an agile
supply chain. The fact that the supply chain is so agile implies that high
levels of inventory are available at the CMD. The model is simulated at the
base case conditions to test how high these inventory levels are. Figure 5.16
shows the percentage of inventory on hand that is over- or understocked every
month. There is on average 267% more units of amikacin than is required each
month. Therefore, it is crucial for the CMD to implement eﬀective inventory
management policies.
5.4.4 Performance Analysis Findings
Although the reliability and agility of the supply chain is acceptable, the re-
sponsiveness (especially from the supply side) should be reviewed for improve-
ment. One of the best practices available for responsiveness improvement is
eﬀective inventory management. Furthermore, although the SLD supply chain
is shown to be agile, the inventory management is shown to be inadequate with
an average of 267% more units of amikacin on hand than what is necessary
every month.
5.4.4.1 Unacceptable Lead Times
The analysis of the performance of the supply chain shows that the biggest
gap for improvement lies in reducing supplier lead times. Although it is nec-
essary to maintain a buﬀer inventory, shorter lead times between receipt of
order and delivery would ensure a smaller stockpile. It is presumed that the
lead time is determined by a number of factors in this supply chain: supplier;
order quantity; and type of drug. These factors are investigated with the data
available and used to determine which extra policies should be tested using
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Figure 5.16: Percentage of surplus (or deficit) inventory on hand at the CMD
the supply chain model.
Before the lead time is altered through scenario modelling, the eﬀect of both:
(i) the quantity of the order from the CMD; and (ii) the supplier on the lead
time, will be tested. Note that these tests are done on all second-line anti-TB
drugs that are stocked at the CMD. Table A.1 lists these drugs.
• Order Quantity:
If there is indeed a correlation between the CMD order quantity and the
supplier lead time, then regression can be used to predict the lead time
based on the order quantity. Regression is a statistical method used to
make predictions. Performing a regression analysis assumes that there is
a linear relationship between the independent and dependent variables;
the order quantity and lead time in this case. Figure 5.17 illustrates the
relationship of the order quantity and the lead times on a scatterplot.
The lead time is the dependent variable, as it is the variable that is being
predicted. The straight line in Figure 5.17 represents the regression line,
and is defined as the ‘best fitting’ line through the data where the sum of
the squared distances between each individual point and the regression
line is a minimum.
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Figure 5.17: Correlation between order quantity and supplier lead time
Regression analysis done in Excel gives the equation of the regression
line as:
y0 = 28.9 + 0.0027x. (5.4.3)
However to determine if the relationship between the order quantity and
lead time is a strong one, further regression analysis is done. The results
are summarised in Table 5.4. The coeﬃcient of determination, or R
squared signifies how strong the relationship between the two variables
are. The coeﬃcient of determination for this case is 0.13, signifying a
weak relationship between order quantity and lead time.
Table 5.4: Regression statistics for correlation between order quantity and
supplier lead time
Regression Statistics
R Square 0.12
Residual Variance 1661.1
Standard Error 40.75
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The regression analysis shows that attempting to improve supplier lead
time by controlling order quantities is likely to be unsuccessful and should
therefore not be implemented at the CMD. Therefore modelling scenarios
that include altering the order quantities to test the impact on lead time
will not be tested.
• Supplier:
The eﬀect of the supplier on the lead time is tested in this subsection.
Each supplier is given a pseudonym in the form of letters (A-M). The
results in Figure 5.18 show that the supplier has a significant impact on
the time it takes for drugs to reach the CMD. The lower position of the
box in Figure 5.19 shows that the majority of the suppliers deliver within
approximately 50 days. Furthermore, Figure 5.18 shows that only two
suppliers (A and B) show poor lead times, while Figure 5.19 shows that
these suppliers are outliers. However, supplier B has been contracted
by the CMD since 2007. Although this is an external variable that the
CMD has no control over, it is important to take note of the significance
of selecting a supplier that performs well in terms of lead time.
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Figure 5.18: Correlation between supplier and supplier lead time
The results of the scenario modelling phase in Chapter 6 will show that
the supplier lead time has a significant impact on the performance of
the supply chain, showing the importance of selecting a supplier that
achieves shorter lead times.
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Figure 5.19: Distribution of supplier lead time for diﬀerent suppliers
5.5 Conclusion: Modelling the Real-World
Problem
This chapter is primarily focused on building a model of the downstream SLD
supply chain using systems dynamics. The model is developed by following
three of the five phases used for systems thinking and modelling, as proposed
by Cavana and Maani (2000): problem structuring; causal loop modelling; and
dynamic modelling. The themes of concern are first identified after which the
relevant data is collected in order to simulate and model the issues. After the
problem is structured, the causal loop model is developed in order to build
a stock-flow diagram, which is validated against real-life data. Finally, the
performance of the current downstream supply chain is evaluated.
The results of the performance analysis shows that the most troubling prob-
lem is the long supplier lead times. The reliability and robustness within
the supply chain are acceptable, however the responsiveness (especially from
the supplier side) is inconsistent and under-performing, thereby requiring im-
provement. Further investigation shows that the lead times are aﬀected by
the supplier, however not the quantity ordered by the CMD. Furthermore, al-
though the current supply chain is shown to be robust, the CMD have very
high levels of stock that are not being used eﬀectively thereby requiring inven-
tory management interventions. Eﬀective inventory management has become
the most crucial theme for strengthening the downstream SLD supply chain,
as it has been: proposed as one of the solutions for strengthening the supply
chain at the various IOM workshops; listed as a best practise for improving
responsiveness; and shown to be ineﬀective in the current supply chain.
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The remaining two phases of the five phase process, namely: scenario planning
and modelling; and implementation will be discussed in Chapter 6. The out-
comes and results of the scenario planning and modelling will also be displayed,
analysed and discussed in Chapter 6.
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Chapter 6
Data Analysis and Findings
This chapter discusses the final two phases of the five phase model-building
process: scenario planning and modelling; and implementation. The themes
that will be tested (through scenarios) using the simulated model are also listed
and discussed. The scenarios involve altering variables, policies and strategies
in order to provide suggestions for improvement. Thereafter, the quantification
process that will be used to measure the overall performance of the supply
chain for each scenario, for the purpose of comparing the diﬀerent policies is
explained. Finally the various scenarios will be tested by altering variables
and policies in the simulation model. These results will be represented both
in graphical and tabular forms to allow for easy communication.
6.1 Scenario Planning and Modelling
This section lists the various scenarios that will be tested in the supply chain
model as discussed in the problem structuring phase, in order to evaluate the
overall performance of the supply chain.
According to Cavana and Maani (2000), a scenario is intended to provide
possible future conditions, not a future state. Becker (1983) explains that
scenarios can be used for three distinct purposes:
• To provide common ground for people involved in planning within an
organisation;
• To asses the performance of alternate strategies and policies and to esti-
mate their risk; and
• To estimate whether policies can either prevent or assist the conditions
of a scenario from coming out.
In scenario planning, both policies and strategies are altered and tested to
evaluate performance attributes under varying conditions. According to Ca-
102
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vana and Maani (2000), policy experiments refer to how a manager uses the
information in the system in the design of policies. Policy experiments can
be done by either changing the parameters of the policies or the structure of
the policies. Policy structures can be changed by either the addition of new
variables or by linking diﬀerent variables in the model, or both. The policies
and strategies that will be tested in this study are a combination of: (i) the
suggestions proposed at the IOM workshops in Subsection 4.1.2; and (ii) the
best practices for responsiveness as highlighted in Table 4.3 and discussed in
Subsection 5.4.4.
Subsection 4.1.2 lists five main themes of improvement as suggested by the
IOM, which include: providing incentives to suppliers and manufacturers; im-
proved forecasting; inventory management; harmonisation and standardisa-
tion; and information systems. Providing incentives to suppliers and manufac-
turers, as well as harmonisation in the supply chain are upstream supply chain
issues and therefore cannot be tested with the downstream model. Informa-
tion systems form part of both the upstream and downstream segment of the
supply chain. Although the available data is limited and does not include the
type of data needed for EMR system, one aspect of information systems that is
tested in the model is the tracking of stock shortages. Inventory management
will be tested in a variety of diﬀerent ways, which includes altering: desired
levels of stock; safety stock policies; and reorder policies. Finally, a form of
demand forecasting will be tested through using exponential smoothing to cal-
culate the reorder quantity for the CMD.
As discussed in Subsection 5.4.4, the weakest performance attribute in the
current supply chain is responsiveness. The best practises that are available
for improving responsiveness are shown in Table 4.3, however not all of them
can be tested in this study. Convergence of SCOR with lean and sigma six
cannot be tested due to the limited availability of data. The data available in
this study consists of aggregate data and therefore is not suitable to test for
lean and sigma six. Purchase order management can also not be tested as this
involves the documentation process followed when ordering stock, on which
no data is available. The long term supplier agreement is contracted out by
the NDoH and is therefore out of the CMD control. Finally, the best prac-
tices that can be tested using the model include: inventory management; and
sales and operations planning. Sales and operations planning will be tested
with: supplier lead time; supplier reliability; and customer service level. One
of the goals of sales and operations planning is to determine the balance be-
tween supply and demand (inventory management). Operations planning is
necessary to manage, amongst others: unacceptable lead times; ineﬀective bot-
tlenecks; excessive obsolescence; and product shortages (Smith and Oﬀodile,
2007). Although the SLD supply chain is shown to be robust, the reason is
due to unnecessarily high inventory levels, therefore inventory management is
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also investigated to improve the attribute within the current supply chain.
Table 6.1: Summary of themes that will be tested
Themes to Model
Inventory management
Demand forecasting
Sales and operations planning
In order to test the themes summarised in Table 6.1, the following variables,
policies and strategies will be applied using the supply chain model:
• Supplier lead time;
• Supplier reliability;
• Inventory management:
– Desired levels of stock;
– Safety stock policies; and
– Reorder policies.
6.1.1 Supplier Lead Time and Reliability
The supplier lead time and reliability vary considerably in the data as new
suppliers are contracted every two years. These two variables will be altered
using the data available from the CMD. These variables will be tested using
constant values throughout the model and by making use of random functions
between the minimum and maximum values. The worst and best values ex-
tracted from the data for both variables will also be tested to evaluate the
diﬀerence in performance when the supply chain is operating at its best and
at its worst.
6.1.2 Inventory Management
Embrey (2012) states that inventory management is the heart of the pharma-
ceutical supply chain. Inventory is kept on hand in order to (Embrey, 2012):
• Ensure availability;
• Maintain confidence in the supply chain;
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• Reduce unit costs by buying in bulk;
• Avoid stock-out costs;
• Reduce ordering and transport costs; and
• Make provisions for fluctuations in demand.
6.1.2.1 Desired Levels of Stock
Currently these variables are changed by pharmacists on a regular basis based
on a variety of factors, of which the most prominent one is demand. During the
scenario analysis these parameters will be tested by comparing the outcomes
when these levels are kept constant throughout the year.
6.1.2.2 Safety Stock Policies
The CMD defines drug shortages, or as they name it ‘dues-out’, as orders that
cannot be filled i.e. backlogged orders. If the inventory on hand cannot satisfy
the demand from the health facilities, the outstanding orders are backlogged.
In order to avoid backlogged orders, the inventory on hand should always
be suﬃcient to satisfy the demand, without being excessive so that obsolete
stock becomes a problem. Embrey (2012) explains that a common way to
measure the performance of a public warehouse is to measure the service level
provided to the clients, in this case the health facilities. Safety stock is an
important factor in preventing shortages and ensuring the promised service
level to clients. The service level (SL) is calculated after the initial shipment
using (6.1.1). However there are cases where public warehouses make partial
shipments, i.e. the items are delivered in stages, which lowers the service level.
SL =
No. of items issued
No. of items ordered
⇥ 100. (6.1.1)
Currently the CMD does not have a safety stock policy, but rather a defined
minimum stock level that determines when orders should be placed, i.e. the
reorder point. This reorder point is calculated using the minimum and max-
imum number of months that stock is desired to be on hand, however these
levels are not predetermined with a set policy. These levels are set regularly
by the pharmacist responsible for the section housing a specific drug at his/her
own discretion. This is a key characteristic of the perpetual inventory model.
However, the safety stock and minimum stock levels are not analogous. Fig-
ure 6.1 shows the ideal inventory model, to prevent stock-outs and reduce
costs. The ideal inventory model shows that the reorder point takes the lead
time into account in order to receive stock before safety stock needs to be used.
If there is however no safety stock and the supplier takes longer to deliver than
expected, the inventory on hand will become zero, resulting in a stock-out.
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Figure 6.1: Ideal inventory control model (Source: Embrey (2012))
Therefore, various safety stock policies will be tested using the model to deter-
mine whether a safety stock policy would be beneficial, and if so which policy
shows the most potential for balancing the fluctuations in demand and lead
time. Embrey (2012) explains that there are many ways to estimate the level
of safety stock required to achieve specific levels of performance, however they
all consider two factors: average consumption; and average lead time, L¯T .
Due to the fact that both the lead time and the demand fluctuates consider-
ably in the SLD supply chain, the standard deviation of consumption and lead
time as well as the corresponding z-score for service level based on a normal
distribution (N(µ;  )) are factors that will be used to forecast safety stock.
6.1.2.3 Reorder Policies
The policies that will be tested include: reorder frequency; reorder quantity;
and reorder point.
• Reorder frequency:
Two groups of inventory control models are available for diﬀerent situa-
tions; based on reorder frequency (Embrey, 2012):
– Periodic review models; and
– Perpetual review models.
Orders are placed at regular planned intervals in periodic models, whereas
orders are placed at any time, as the situation demands, in perpetual
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models. Pharmaceutical supply chains most commonly use: annual pur-
chasing; scheduled purchasing; perpetual purchasing; and draw-downs
control models (Embrey, 2012). The supply chain for SLDs uses the
perpetual review model; where the user or the minimum stock level de-
termines when orders should be placed and the quantities thereof. In
this model, the inventory on hand should be assessed on a regular basis
in order to make sure orders are placed at specified reorder levels. Due
to the dynamic behaviour of the purchasing in this model, the average
inventory and safety stocks are lower than with other models. Due to
the fact that many shortages still occur in the CMD with this model,
despite the high levels of stock, the periodic review model will also be
tested using the supply chain model to test for any improvements.
• Reorder point:
Due to lead times being relatively long, inventory levels decrease to zero
even after an order has been placed at the reorder point (ROP ). This
reorder point will be altered by adding safety stock to the level of inven-
tory and by altering the point at which orders are placed to make sure
they are placed earlier to account for the long lead times. One of the
most popular formulas for calculating the reorder point is:
ROP = ¯DHF ⇥ L¯T + SS. (6.1.2)
Currently the CMD calculate the reorder point based on the following
formula:
ROP = ¯DHF ⇥ Tmin, (6.1.3)
where the average demand is based on the previous three months’ de-
mand history. The reorder point will be altered according to the reorder
policy being tested. Wherever the minimum and maximum stock level
formula is used the reorder point will be calculated using the current
reorder point policy, shown in (6.1.3). Alternatively, the reorder point
will be calculated using (6.1.2) for any policies that do not make use of
the minimum and maximum level stock level formula.
• Reorder quantity:
The CMD demand (DCMD) is analogous to the reorder quantity in this
model and therefore each method for determining the reorder quantity
will be represented by DCMD. This research project will focus on the
following methods available for calculating reorder quantity:
– Economic order quantity
– Exponential smoothing; and
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– Minimum and maximum stock level formula.
The most common method for calculating reorder quantity is to calculate
the economic order quantity (EOQ):
EOQ =
r
2⇥DHF ⇥ CO
CH
, (6.1.4)
where CO and CH represent the ordering costs and the holding costs
respectively. The economic order quantity is calculated to minimise the
total inventory holding costs and ordering costs when placing an order
quantity. This calculation is based on the following assumptions:
– The ordering cost is constant;
– The demand rate is known and spread evenly; and
– The lead time is known and fixed.
These assumptions do not hold for the real-world problem, therefore the
economic order quantity method is not appropriate for this supply chain
and will not be tested using the stimulated model.
Another method available for calculating the reorder quantity is to fore-
cast the demand and then order based on the forecast. The demand for
the next period is predicted using exponential smoothing. Exponential
smoothing calculates the projected demand for the period based on pre-
vious months’ demand and a smoothing constant (↵), which should be
tested with each individual case. Exponential smoothing is calculated as
follows:
DCMD(t) = ↵⇥DHF +DCMD(t 1) ⇥ [1  ↵]. (6.1.5)
Finally Embrey (2012) describes the minimum and maximum stock level
formula, which the CMD is currently using to calculate reorder quan-
tity once the reorder point is reached. As described in the name, the
minimum and maximum stock-level formula requires that a theoretical
minimum and maximum level of stock be predetermined to ensure a suf-
ficient quantity of stock, without creating obsolete stock. The demand
is then calculated using:
DCMD = Tmax ⇥ C¯A + SS   IP. (6.1.6)
The exponential smoothing formula and the minimum-maximum stock
level formula will be compared using the simulated model, to test the
impact on performance.
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 6. DATA ANALYSIS AND FINDINGS 109
6.2 Implementation and Evaluation Criteria
In order to make the decision of whether a policy or strategy should be imple-
mented or changed, a method of quantification of the overall performance of
the system for the purpose of comparing various policies is necessary (Cavana
and Maani, 2000).
In order to quantify how these policies will aﬀect the supply chain, ‘stock
performance’ and ‘cost performance’ will be evaluated. Although the ‘cost’
attribute could not be evaluated during the performance analysis of the current
supply chain due to lack of data, the cost performance that is evaluated here is
based on the additional costs that the CMD would incur based on the results
of the diﬀerent scenarios. These evaluation criteria will be further divided into
the sub-criteria as shown in Table 6.2.
Table 6.2: Evaluation criteria for scenario modelling
Stock Performance
Shortages
Obsolete stock
Total inventory
Cost Performance
Inventory holding costs
Obsolescence costs
Replacement therapy costs (shortage costs)
Total costs
To evaluate the policy and strategy changes and their eﬀect on cost and stock
performance, the simulated model must be further expanded in Vensim to
include the following variables:
• Holding costs;
• Obsolescence costs;
• Base therapy costs;
• Replacement therapy costs; and
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• Total costs.
The expanded model is illustrated in Figure 6.2.
6.2.1 Stock Performance
The following criteria will be measured to test the impact of changes on the
stock performance of the supply chain.
6.2.1.1 Shortages (BCMD)
It is important to note that this variable is not necessarily a stock-out, where
the inventory decreases to zero, but rather a shortage that prevents satisfying
an order. This variable is represented as order backlogs and is evaluated to
make sure a policy is implemented that results in the least number of shortages.
When testing the eﬀect of parameter changes on shortages, the cumulative
order backlogs variable will be evaluated at month 120 i.e. the total number
of shortages over the 10 year period, calculated as follows:
BCMD(t) = BCMD(0) +
Z
[DHF   S1]dt. (6.2.1)
6.2.1.2 Obsolete Stock (OAm)
In order to reduce shortages, additional inventory should be available in the
CMD at all times. However, this could possibly result in an increase of ex-
pired stock. Therefore this variable will be evaluated to make sure that the
number of obsolete drugs do not become an additional problem in the supply
chain. The data does show that it is a rare occurrence for drugs to expire, or
to be declared obsolete at the CMD, therefore it is assumed that the CMD
follows the correct rotation policy to ensure the oldest drugs are dispatched
first. Amikacin has a total shelf-life of 36 months, however by the time the
drugs have reached the CMD the shelf-life is already considerable lower. For
the purpose of this model it is assumed that the maximum shelf life of amikacin
(TE) is 30 months by the time it reaches the CMD.
Systems dynamics is unable to measure discrete events and therefore will not
be able to measure the shelf-life and activity of each individual drug in the
CMD. Therefore there is no accurate way to model this variable with the
current systems dynamics model. The only way to measure this variable with
systems dynamics is to assume that inventory stored in the CMD longer than a
certain period of time each month will expire. This period of time is calculated
as the 30 months minus the time taken to deliver the drugs to the CMD (LT ),
i.e. the remaining shelf-life once the drugs are delivered to the CMD. It is
important to note that this method of calculating obsolete stock will result in
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considerably higher quantities of obsolete stock than what is currently being
realised at the CMD. However, this method is the only one available to take
obsolete stock into account when comparing the diﬀerent policies, and the
obsolescence costs are significantly lower than the holding costs and shortage
costs, therefore the impact of this variable will not be significant. To make
provision for obsolete stock the following formula will be used:
OAm(t) = OAm(0) +
Z
[
SCMD
TE   LT ]dt. (6.2.2)
6.2.1.3 Total Inventory
A surplus of inventory is needed in order to ensure the prevention of stock-
outs, however holding extra inventory incurs additional costs. This variable
is evaluated to compare the total inventory ordered by the CMD, to the to-
tal number of shortages. This variable can evaluate and compare scenarios
that accumulate high quantities of inventory but produce diﬀerent amounts of
shortages, to evaluate which scenarios are wasteful in terms of the amount of
inventory required to achieve the performance.
6.2.2 Cost Performance
The following criteria will be measured to test the impact of changes on the
cost performance of the supply chain. According to Embrey (2012), one of the
goals of inventory management is to balance holding costs on one hand and
shortage costs on the other. Therefore these costs need to be identified and
analysed to achieve this balance.
6.2.2.1 Inventory Holding Costs (CH)
The cost of storing inventory at the CMD is assumed to be 25% of the value
of the inventory on hand every month (Vermorel, 2013; Hou, 2013; REM As-
sociates). This is another factor that will be taken into consideration when
testing safety stock policies, as the holding costs contribute to a large portion
of the total costs. Inventory holding costs are a function of:
• Capital costs;
• Storage space costs;
• Inventory services costs; and
• Inventory risk costs.
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6.2.2.2 Obsolescence Costs (COb)
The total financial loss of amikacin that is disposed of will be added to the
expenses of the supply chain. Obsolescence costs are a function of: the quantity
of drugs expired (OAm); and the cost per unit of amikacin. As discussed earlier,
this cost is considerably lower than both the holding costs and shortage costs
and will therefore not a have a significant impact on the total costs.
6.2.2.3 Replacement Therapy (Shortage) Costs (CS)
Shortages of drugs cause interruptions in treatment and can therefore possibly
result in the following:
• Increased infectiousness;
• Allocation of substitute drugs;
• Resistance to the drug that is out of stock;
• Development of XDR-TB;
• Patient drop-outs; and, in extreme cases
• Death.
In order to quantify the total cost of a shortage, the eﬀects of stock-outs as
listed above need to be quantified: however the infectiousness; development
of XDR-TB; drop-out rate; and number of deaths will be not be quantified in
this study. Therefore the cost of a shortage will be a function of the cost of
allocating substitute drugs and the cost of resistance to amikacin, and there-
fore kanamycin and streptomycin. Furthermore it should be noted that the
conservative approach will be taken to do this evaluation and therefore the
most extreme cases will be evaluated, i.e. resistance to amikacin ensues as
soon as a dosage is skipped and treatment is interrupted.
As discussed in Section 2.5.1, the regimen that should be followed for an
adult that suﬀers from MDR-TB includes amikacin for the first eight months.
Amikacin is interchangeable with kanamycin and capreomycin, however Crofton
et al. (1997) suggest that amikacin and kanamycin should be seen as the same
drug, as they are equally active and therefore resistance to amikacin results in
resistance to kanamycin. Firstly the assumption is that if amikacin is out of
stock, then the CMD will have to replace it with capreomycin, as there will
still be susceptibility. Secondly if amikacin is out of stock, a patient’s regi-
men will be interrupted which will create resistance to amikacin and therefore
kanamycin. Therefore, for the remainder of the treatment the patient needs
to complete the eight month course with capreomycin instead (replacement
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regimen), incurring additional costs for the CMD.
The cost of the replacement will be evaluated over the eight months following a
shortage, as amikacin is only taken during the first eight months of a MDR-TB
treatment regimen. For example, a shortage of 10 units of amikacin will result
in 10 units of amikacin being replaced by 10 units of capreomycin for the next
eight months, as 10 treatments would have been interrupted. Therefore there
are patients that may only have one month left of the eight month phase after
the shortage and will therefore only need to take capreomycin for one more
month and there are patients that will start their regimen on capreomycin
at the point of a shortage and end eight months later on capreomycin. On
the other hand there are also patients who will only start treatment once the
shortage is over and the amikacin stock has already been replenished. These
patients can start on amikacin one month into the eight month evaluation pe-
riod or in the last month of the evaluation period. This eight month phase
is shown graphically in Figure 6.3, illustrating the patients and the length
of their respective treatment regimens. Figure 6.3 shows that approximately
53% of the patients will need to be on the replacement regimen for the eight
months following a shortage, while 47% can remain on amikacin. Therefore
more than 50% of the costs will be for the procurement of capreomycin and the
rest for the procurement of amikacin during the eight month period following
a shortage. These shortages will also aﬀect the holding costs, as the CMD
would have to have capreomycin on hand in times of replacement therapy.
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Figure 6.3: Impact of a stock shortage
The cost of shortages will be the diﬀerence between the therapy costs when
no shortages are experienced, and when shortages are experienced over the 10
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year period.
The unit costs of both amikacin and capreomycin are required to calculate the
overall cost performance of the supply chain. These unit costs are shown in
Table 6.3.
Table 6.3: Unit cost of amikacin and capreomycin
Cost per drug Amikacin Capreomycin
Unit price $ 2.06 $ 6.25
Holding costs $ 0.02 $ 0.05
It should be noted that a stock-out at the CMD does not equate to a stock-
out in a health facility, however without data from health facilities and the
fact that a conservative approach is being followed, the assumption is that a
shortage in the CMD directly translates to a shortage in a health facility and
therefore an interruption in a patients’ treatment regimen.
6.2.2.4 Total Costs
The total costs are made up of: the holding costs; the obsolescence costs;
and the shortage costs as shown in (6.2.3). The cumulative cost of therapy
i.e. when there are no shortages and all orders are satisfied by the CMD, is
approximately $560, 000, therefore when the replacement therapy is equal to
this cost then there are no shortages and all orders are filled. The shortage
costs show the diﬀerence between replacement and base therapy costs.
CT = CH + COb + CS. (6.2.3)
6.2.3 Evaluation Criteria Analysis
The results, insights and recommendations of the scenario modelling phase will
be communicated through the use of these evaluation criteria. In eﬀect this is a
multi-objective minimisation function, as the aim is to ensure the lowest total
cost and the lowest number of shortages. The results of the evaluation criteria
from each scenario, namely the total shortages and the total costs will be
plotted against each other on a scatter plot in order to determine the optimal
solutions. A pareto set will be created and used in the following chapter to
identify the most optimal solutions obtained from the scenario modelling.
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6.3 Scenario Results
This section will test the impact that certain variables in the supply chain will
have on the overall performance of the supply chain. As previously discussed
in Section 6.1, the following policies will be altered and tested:
• Supplier lead time;
• Supplier reliability;
• Desired levels of stock;
• Safety stock policies; and
• Reorder policies.
Before changing any parameters in the model, the base case (BC), i.e. the
current operation is first evaluated. The performance of the current supply
chain with the exogenous variables set as shown in Table 6.4 results in a
total cost of $880, 000 over the 10 years, as shown in Table 6.5. The stocks
and costs shown in Table 6.5 are all cumulative quantities over the 10 year
period, 2005-2014. The holding and shortage costs make up the majority of
the total costs to the CMD, therefore any scenarios that reduce these costs
will result in the lowest total cost. However, a balance needs to be found
between inventory levels and shortages as these are competing objectives. The
cumulative demand over the 10 year period from health facilities for amikacin
is 272, 000 units, therefore inventory levels higher than this are surplus. The
results of the base case (BC) model will be shown in each table for the diﬀerent
scenario sets for easy reference.
Table 6.4: Base case values
Parameter Value
Lead Time 0.25 > < 5.6 months
Reliability 98%
Minimum level 2, 3, 4 months
Maximum level 4, 5, 6 months
Safety Stock 0
The base case shows that enough inventory is available over the 10 year period
to cover the demand, however there are still many shortages. This indicates
poor planning and operations management. The shortages occur due to the
fact that CMD reorder quantities are based on demand for the previous three
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months. Figure 6.4 shows that the health facility demand spikes at month
43, however the spike is only translated to the CMD inventory in month 47.
The required stock only arrives a few months later, resulting in an inability to
satisfy the spike in demand and creating too much inventory in the months fol-
lowing the spike in demand. Furthermore the minimum and maximum levels
of stock are also changed based on the demand history. Therefore, the min-
imum and maximum levels will be adjusted in the months showing demand
spikes, producing more inventory in the months following a spike in demand.
Table 6.5: Base case stock and cost performance
Criteria Cumulative values
Shortages 19, 200 units
Obsolete stock 25, 700 units
Total inventory 275, 000 units
Holding costs $603, 000
Obsolescence costs $53, 000
Shortage costs $224, 000
Total costs $880, 000
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Figure 6.4: Relationship between health facility demand and CMD inventory
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The following subsections show the results of the scenario modelling.
6.3.1 Supplier Lead Time(LT )
As shown in Figure 5.14 approximately 13% of the SLDs that are ordered by
the CMD take more than three months to be delivered by the suppliers, there-
fore lead time is one of the biggest bottlenecks in this supply chain. The lead
time will be tested by altering the time in the model to evaluate the impact
on the supply chain.
To test the eﬀect that the supplier lead time has on the performance of the
downstream segment of the supply chain, three diﬀerent scenarios are run.
The supplier lead times that are tested are statistics that are obtained from
the real data for amikacin over the past 10 years, namely: minimum lead time;
average lead time; and maximum lead time to fulfil an order. The minimum
time taken to fulfil an order is approximately a week, whilst the maximum
lead time is calculated to be more than 5 months. Tables 6.6 and 6.7 show
the stock and cost performance results respectively, after running the diﬀerent
simulations on the model.
It is important to note that these scenarios are simulated using the current
policies at the CMD, i.e. high minimum and maximum desired stock levels
shown in Table 6.4.
Table 6.6: Eﬀect of supplier lead time on stock performance
Code Lead Time
(months)
Shortages Obsolete
stock
Total
inventory
BC Variable 19, 200 25, 700 275, 000
LT1 0.25 6, 220 33, 600 297, 000
LT2 1.2 22, 500 24, 500 270, 000
LT3 5.6 158, 000 5, 430 114, 000
The results indicate that the supplier lead time has a large impact on both the
stock and cost performance. If the CMD experiences the minimum lead time
for every order using their current operations and policies, they will limit the
amount of shortages to approximately 622 (value in table10 years ) units of amikacin per
year. There are 25, 000 more units of amikacin than what is necessary in this
case (the cumulative demand for amikacin was 272, 000 units). This is due to
the minimum and maximum levels of stock being so high to accommodate for
the variable lead time, with the minimum stock level being three months on
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average.
Table 6.7: Eﬀect of supplier lead time on cost performance
Code Lead Time
(months)
Holding
costs
Obsolescence
costs
Shortage
costs
Total costs
BC Variable $603, 000 $53, 000 $224, 000 $880, 000
LT1 0.25 $702, 000 $69, 200 $92, 200 $863, 000
LT2 1.2 $598, 000 $50, 400 $249, 000 $897, 000
LT3 5.6 $129, 000 $11, 200 $562, 000 $701, 000
The CMD calculates reorder quantities based on high minimum and maxi-
mum levels as the current lead times fluctuate significantly. Therefore when
constant shorter lead times are tested the inventory levels will increase signif-
icantly, creating high levels of obsolete stock and high holding costs. Under
normal circumstances shorter lead times will result in: more frequent ordering;
a decrease in inventory on hand; lower obsolete stock; and lower obsolescence
and holding costs. Tables 6.6 and 6.7 show that this is not the case. Therefore,
if the CMD were to improve the supplier lead time, the method of calculating
the desired levels of stock would need to be adjusted to lower desired levels, or a
diﬀerent policy for calculating reorder quantity would need to be implemented.
The following scenario shows the impact of shorter lead times with the cur-
rent minimum and maximum desired stock levels lowered from the base case
scenario to correspond to the shorter lead times. The minimum desired stock
levels are decreased to between 1 and 2 months, while the maximum levels are
decreased to between 2 and 4 months. Shorter lead times will also be tested
along with diﬀerent reorder policies in Subsection 6.3.6. Table 6.9 shows that
decreasing the supplier lead time and adjusting the desired stock levels accord-
ingly will decrease the total costs by $206, 000.
Table 6.8: Eﬀect of supplier lead time on stock performance-adjusted policy
Code Lead Time
(months)
Shortages Obsolete
stock
Total
inventory
BC Variable 19, 200 25, 700 275, 000
LT4 0.25 13, 800 18, 400 273, 000
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Table 6.9: Eﬀect of supplier lead time on cost performance-adjusted policy
Code Lead Time
(months)
Holding
costs
Obsolescence
costs
Shortage
costs
Total costs
BC Variable $603, 000 $53, 000 $224, 000 $880, 000
LT4 0.25 $448, 000 $37, 900 $188, 000 $674, 000
6.3.2 Supplier Reliability(R)
The supplier reliability for amikacin is generally very acceptable with an av-
erage reliability of 98%. To test the eﬀect of supplier reliability on the perfor-
mance of the supply chain, the reliability is set to 50%, 80% and 100%, even
though historical data shows that the reliability is never below 80%. This
parameter refers to receiving the correct quantity of amikacin, based on the
orders received from the CMD, regardless of the lead time. The results are
displayed in Tables 6.10 and 6.11.
Table 6.10: Eﬀect of supplier reliability on stock performance
Code Reliability Shortages Obsolete
stock
Total
inventory
BC 98% 19, 200 25, 700 275, 000
R1 50% 53, 200 16, 400 231, 000
R2 80% 26, 800 23, 400 265, 000
R3 100% 18, 700 26, 000 276, 000
Table 6.11: Eﬀect of supplier reliability on cost performance
Code Reliability Holding
costs
Obsolescence
costs
Shortage
costs
Total costs
BC 98% $603, 000 $53, 000 $224, 000 $880, 000
R1 50% $425, 000 $33, 800 $368, 000 $827, 000
R2 80% $566, 000 $48, 200 $268, 000 $883, 000
R3 100% $606, 000 $53, 500 $220, 000 $879, 000
Once again the results show that having less inventory has a positive impact
on the cost performance, even with an increase in the frequency of shortages.
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This is again due to the high levels of desired stock (minimum and maximum
levels). However, if the reliability were to decrease to 50%, the shortages would
increase to almost three times that of the base case. Although the scenario set
at 50% shows the lowest total cost, the scenario running at 100% reliability
shows a decrease in shortages and total cost when compared to the scenario
run at 80% reliability.
6.3.3 Desired Stock Levels
This variable is changed on a regular basis by a pharmacist, depending on
the nature of the demand over the past three months. Some of the factors
considered by the pharmacists include (Deacon, 2015):
• Average supplier lead times;
• Seasonal variations in demand and supply;
• Anticipated external factors; and
• Capacity available in the warehouse.
These pharmacists are responsible for diﬀerent sections of the warehouse and
can alter these desired stock levels in their respective sections at their own dis-
cretion, as often as desired. Therefore, not only are the changes inconsistent
in each section, but the changes across the various sections are not aligned.
This is due to the fact that a policy is not available to aid the pharmacists in
determining the optimum stock levels as the situation demands. This unregu-
lated process has resulted in ineﬀective inventory management.
To test the impact of minimum and maximum number of weeks, scenarios
are modelled where the desired stock levels are kept constant. The maximum
level of stock can be calculated based on the minimum level of stock and the
procurement period (PP ), as shown in the following formula:
Tmax = Tmin + PP. (6.3.1)
The procurement period (PP ) is defined as the time between an order to a sup-
plier and the next scheduled order (Embrey, 2012). The current supply chain
is based on perpetual and not periodic purchasing, therefore the procurement
period is not constant but rather fluctuating. However, the data shows that
on average six orders are placed every year. Therefore for this calculation the
procurement period is set at two months. Two scenarios are run where Tmin is
set at both two and three months (based on real-data), and the Tmax variable
is set at four and five months respectively.
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Table 6.12: Eﬀect of static desired stock levels on stock performance
Code Stock levels
(months)
Shortages Obsolete
stock
Total
inventory
BC Variable 19, 200 25, 700 275, 000
DS1 Static (2 & 4) 30, 500 17, 500 255, 000
DS2 Static (3 & 5) 17, 600 25, 900 277, 000
Table 6.13: Eﬀect of static desired stock levels on cost performance
Code Stock levels
(months)
Holding
costs
Obsolescence
costs
Shortage
costs
Total costs
BC Variable $603, 000 $53, 000 $224, 000 $880, 000
DS1 Static (2 & 4) $416, 000 $36, 000 $266, 000 $718, 000
DS2 Static (3 & 5) $547, 000 $53, 300 $201, 000 $801, 000
The results show that setting the minimum and maximum levels of stock at
constant values reduces the total cost when compared to the base case. This
is due to the fact that minimum and maximum levels are currently set using
historical demand; which fluctuates significantly. Setting the desired minimum
and maximum levels of stock to three and five months respectively not only
decreases the total costs, but also the number of shortages, when compared to
the base case. However, the CMD would have to have suﬃcient space to store
a five month supply of amikacin every time an order is placed if the static level
policies are implemented. However, keeping the desired stock levels constant
will require safety stock to address unexpected increases in demand. Scenarios
will be modelled in Subsection 6.3.6 that integrate safety stock into constant
desired stock level scenarios.
6.3.4 Safety Stock Policies
The first scenario that will be tested is the very basic safety stock formula
as shown in (6.3.2). A safety factor (SF ) is added to the current method of
calculating CMD demand, to cope with the variations in both lead time and
demand from the health facilities. The scenario was tested with a safety factor
of 1.5, where an extra 50% is added to the original reorder quantity.
SS = DCMD ⇥ SF. (6.3.2)
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The second scenario will provide a constant safety stock level over the 10 years
and will be calculated based on the fact that the CMD shows an average back-
log of 4, 000 units of amikacin per month in the base case scenario.
In the third scenario the safety stock will be calculated based on a desired ser-
vice level and the fact that the consumption and lead time pattern both have
large fluctuations. Embrey (2012) explains that when both the consumption
and lead times are highly variable, the standard deviation of both variables
should be calculated to set safety stock levels using (6.3.3).
SS = Z ⇥
r
(
LT
PC
⇥ SD2C) + (C2A ⇥ SD2LT ). (6.3.3)
The Z value represents the desired service level, i.e. confidence level according
to statistical analysis to achieve the service level. The CMD aims to never
have stock-outs and therefore a service level of 100% is tested. The corre-
sponding Z-score for a confidence level of 99.9% is 3.09. The safety stock is
evaluated every month and therefore the production cycle (PC) is one month.
The standard deviations and averages are calculated over one production cycle.
The left hand side of (6.3.3), namely:
SS =
r
(
LT
PC
⇥ SD2C), (6.3.4)
focuses on demand variability, while the right:
SS =
q
(C2A ⇥ SD2LT ), (6.3.5)
focuses on lead time variability. Finding the dominant influence on safety
stock requirements, i.e. the part of the equation that results in higher safety
stock requirements, helps decide which improvements to focus on. In this case
the model shows that the variability in lead time is the dominant influence on
safety stock levels and should therefore be the focus of improvements.
In the final scenario the quantity of safety stock will be determined based on
the previous months demand and the current demand. The percentage increase
in health facility demand from the previous month will be used to calculate
the safety stock for the current month based on the following formula:
SS =
DHF (t) DHF (t  1)
DHF (t  1) ⇥DHF (t). (6.3.6)
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Table 6.14: Eﬀect of safety stock on stock performance
Code Safety
stock
Shortages Obsolete
stock
Total
inventory
BC No SS 19, 200 25, 700 275, 000
SS1 SF 11, 200 40, 600 299, 000
SS2 Constant 7, 280 41, 800 306, 000
SS3 SD 5, 700 66, 200 332, 000
SS4 % increase 4, 610 31, 900 296, 000
Table 6.15: Eﬀect of safety stock on cost performance
Code Safety
stock
Holding
costs
Obsolescence
costs
Shortage
costs
Total costs
BC) No SS $603, 000 $53, 000 $224, 000 $880, 000
SS1 SF $850, 000 $83, 600 $140, 000 $1.07M
SS2 Constant $741, 000 $85, 900 $100, 000 $927, 000
SS3 SD $1.19M $136, 000 $84, 600 $1.41M
SS4 % increase $659, 000 $65, 700 $67, 000 $792, 000
Overall these safety stock policies merely add inventory to the high levels of in-
ventory currently on hand at the CMD. Therefore the inventory pattern found
in the base case stays the same, i.e. the same unnecessary spikes in the level
of inventory are still present. Although extra stock is ordered to cover for
variations in demand, the extra stock also arrives too late.
The standard deviation formula (6.3.3) calculates the safety stock requirements
based on the fact that a shortage should never occur, even with the large fluc-
tuations in both demand and lead time, therefore the formula overcompensates
and results in surplus inventory on hand every month. The holding costs and
the costs of obsolete stock are too high to implement this safety stock policy.
The basic safety stock policy too incurs high costs and also produces large
amounts of shortages. The final safety stock policy shows the most poten-
tial, as it incurs the lowest total cost and lowest number of shortages when
compared to the base case and the other safety stock scenarios.
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6.3.5 Reorder Policies
This section will focus on policies that relate to reordering, namely: reorder
frequency; reorder points; and reorder quantities. The CMD is currently us-
ing perpetual purchasing and calculating the reorder quantity with regularly
changing minimum and maximum desired levels of stock.
6.3.5.1 Reorder Frequency
The base case model is developed to represent the current situation at the
CMD, where reorder frequency is based on perpetual purchasing. However,
according to Embrey (2012) this method is not ideal for supplier lead times
longer than a month, which the CMD often experiences.
As previously discussed in Subsection 5.4.1.3, periodic purchasing refers to
placing demands at regular scheduled intervals. Therefore the calculation for
CMD demand (DCDM) will be adjusted to ensure orders are placed at regular
intervals. These regular intervals are called procurement periods (PP ) i.e.
the time between placing orders. The scenarios include placing orders every
one, two and three months respectively. The reorder quantity is based on the
calculation currently used by the CMD, however adjusted for the procurement
period. The stock ordered at every interval would need to cover the demand
for that procurement period as well as the supplier lead time, until the next
order can be placed. Historical data shows that most of the lead times fall
below 2.4 months, therefore the lead time that will be used to evaluate these
scenarios is 2.4 months, which is the average plus one standard deviation. The
following formula is used to calculate the reorder quantity:
DCMD = ¯DHF ⇥ (L¯T + PP ) + SS   IP. (6.3.7)
Table 6.16: Eﬀect of periodic purchasing on stock performance
Code Periodic
purchasing
Shortages Obsolete
stock
Total
inventory
BC Perpetual 19, 200 25, 700 275, 000
PP1 ¯DHF ⇥ 3.4 22, 100 23, 100 269, 000
PP2 ¯DHF ⇥ 4.4 30, 900 23, 500 261, 000
PP3 ¯DHF ⇥ 5.4 34, 000 24, 200 258, 000
The results in Tables 6.16 and 6.17 show that the best outcome is to order
on a monthly basis to compensate for the variable health facility demand. A
procurement period of longer than a month increases the number of shortages
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Table 6.17: Eﬀect of periodic purchasing on cost performance
Code Periodic
purchasing
Holding
costs
Obsolescence
costs
Shortage
costs
Total costs
BC Perpetual $603, 000 $53, 000 $224, 000 $880, 000
PP1 ¯DHF ⇥ 3.4 $525, 000 $47, 600 $242, 000 $814, 000
PP2 ¯DHF ⇥ 4.4 $545, 000 $48, 400 $267, 000 $861, 000
PP3 ¯DHF ⇥ 5.4 $552, 000 $49, 900 $262, 000 $864, 000
due to the variability in demand. Neither the demand nor the lead time is
stable enough to calculate the reorder quantity based on data older than a
month, therefore orders should rather be placed more frequently based on
more current data. Moreover, it should be noted that procurement periods
longer than a month increases the total holding costs even though the total
inventory is lower, showing the ineﬀective use of inventory. Finally, ordering
on a monthly basis results in the lowest total cost when compared to the base
case and the other scenarios, and the least number of shortages when compared
to the other scenarios.
6.3.5.2 Reorder Quantity
The CMD is currently using the minimum and maximum stock level formula
to determine reorder quantity. This method has however shown that the in-
ventory levels are unnecessarily high at times when demand is low and inade-
quate when demand is high, as shown in Figure 6.4. As discussed in Subsection
5.4.2.3, EOQ and exponential smoothing are additional methods that are avail-
able to calculate reorder quantity. The assumptions on which EOQ is based do
not hold in this supply chain and therefore will not be tested using the model.
However, exponential smoothing is tested in this section, with each scenario
being tested with a diﬀerent smoothing constant (↵), as shown in Tables 6.18
and 6.19. As the minimum and maximum stock level formula is not used to
calculate the reorder quantity in this scenario, the reorder point is calculated
using the average supplier lead time plus one standard deviation (2.4 months),
as defined in (6.1.2), instead of the minimum desired level of stock.
Overall this set of scenarios results in the lowest total costs, but also the high-
est number of shortages. The exponential smoothing method is a forecasting
method and therefore uses the demand from the previous month to calculate
the current demand. The reason this method produces lower reorder quanti-
ties is because this calculation is based on previous months’ demands, which
fluctuates significantly. The demand from health facilities is too unstable for
this method of reordering, unless enough safety stock is on hand to cover for
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the months that experience considerable increases in demand.
Table 6.18: Eﬀect of exponential smoothing on stock performance
Code Exponential
smoothing
Shortages Obsolete
stock
Total
inventory
BC Min-max 19, 200 25, 700 275, 000
ES1 ↵ = 0.1 122, 000 8, 510 154, 000
ES2 ↵ = 0.5 70, 200 13, 900 211, 000
ES3 ↵ = 0.9 59, 400 15, 300 223, 000
Table 6.19: Eﬀect of exponential smoothing on cost performance
Code Exponential
smoothing
Holding
costs
Obsolescence
costs
Shortage
costs
Total costs
BC Min-max $603, 000 $53, 000 $224, 000 $880, 000
ES1 ↵ = 0.1 $232, 000 $17, 500 $496, 000 $746, 000
ES2 ↵ = 0.5 $350, 000 $28, 500 $376, 000 $755, 000
ES3 ↵ = 0.9 $384, 000 $31, 600 $352, 000 $768, 000
6.3.6 Combination of Best Scenarios
The next set of scenarios include altering and combining the various policies
and variables tested earlier to test for any improvement on the original sce-
narios. The safety stock and lead time scenarios show the most potential for
decreasing the number of shortages experienced. Shorter lead times will en-
sure that sudden spikes in health facility demand be translated to the CMD
inventory in time for the increased demand, thereby reducing the excess stock
following a demand spike. Safety stock ensures that additional stock is avail-
able when demand increases unexpectedly.
The first set of scenarios that are tested include combining the best run from
the safety stock scenario set with the best runs from the other scenario sets,
with regards to number of shortages. The results from the safety stock scenario
set show that the final scenario results in the greatest decrease in number of
shortages. This safety stock policy will be therefore integrated into the best
runs in: the supplier lead time scenario set (0.25 months); the periodic pur-
chasing scenario set (monthly ordering); the exponential smoothing scenario
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set (↵ = 0.9); and the desired stock levels scenario set, where the minimum
and maximum levels of stock are set at three and five months respectively. Ta-
bles 6.20 and 6.21 show the results after running the following four scenarios:
1. Minimum lead time (0.25 months) with safety stock;
2. Periodic purchasing with safety stock;
3. Exponential smoothing reorder quantity with safety stock; and
4. Static desired minimum and maximum stock levels with safety stock.
Table 6.20: Eﬀect of safety stock combination scenarios on stock performance
Code Shortages Obsolete
stock
Total
inventory
CS1 2, 910 22, 800 288, 000
CS2 5, 560 27, 500 290, 000
CS3 9, 590 24, 300 283, 000
CS4 3, 130 31, 700 298, 000
Table 6.21: Eﬀect of safety stock combination scenarios on cost performance
Code Holding
costs
Obsolescence
costs
Shortage
costs
Total costs
CS1 $498, 000 $47, 000 $44, 500 $590, 000
CS2 $550, 000 $56, 700 $83, 200 $690, 000
CS3 $516, 000 $87, 300 $117, 000 $948, 000
CS4 $595, 000 $50, 000 $129, 000 $695, 000
Tables 6.20 and 6.21 show that improving the lead time results in the biggest
improvement with regards to total cost and number of shortages. Therefore,
to further test the impact of lead time, additional combination scenarios will
be run. As discussed earlier, decreasing the lead time with the current desired
levels of stock does not accurately show the eﬀect of reduced lead times due to
the high levels of desired stock. Instead of adjusting the minimum and maxi-
mum levels using the current perpetual purchasing, shorter lead times will be
tested using periodic purchasing along with safety stock.
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Furthermore, keeping the minimum and maximum levels of stock constant
(combination scenario 4) shows the second best result with regards to short-
ages, and will therefore also be tested with reduced supplier lead times. Due to
the lead times being shorter, the lower minimum and maximum desired levels
of stock tested in Subsection 6.3.3 will also be tested, i.e. 2 and 4 months.
In summary, Tables 6.22 and 6.23 show the results after running the following
combined scenarios:
5. Periodic purchasing with minimum lead time and safety stock;
6. Static levels of stock (3 & 5 months) with minimum lead time and safety
stock; and
7. Static levels of stock (2 & 4 months) with minimum lead time and safety
stock.
Table 6.22: Eﬀect of lead time combination scenarios on stock performance
Code Shortages Obsolete
stock
Total
inventory
CS5 9, 740 16, 100 274, 000
CS6 211 38, 600 309, 000
CS7 811 29, 900 299, 000
Table 6.23: Eﬀect of lead time combination scenarios on cost performance
Code Holding
costs
Obsolescence
costs
Shortage
costs
Total costs
CS5 $437, 000 $33, 200 $147, 000 $618, 000
CS6 $647, 000 $79, 800 $3, 240 $730, 000
CS7 $538, 000 $61, 600 $12, 700 $613, 000
6.3.7 Scenario Findings
Due to the competing objectives: (i) shortages; and (ii) total cost, there is no
simple way to evaluate which scenario shows the most potential. However the
results show that the combined scenarios show the biggest improvement with
regards to both number of interrupted treatments (shortages) and total cost.
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The results of these two objectives from each of the scenarios tested will be
plotted on a scatter plot in Chapter 7 in order to compare and evaluate.
6.4 Conclusion: Data Analysis and Findings
This chapter focuses on the last two phases of systems thinking and modelling.
The systems dynamics model of the SLD supply chain developed in Chapter
5 is used to test various scenarios, based on: suggestions made at the IOM
workshops; and the performance analysis of the current supply chain. A sum-
mary of the themes that are tested are shown in Table 6.1. The eﬀect of these
scenarios on both: (i) stock levels; and (ii) cost performance are evaluated to
aid in the decision-making process of whether policies should be changed or
implemented. The groups of policies that are tested include:
• Supplier lead time;
• Supplier reliability;
• Desired levels of stock;
• Safety stock levels; and
• Reorder policies.
Shortages and stock-outs of SLDs are unacceptable due to the consequences
thereof, which include: patient drop-out; resistance and development of XDR-
TB; increased infectiousness; and possibly death. Therefore the supply chain
should be stable and robust enough to ensure adequate inventory. However,
safety stock is required to prevent shortages, which increases inventory holding
costs. These costs are approximately 25% of the value of the stock on hand
and therefore contribute to a large portion to the total costs. As described in
Subsection 2.4.3.2, financing of MDR-TB is a challenge, thereby requiring that
policies that reduce costs be implemented. Therefore there are two competing
objectives for the CMD: (i) to reduce costs; and (ii) prevent shortages. Each
of the scenarios tested are evaluated for these two variables in order to decide
which policies show the most potential for improvement. Overall, reducing
lead times and implementing a safety stock policy results in the biggest im-
provements. The detailed comparison and analysis of each scenario will be
done in Chapter 7. Chapter 7 will also discuss the conclusions of this research
project and provide recommendations for further research.
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Chapter 7
Conclusion and Recommendations
This chapter analyses the stock and cost impact of the interventions tested in
Chapter 6 on the SLD supply chain, by plotting holding costs against num-
ber of interrupted treatments. A pareto set of the best interventions, and
combinations thereof is obtained. Moreover, the decision-making tools that
are available for comparing the diﬀerent pareto solutions are discussed. Rec-
ommendations will be provided for both; improving the performance of the
downstream SLD supply chain based on the scenario modelling results; and
the suitability of the methodology followed in this study. The limitations of
the system dynamics model will also be discussed as opportunities for improve-
ment. Finally, suggestions for the improvement of this study in future research
will be presented.
7.1 Analysis of Scenario Modelling Results
The interventions tested in Chapter 6 are evaluated in terms of their impact
on stock and cost in the supply chain. A summary of each scenario tested, the
changes in variables for each scenario and the impact of each scenario on total
cost and number of shortages is provided in Table 7.1. The number of inter-
rupted treatments and total costs, which include: obsolescence costs; holding
costs; and shortage costs, are the focus of the evaluation for each interven-
tion. The total cost and total shortages (number of interrupted treatments)
are plotted against one another for each scenario tested in Chapter 6. These
points are plotted on Figure 7.1 and grouped according to the scenario sets
in Chapter 6. The x axis represents the total cost and the y axis represents
the total number of shortages, and therefore the total number of interrupted
treatments over the 10 year period.
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Table 7.1: Summary of tested scenarios and their results
Variables
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LT4 0.25 13, 800 $674, 000
LT2 1.2 22, 500 $897, 000
LT3 5.6 158, 000 $701, 000
R1 50% 53, 200 $827, 000
R2 80% 26, 800 $883, 000
R3 100% 18, 700 $879, 000
DS1 2 & 4 30, 500 $718, 000
DS2 3 & 5 17, 600 $801, 000
SS1 SF[1] 11, 200 $1.07M
SS2 4, 000[2] 7, 280 $927, 000
SS3 SD [3] 5, 700 $1.41M
SS4 % increase [4] 4, 610 $792, 000
PP1 1 22, 100 $814, 000
PP2 2 30, 900 $861, 000
PP3 3 34, 000 $864, 000
ES1 ↵ = 0.1 122, 000 $746, 000
ES2 ↵ = 0.5 70, 200 $755, 000
ES3 ↵ = 0.9 59, 400 $768, 000
CS1 0.25 %increase 2, 910 $590, 000
CS2 %increase 1 5, 560 $690, 000
CS3 %increase ↵ = 0.9 9, 590 $948, 000
CS4 3 & 5 %increase 3, 130 $695, 000
CS5 0.25 %increase 1 9, 740 $618, 000
CS6 0.25 3 & 5 %increase 211 $730, 000
CS7 0.25 2 & 4 %increase 811 $613, 000
[1] Safety stock calculated with a safety factor (SF)
[2] Safety stock set at a constant of 4, 000 units
[3] Safety stock calculated with standard deviation formula
[4] Safety stock calculated based on % increase in demand
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7.1.1 Pareto Optimal Solutions
This is a multi-objective minimisation decision as both total cost and number
of interrupted treatments should be as low as possible. Multi-objective opti-
misation involves simultaneously optimising several objectives, that are often
competing. This is the case in this research study as decreasing the number of
shortages is likely to result in an increase in holding costs, and therefore total
costs. In order to compare the points in Figure 7.1 and determine the optimal
points, a pareto optimal set is generated.
A pareto solution can be described as a solution wherein an improvement in
one objective function will result in deterioration of any other objective value.
A pareto optimal set involves a complete set of these solutions. Therefore each
pareto optimal solution in eﬀect achieves a trade oﬀ between the objective
functions.
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Figure 7.1: Scenario modelling results
The pareto set is highlighted in Figure 7.1 using the dotted circular markers.
The coordinates of each pareto solution is recorded in Table 7.2.The long lead
times and fluctuating supplier lead times are the most prominent problems
experienced within the downstream SLD supply chain. The long lead times
result in stock arriving too late to satisfy sudden spikes in demand, and further
creates an unnecessary surplus in stock following a demand spike. The eﬀect
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of the fluctuating supplier lead times can be seen when analysing the left hand
side of the standard deviation safety stock equation (6.3.3) compared to the
right hand side. The dominant influence on safety stock requirements in this
equation is the variable supplier lead time, indicating the need for improve-
ment. The significant impact supplier lead time has on the performance of
the supply chain is illustrated by the fact that each pareto solution depicts a
scenario wherein the lead time is set to the minimum (0.25 months).
Table 7.2: Pareto solutions
Code Shortages Total cost
CS6 211 $730, 000
CS7 811 $613, 000
CS1 2, 910 $590, 000
The results of the scenario modelling phase has shown that improving lead
times can improve the performance of the supply chain significantly, therefore
emphasis should be placed on improving this variable. The findings in Subsec-
tion 6.2.1 show that, if the supply chain operates as it is currently, controlling
order quantities in an eﬀort to decrease lead times is likely to be unsuccessful.
However the findings also show that the supplier has a notable eﬀect on the
duration of the lead times. Unfortunately the data has shown that one of the
suppliers with the worst average lead time has been contracted since 2007 and
is still supplying SLDs to the CMD. Many suggestions have been proposed
regarding improving the performance of the SLD supply chain, however due to
the long and variable lead times and the impact of the supplier on lead time,
supplier selection has become the biggest factor. Therefore selecting suppliers
that perform well in terms of lead time should be a priority. Unfortunately,
the supplier lead time cannot readily be improved upon by the CMD as it is
a variable that is out of their control. The supplier contracts are awarded by
the NDoH in Pretoria, normally for a contract period of two years, according
to responses received on tenders. Although the process whereby suppliers are
chosen is driven by the NDoH, it is important to note the impact that supplier
lead time has on the performance of the supply chain. The lead time should
therefore be one of the highest weighted factors when selecting suppliers.
Furthermore the results in Chapter 6 show that the CMD have excess levels of
inventory following a spike in health facility demand due to the fact that the
desired levels of stock change according to historical demand. The demand is
however too dynamic to change the levels of stock based on historical data.
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Two of the pareto solutions show that keeping desired levels of stock constant
reduces both the costs and the number of shortages experienced at the CMD.
The scenario modelling results have shown that ordering safety stock when
demand fluctuates, instead of altering the minimum and maximum desired
levels of stock produces better results.
7.1.2 Eﬀect of Lead Time on Total Costs
The total costs and number of interrupted treatments are competing objectives
in this study because of the long supplier lead times. In cases where lead times
are long, safety stock is required to ensure availability and make provisions for
fluctuations in demand. Storing extra stock increases inventory holding costs
and obsolescence costs, however the obsolescence costs do not have as high an
impact on total costs as inventory holding costs. Inventory holding costs make
up a very large portion of the total costs and therefore policies that minimise
holding costs should be implemented. This includes reducing supplier lead
times in order to avoid the need for safety stock. Reduced lead times will
increase the frequency of orders, reduce the required inventory on hand and
therefore reduce the holding costs. The impact that supplier lead time has on
the holding costs are tested and shown in Figure 7.2. The cumulative holding
costs are calculated using the minimum, maximum and average lead time from
real data (0.25, 1.2 and 5.6 months) when the same customer service level is
provided to the health facilities, i.e. the same number of drugs are dispatched
to the health facilities in each scenario. To provide the same service level,
the CMD would have to pay more than double over the 10 year period if the
supplier lead time is 5.6 months as opposed to 0.25 months.
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Figure 7.2: Eﬀect of supplier lead time on cumulative holding costs
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7.2 Recommendations to Stakeholders
As mentioned earlier, the greatest contribution to performance improvement
in the supply chain is the reduction of supplier lead time. Supplier selection
has a significant impact on lead time and is therefore the biggest factor in
lead time reduction. Although the suppliers are contracted through the NDoH
every two years, the CMD could possibly provide incentives to the current
suppliers to deliver within a certain period of time. In addition to reducing
lead times within the supply chain, the CMD could consider policy changes
using the results obtained from the scenario modelling phase to aid in the
decision-making process. The results show the generation of a pareto set with
three optimal solutions, thereby requiring decision support tools to select the
best intervention for all stakeholders involved. Furthermore, the results show
that the current reorder policies are dominated by the minimum and maxi-
mum desired levels of stock that are changed as often as desired by diﬀerent
pharmacists responsible for diﬀerent sections of the CMD at their own dis-
cretion. This has created ineﬀective inventory management, with 267% more
units of amikacin in stock on average than what is required every month. The
scenario modelling has shown that interventions are available that could be
implemented to improve inventory management.
7.2.1 Decision-Making Tools
Each point in Figure 7.1 represents the impact of a diﬀerent intervention/policy,
or a combination thereof. The pareto set oﬀers three optimal solutions for im-
proving the downstream supply chain, however the supply chain cannot oper-
ate at each pareto solution simultaneously. A decision-making tool is therefore
necessary in order to decide which pareto solution, and therefore intervention,
is best for: the CMD; the health facilities; and the patients alike. It is therefore
suggested to take the following three factors into account in order to determine
the optimal pareto solution. These concepts are discussed in more detail in
Section 7.6.
7.2.1.1 GDP
The gross domestic product (GDP) per capita is one of the determinants used
to establish health expenditure. The GDP is a measure of a country’s eco-
nomic health and can therefore be used as an indicator to determine how
much money is available for TB R&D and TB treatment. Between the years
2010 and 2014, South Africa has spent approximately 8.9% of the total GDP
on health expenditure (World Bank Group, 2015). Increasing inventory lev-
els to prevent shortages when lead times are poor has a significant impact on
the cost of operating the supply chain and therefore requires further funding.
Therefore the GDP should be used to determine how much extra funding can
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be allocated to MDR-TB specifically. However, the consequences of increased
TB incidence may actually negatively impact the GDP more significantly than
allocating extra funds.
The burden of TB has significant social and economic implications for a coun-
try. According to the Global Alliance for TB Drug Development (2013) TB is a
debilitating disease that mostly aﬀects the working class, with 75% of TB cases
aﬀecting people between the ages of of 15 and 54. This results in diminished
labour capacity as people infected with TB are significantly less productive
than healthy people, stunting economic prosperity (Hart). Lonnroth (2011)
explains that research has shown that there is a strong correlation between
high TB incidence in a country and low gross national per capita income.
7.2.1.2 Population Simulations
In order to test the impact of increased infectiousness and the possible de-
velopment of XDR-TB when treatment regimens are interrupted, population
simulations should be developed. Population simulations can be used to simu-
late future trends based on current data. The future trend of newly diagnosed
XDR-TB and MDR-TB cases due to treatment interruptions and stock-outs
can be developed using current data on shortages and rates of infection. Com-
paring the cost of having more patients on longer treatments regimens using
more expensive drugs to the cost of storing extra inventory will aid in the
decision-making process of whether more money should be spent to prevent
shortages and improve lead times.
7.2.1.3 Quality-Adjusted Life Years
In order to determine what additional costs will be necessary to improve the
lives of patients, and how many lives these additional costs will actually im-
prove, a quality-adjusted life-year (QALY) calculation should be done. The
total additional costs incurred to reduce shortages to gain one extra QALY can
be calculated to determine which interventions from Figure 7.1 are the most
economically viable. QALY’s are explained in more detail in Section 7.6.
7.2.2 Reorder Policy Analysis
As discussed earlier the minimum and maximum desired levels of stock are
changed without policies and can be changed as often as desired. The lack
of a policy with regards to reorder quantity has led to ineﬀective inventory
management. It is suggested that a decision-making policy with regards to
reorder policies during demand fluctuations be implemented. A decision sup-
port system will aid in ensuring that consistent decisions are made even when
a specific pharmacist is unavailable, to allow any other individual to make the
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correct decision.
A decision tree is a decision support tool that uses a schematic tree shaped
diagram to determine a course of action. The branching method is used to
show alternative decisions and every possible outcome of a decision. Xu et al.
(2013) state that decision trees are commonly used in decision analysis to
identify the strategy with the most potential to reach a specific goal. The goal
in this case would be to identify the strategy which results in the most eﬀec-
tive inventory management when demand and lead time fluctuate significantly.
Overall, for both increases and decreases in demand, the scenario modelling
results show that keeping the desired levels of stock constant provide better
results. However, to control shortages more aggressively the results show that
ordering safety stock to make provision for demand increases, rather than
altering the desired levels of stock is more eﬀective. Figure 7.3 shows an
example of a decision tree that could possibly be used by the CMD.
Set constant min/max 
desired levels of stock
Yes
Increase?
No
Reorder quantity≻
Inventory position? 
Standard reorder 
quantity
Change in health 
facility demand?
YesNo
Standard reorder 
quantitysafety
stock
Calculate reorder 
quantity using min/
max level formula?
Reorder point 
reached?
YesNo
Do not place order YesNo
Do not place order
Standard reorder 
quantity
Yes
Figure 7.3: Inventory management decision flow chart
The diamond shapes show events and the blocks show actions. The standard
reorder quantity policy and best safety stock policy (as shown in Subsection
6.3.4) used to calculate the CMD demand, as shown in the decision tree are
calculated as follows:
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DCMD = Tmax ⇥ C¯A + SS   IP, (7.2.1)
SS =
DHF (t) DHF (t  1)
DHF (t  1) ⇥DHF (t). (7.2.2)
7.2.3 Impact of IOM Suggestions and Best Practices
The impact of the themes tested using the system dynamics model on the per-
formance of the SLD supply chain are evaluated. The themes that were tested
include: inventory management; demand forecasting; and sales and operations
planning. The demand forecasting was tested through the use of exponential
smoothing as a reorder quantity policy however, this showed no improvement.
This is due to the fact that the SLD supply chain is predominantly donor
funded, meaning that demand is unstable and irregular due to the fact that the
demand is not voluntary (Haghani and Afshar, 2009). There will be periods of
irregular demand at irregular intervals due to increased awareness campaigns
or the improvement of diagnostic capabilities. However, inventory manage-
ment and sales and operations planning had significant positive impacts on
the performance of the supply chain which can be seen by: the various reorder
policy interventions; the reduced lead time interventions; and the safety stock
interventions.
7.3 Recommendations on the Methodology
Developing a model of a supply chain in order to test the impact of vari-
ous interventions on the performance of the supply chain is the recommended
methodology to follow. Running various scenarios on a model that represents
a real-world system will give the best estimate on how the changes will impact
the current system.
As discussed in Chapter 3, there are many diﬀerent techniques available for
modelling supply chains. The technique chosen should depend on the purpose
of the study. System dynamics is the chosen methodology for this study, and
is highly recommended for the purpose of this study and any similar projects.
System dynamics aids in decision making processes about policies and strate-
gies, and provides understanding of the non-linear behaviour of complex sys-
tems over time. It is not highly accurate for each individual entity i.e. each
drug, but gives an accurate representation of the overall system. Furthermore,
the software used to develop this systems dynamics model (Vensim) is also
highly recommended as it is user friendly.
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 7. CONCLUSION AND RECOMMENDATIONS 140
7.4 Model Assumptions and Limitations
This section discusses the limitations in the simulated model. These limitations
are due to either the properties of system dynamics or the limited availability
of data.
There are instances in the model where the limitations of system dynamics im-
pact the accuracy of the model. Firstly, the state changes in systems dynamics
are continuous, therefore individual units cannot be modelled. For example
the obsolete stock is calculated as a percentage of the units of amikacin on
hand for each month. Therefore the model overcompensates and produces
more obsolete stock than what is actually produced. However, with system
dynamics there is no way to track each individual drug through the stages of
the supply chain to test if it does indeed expire. In order to track individual
activities at discrete points of time, discrete event simulation should be used.
All of the necessary CMD data required to develop the downstream SLD sup-
ply chain was provided by the WCDoH, however there are some activities that
cannot be modelled accurately. The minimum and maximum desired levels
of stock can be changed regularly by a pharmacist, depending on: demand;
external factors; warehouse capacity; and supplier lead time. These minimum
and maximum levels only date back five years and are recorded as snapshots in
the form of text files, therefore extracting this data is a laborious task. Since
there is no set policy for determining these levels, the model cannot accurately
represent the real-life situation. Therefore to represent the current supply
chain, the levels are adjusted to fit the real-life trends. Furthermore, although
there is a policy for determining reorder quantity, the CMD can override this
in times of emergencies. The data shows instances where the quantity ordered
is higher than what is calculated with the policy, therefore the model cannot
represent these instances accurately. This is apparent during the validation
process in Chapter 5, Subsection 5.3.3.
Finally, the data collected for this study was provided by the CMD and there-
fore the simulated model is developed around the CMD. The shortages that
are calculated in this model are the shortages experienced at the CMD, and
not necessarily at the health facilities. Due to the limited data, there is no ac-
curate method of determining how and when these shortages aﬀect each of the
345 health facilities that the CMD supplies to. Therefore the assumption was
made that any shortages experienced at the CMD are immediately translated
to shortages at the health facilities and therefore interruptions in treatment.
This is one of the biggest limitations with the current model.
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7.5 Suggestions for Future Research
This section discusses the possibilities of further research based on the findings
of this research project.
7.5.1 Expanding the Model
This model is only developed for one second-line anti-TB drug, therefore the
first suggestion is to develop similar models for the other second-line anti-TB
drugs, to test if they behave in the same way and achieve the same results as
this model. This model could also be used to test other pharmaceutical supply
chains, adjusting the necessary parameters as necessary. Moreover, in order to
represent the downstream supply chain more accurately, data should also be
collected from both the health facilities and the suppliers in order to increase
accuracy. The model developed for this study is focused only on the CMD,
limiting what can be tested. As discussed earlier, data from both the CMD
and the health facilities will aid in determining how long it takes for shortages
in the CMD to be translated into shortages in the health facilities.
Furthermore, this model should be expanded to include the upstream segment
of the supply chain. The upstream and downstream segments of the SLD
supply chain are decoupled from one another in terms of financing, therefore
creating unique implications with regard to the operations in each segment.
Developing a model that integrates both segments of the SLD supply chain
will not only allow better understanding of the global supply chain, but will
also illustrate how the segments influence one another, and to what extent.
7.5.2 In-Depth Impact of Shortages
The overall eﬀect of drug shortages and ultimately treatment interruptions can
never be fully quantified, as shortages can create life threatening situations.
This research project only takes the cost of substitute drugs due to resistance
into account when treatments are interrupted. However the other factors that
need to be considered when treatments are interrupted include: increased
infectiousness; development of XDR-TB; patient drop-out; and possible death.
This section provides suggestions on how to further quantify the impact of
shortages on infectiousness, increased resistance and mortality.
7.5.2.1 Quality-Adjusted Life-Year Analysis
In order to determine the true cost of shortages and stock-outs it is suggested
that more research should be done on quality-adjusted life-years (QALY). Ac-
cording to Prieto and Sacristán (2003), the QALY is the measure of the value
of health outcomes. The QALY was developed to combine both the values of
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length (quantity) of life and quality of life into a single measure. The QALY
is calculated as follows:
QALY s gained = utility score⇥ additional years. (7.5.1)
Utility scores are given to specific predetermined health states. These health
state values vary from one (perfect health) down to negative values, depending
on the problem. A utility of zero is equivalent to being dead, therefore health
states with negative utilities are regarded as being worse than death. The ad-
ditional years refer to the number of extra years generated in a health state due
to some or other health intervention. Although the measure has ethical short-
falls, QALYs can be used as a common currency to asses the extent of health
related benefits gained from interventions. Therefore comparisons between in-
terventions can be made to establish priorities and cost benefits. Combining
the cost of interventions with the QALY measure creates a cost-utility ratio.
A cost-utility ratio indicates the additional cost associated with producing
one extra year of perfect health (one QALY). Interventions can therefore be
compared by assessing the additional costs for each QALY gained in order to
decide which intervention shows the most potential.
7.5.2.2 Population Simulations
Poor adherence to and interruption of treatments can lead to prolonged infec-
tiousness (Volmink and Garner, 2007). Furthermore, if treatment has gone on
for long enough for the infectiousness to disappear, the patient can become in-
fectious again if treatment is interrupted (World Health Organization, 2013d).
In order to test the impact of increased infectiousness and the development
of XDR-TB when treatment regimens are interrupted, population simulations
should be developed. Population simulations can be used to simulate future
trends based on current data. The future trend of new diagnosed XDR-TB
and MDR-TB cases due to treatment interruptions and stock-outs can be de-
veloped using current data on shortages and rates of infection. These trends
can be used to quantify the impact that treatment interruptions have on treat-
ment costs in order to perform a cost-benefit analysis to estimate the amount
of savings better inventory management may produce.
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Appendix A
List of MDR-TB SLDs
Table A.1: MDR-TB SLDs stocked at the CMD
Drug Name
Amikacin sulphate injection 500mg;2ml;1’s
Capreomycin 1g injection;10ml
Clofazimine capsules 100mg;100’s
Ethambutol hydrochloride tablets 400mg;100’s
Ethambutol hydrochloride tablets PRP 400mg;84’s
Ethambutol hydrochloride, RIF, INH & pyrazinamide tablets 275, 150, 75, 400mg;500’s
Ethambutol hydrochloride, RIF, INH & pyrazinamide tablets PRP 275, 150, 75, 400mg;100’s
Ethambutol hydrochloride, RIF, INH & pyrazinamide tablets PRP 275, 150, 75, 400mg;112’s
Ethambutol hydrochloride, RIF, INH & pyrazinamide tablets PRP 275, 150, 75, 400mg;28’s
Ethambutol hydrochloride, RIF, INH & pyrazinamide tablets PRP 275, 150, 75, 400mg;40’s
Ethambutol hydrochloride, RIF, INH & pyrazinamide tablets PRP 275, 150, 75, 400mg;56’s
Ethambutol hydrochloride, RIF, INH & pyrazinamide tablets PRP 275, 150, 75, 400mg;60’s
Ethambutol hydrochloride, RIF, INH & pyrazinamide tablets PRP 275, 150, 75, 400mg;80’s
Ethambutol hydrochloride, RIF, INH & pyrazinamide tablets PRP 275, 150, 75, 400mg;84’s
Kanamycin injection 1g;3ml;1’s
Kanamycin injection 1g/3ml
Levofloxacin hemihydrate tablets 250mg;28’s
Levofloxacin hemihydrate tablets 250mg;30’s
Levofloxacin hemihydrate tablets 250mg;5’s
Moxifloxacin hydrochloride tablets 400mg;30’s
Moxifloxacin hydrochloride tablets 400mg;5’s
Ofloxacin tablets 200mg;10’s
Ofloxacin tablets PRP 200mg;28’s
Ofloxacin tablets PRP 400mg;28’s
Ofloxacin tablets PRP 400mg;56’s
Para-amino salicylic acid 4g;30’s
Terizidone capsules 250mg;100’s
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